DEF 14A
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14A
(Rule 14a-101)
INFORMATION REQUIRED IN PROXY STATEMENT
SCHEDULE 14A INFORMATION
PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES
EXCHANGE ACT OF 1934 (AMENDMENT NO.
)
Filed by the Registrant [X]
Filed by a Party other than the Registrant [ ]
Check the appropriate box:
|
|
|
|
|
|
|
[ ] |
|
Preliminary Proxy Statement
|
|
|
|
|
[ ] |
|
Confidential, for Use of the
Commission Only (as permitted by
Rule 14a-6(e)(2)) |
|
|
|
|
[X] |
|
Definitive Proxy Statement |
|
|
|
|
[ ] |
|
Definitive Additional Materials |
|
|
|
|
[ ] |
|
Soliciting Material Pursuant to
Section 240.14a-11(c) or Section 240.14a-2. |
ALPHARMA INC.
(Name of Registrant as Specified In Its
Charter)
(Name of Person(s) Filing Proxy Statement, if
other than Registrant)
Payment of Filing Fee (Check the appropriate box):
[ ] |
|
Fee computed on table below per Exchange Act Rules 14a-6(i)(4) and 0-12. |
|
(1) |
Title of each class of securities to which transaction applies: |
|
(2) |
Aggregate number of securities to which transaction applies: |
|
(3) |
Per unit price or other underlying value of transaction computed
pursuant to Exchange Act Rule 0-11 (Set forth the amount on which the
filing fee is calculated and state how it was determined): |
|
(4) |
Proposed maximum aggregate value of transaction: |
[ ] |
|
Fee paid previously with preliminary materials. |
|
[ ] |
|
Check box if any part of the fee is offset as provided by Exchange Act Rule
0-11(a)(2) and identify the filing for which the offsetting fee was paid
previously. Identify the previous filing by registration statement number,
or the Form or Schedule and the date of its filing. |
|
(1) |
Amount Previously Paid: |
|
(2) |
Form, Schedule or Registration Statement No.: |
ALPHARMA INC.
440 Route 22
Bridgewater, New Jersey 08807
Notice of Annual Meeting of
Stockholders
To Be Held on June 5,
2007
To the Stockholders of ALPHARMA INC.:
NOTICE IS HEREBY GIVEN that the Annual Meeting of Stockholders
of Alpharma Inc., a Delaware corporation (the
Company), will be held at the Companys offices
at 440 Route 22, Bridgewater, New Jersey on Tuesday,
June 5, 2007, at 9:00 a.m., local time, to consider
and act upon the following matters:
1. Election of six directors to the Companys Board of
Directors, each to hold office until the 2008 Annual Meeting of
Stockholders and until his or her successor shall be elected and
shall qualify.
2. Ratifying the appointment of BDO Seidman, LLP as the
Companys independent registered public accounting firm for
the 2007 fiscal year.
3. Transaction of such other business as may properly come
before the meeting or any adjournments or postponements thereof.
The Board of Directors has fixed the close of business on
April 9, 2007 as the record date for determining the
Companys stockholders entitled to notice of, and to vote
at, the Annual Meeting or any adjournment thereof.
Your representation at this meeting is important. Whether or not
you expect to attend the Annual Meeting in person, please
complete, date, sign and return the enclosed proxy (or complete
your voting telephonically or by email). An envelope is enclosed
for your convenience which, if mailed in the United States,
requires no additional postage. If you attend the Annual
Meeting, you may then withdraw your proxy and vote in person.
A copy of the Companys Annual Report to Stockholders for
the year ended December 31, 2006 and a Proxy Statement
accompany this notice.
By order of the Board of Directors,
Robert F. Wrobel
Secretary
April 27, 2007
TABLE OF CONTENTS
ALPHARMA INC.
440 Route 22
Bridgewater, New Jersey 08807
MAILING DATE
April 27, 2007
Proxy Statement for Annual Meeting of Stockholders
To Be Held on June 5, 2007
This proxy statement (this Proxy Statement) is
furnished in connection with the solicitation of proxies by the
Board of Directors of Alpharma Inc., a Delaware corporation (the
Company), for use at the Annual Meeting of
Stockholders (the Annual Meeting) to be held on
Tuesday, June 5, 2007 at the Companys offices at 440
Route 22, Bridgewater, New Jersey at 9:00 a.m., local
time, and at any adjournment or postponement thereof. The cost
of solicitation of the Companys stockholders (the
Stockholders) will be paid by the Company. Such cost
will include the reimbursement of banks, brokerage firms,
nominees, fiduciaries and other custodians for expenses of
forwarding solicitation materials to beneficial owners of
shares. In addition to the solicitation of proxies by use of
mail, the directors, officers and employees of the Company may
solicit proxies personally or by telephone,
e-mail or
facsimile transmission. Such directors, officers and employees
will not be additionally compensated for such solicitation but
may be reimbursed for
out-of-pocket
expenses incurred in connection therewith.
It is anticipated that this Proxy Statement and form of proxy
will first be sent to the Stockholders on or about
April 27, 2007.
THE
ANNUAL MEETING
Purpose
of Meeting
At the Annual Meeting, the Stockholders will consider and act
upon the following matters:
1. Election of six directors to the Companys Board of
Directors (the Board), each to hold office until the
2008 Annual Meeting of Stockholders and until his or her
successor shall be elected and shall qualify;
2. Ratifying the appointment of BDO Seidman, LLP as the
Companys independent registered public accounting firm for
2007 fiscal year; and
3. Transaction of such other business as may properly come
before the meeting or any adjournments or postponements thereof.
Record
Date; Shares Entitled to Vote
The close of business on April 9, 2007 (the Record
Date) has been fixed as the record date for determining
holders of outstanding shares of the Companys Class A
Common Stock, par value $.20 per share (Class A
Common Stock), entitled to notice of, and to vote at, the
Annual Meeting. As of the Record Date, 43,238,842 shares of
Class A Common Stock were outstanding and entitled to vote.
11,872,897 shares of the Companys Class B Common
Stock
(Class B Stock) are currently held by
wholly-owned subsidiaries of the Company and as a result have no
voting rights and are treated for financial purposes and for
purposes of the Companys Charter as treasury stock.
Quorum
For each matter to be voted upon at the Annual Meeting, the
presence in person or by proxy of holders of stock entitled to
be voted with respect to such matter, representing one-third of
the aggregate voting power of all shares of stock entitled to be
voted with respect to such matter is necessary to constitute a
quorum with respect to such matter and to transact business with
respect to such matter at the Annual Meeting. For purposes of
determining whether a quorum exists with respect to the election
of directors, shares as to which authority to vote in the
election of directors has been withheld and broker non-votes
(where a broker submits a proxy but does not have authority to
vote a customers shares on one or more matters) with
respect thereto will be considered present at the Annual
Meeting. For the purpose of determining whether a quorum exists
with respect to ratifying the appointment of the Companys
independent accountants for the 2007 fiscal year and any other
matter which may properly come before the Annual Meeting, shares
abstaining on such matter and all broker non-votes with respect
to such matter will be considered present at the Annual Meeting.
Required
Vote
Election of Directors. Six directors will be
elected at the Annual Meeting. Under the Companys
Certificate of Incorporation, the holders of the Class A
Common Stock are entitled, voting as a separate class, to elect
at least
331/3%
of the Companys Board of Directors (rounded to the nearest
whole number, but in no event less than two members of the
Board), and the holders of the Class B Stock are entitled,
voting separately as a class, to elect the remaining directors.
However, since the Class B Stock is currently held by
wholly-owned subsidiaries of the Company and is treated as
treasury stock, its voting rights are not exercisable and the
holders of the Class A Common Stock are entitled to vote
for 100% of the directors. Therefore, the holders of the
Class A Common Stock will elect all six of the directors
(Directors). Directors are elected by the
affirmative vote of a plurality of the votes cast at the Annual
Meeting.
Ratification of the Appointment of the Independent Registered
Public Accounting Firm. Ratification of the
appointment of the independent registered public accounting firm
for fiscal 2007 requires the affirmative vote of holders of a
majority of the shares of the Companys Class A Common
Stock present in person or by proxy and entitled to vote at the
Annual Meeting.
Proxies
The enclosed proxy provides space for holders of Class A
Common Stock to vote for, or withhold authority to vote for, all
of the Companys six nominees for Directors. Shares of
Class A Common Stock represented by properly executed
proxies received at or prior to the Annual Meeting, which have
not been revoked, will be voted in accordance with the
instructions indicated therein. If no instructions are
indicated, such proxies will be voted FOR (i) the election
as directors of the six nominees for Directors nominated by the
Board (see Election of Directors; Nominees for
Directors below), (ii) the proposal to ratify the
appointment of the Companys independent accountants and
(iii) in the discretion of the proxy holder, as to any
other matter which may properly come before the Annual Meeting.
As of the date of this Proxy Statement, the Company is not aware
of any matters that are to be presented at the Annual Meeting
other than the election of directors and the ratification of the
appointment of BDO Seidman, LLP as the independent registered
public accounting firm for the 2007 fiscal year. With respect to
the election of Directors, neither shares as to which authority
to vote has been withheld (to the extent withheld) nor broker
non-votes will be considered affirmative votes. With respect to
the ratification of the appointment of the Companys
independent accountants, (i) abstentions, pursuant to
Delaware law,
2
will be considered present and entitled to vote but will not
have been cast and therefore would have the same effect as a
vote against ratification and (ii) broker non-votes will be
considered not entitled to vote on such proposal and thus will
not be counted in determining whether such proposal has received
the requisite votes.
YOUR VOTE IS IMPORTANT. WHETHER OR NOT YOU PLAN TO ATTEND THE
ANNUAL MEETING, PLEASE COMPLETE, DATE, SIGN AND RETURN YOUR
PROXY (OR COMPLETE YOUR VOTING TELEPHONICALLY OR BY EMAIL) IN
ORDER TO ENSURE THAT YOUR SHARES WILL BE REPRESENTED AT THE
ANNUAL MEETING. THE GIVING OF SUCH PROXY DOES NOT AFFECT YOUR
RIGHT TO VOTE IN PERSON IN THE EVENT YOU ATTEND THE ANNUAL
MEETING.
A holder of Class A Common Stock who has given a proxy may
revoke such proxy at any time prior to its exercise at the
Annual Meeting by (i) giving written notice of revocation
to the Secretary of the Company, (ii) properly submitting
to the Company a duly executed proxy bearing a later date, or
(iii) attending the Annual Meeting and voting in person.
Attendance at the Annual Meeting will not automatically revoke a
proxy. All written notices of revocation and other
communications with respect to revocation of proxies should be
sent to the attention of the Secretary of the Company at the
Companys United States executive offices, located at 440
Route 22, Bridgewater, New Jersey 08807.
If a quorum is not obtained, the Annual Meeting may be adjourned
for the purpose of obtaining additional proxies or for any other
purpose, and, at any subsequent reconvening of the Annual
Meeting, all proxies will be voted in the same manner as such
proxies would have been voted at the original convening of the
meeting (except for any proxies which have been effectively
revoked or withdrawn), notwithstanding that they may have been
effectively voted on the same or any other matter at a previous
meeting.
Electronic
and Telephonic Voting
You may vote your proxies by touch-tone telephone from the U.S.,
using the toll-free telephone number on the proxy card, or via
the Internet using the procedures and instructions described on
the proxy card. Stockholders who own their common stock through
a broker, also known as street name holders, may
vote by telephone or via the Internet if their bank or broker
makes those methods available, in which case the bank or broker
will enclose instructions with the Proxy Statement. The
telephone and Internet voting procedures, including the use of
control numbers found on the proxy card, are designed to
authenticate Stockholder identities, to allow Stockholders to
vote their shares of common stock, and to confirm that their
instructions have been properly recorded. Stockholders voting
via the Internet should understand that there may be costs
associated with electronic access, such as usage charges from
Internet access providers and telephone companies, which must be
paid by the Stockholder.
3
SECURITY
OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
Ownership
of Common Stock
The following table sets forth, as of February 28, 2007
(unless otherwise noted), certain information regarding the
beneficial ownership of Class A Common Stock of
(a) each person who is known to the Company to be the
beneficial owner of more than 5% of the outstanding shares,
(b) each director and each nominee for director of the
Company, (c) each executive officer named in the Summary
Compensation Table, and (d) all directors, nominees for
director and executive officers of the Company as a group.
Unless otherwise indicated, (i) each beneficial owner
possesses sole voting and dispositive power with respect to the
shares listed for such beneficial owner in this table, and
(ii) the address of such beneficial owner is the
Companys offices at 440 Route 22, Bridgewater, New
Jersey 08807. This table does not include Class B Stock as
it is currently 100% owned by wholly-owned subsidiaries of the
Company and as a result has no voting rights and is treated for
financial purposes and for purposes of the Companys
Charter, as treasury stock.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Amount and
|
|
|
|
|
|
|
|
|
Nature of
|
|
|
Percent of
|
|
|
|
|
|
Beneficial
|
|
|
Class
|
|
Title of Class of Stock
|
|
Name of Beneficial Owner
|
|
Ownership
|
|
|
Outstanding
|
|
|
Class A Common Stock
|
|
Barclays Global Investors NA.(2)
|
|
|
2,760,950
|
|
|
|
6.40
|
|
Class A Common Stock
|
|
Dimensional Fund Advisors
LP(3)
|
|
|
3,390,282
|
|
|
|
7.85
|
|
Class A Common Stock
|
|
LSV Asset Management(4)
|
|
|
2,827,010
|
|
|
|
6.55
|
|
Class A Common Stock
|
|
Ingrid Wiik(1)
|
|
|
149,167
|
|
|
|
*
|
|
Class A Common Stock
|
|
Ronald N. Warner(1)
|
|
|
79,347
|
|
|
|
*
|
|
Class A Common Stock
|
|
Robert F. Wrobel(1)
|
|
|
73,241
|
|
|
|
*
|
|
Class A Common Stock
|
|
Jeffrey S. Campbell(1)
|
|
|
42,223
|
|
|
|
*
|
|
Class A Common Stock
|
|
Dean Mitchell(1)
|
|
|
40,000
|
|
|
|
*
|
|
Class A Common Stock
|
|
Glen E. Hess(1)(5)
|
|
|
36,367
|
|
|
|
*
|
|
Class A Common Stock
|
|
Peter G. Tombros(1)
|
|
|
32,318
|
|
|
|
*
|
|
Class A Common Stock
|
|
Matthew T. Farrell
|
|
|
6,658
|
|
|
|
*
|
|
Class A Common Stock
|
|
George Rose
|
|
|
181
|
|
|
|
*
|
|
Class A Common Stock
|
|
Ramon M. Perez(1)
|
|
|
0
|
|
|
|
|
|
Class A Common Stock
|
|
Finn Berg Jacobsen(1)
|
|
|
0
|
|
|
|
|
|
Class A Common Stock
|
|
Peter W. Ladell
|
|
|
0
|
|
|
|
|
|
Class A Common Stock
|
|
David C. UPrichard
|
|
|
0
|
|
|
|
|
|
Class A Common Stock
|
|
All directors and executive
officers as a group (16 persons)(1)
|
|
|
604,771
|
|
|
|
1.4
|
%
|
|
|
|
* |
|
indicates ownership of less than 1% |
|
(1) |
|
The shares reflected in the table include shares that the
executive officer or director has the right to acquire upon the
exercise of stock options granted under the 1997 Incentive Stock
Option and Appreciation Right Plan, the Non-Employee Director
Option Plan or the 2003 Omnibus Incentive Compensation Plan,
which are exercisable as of February 28, 2007 or within
60 days thereafter, as follows: Dr. Warner
36,663 shares, Mr. Wrobel
50,333 shares, Mr. Campbell
3,625 shares, Ms. Wiik 68,750 shares
and each of Messrs. Hess and Tombros
31,500 shares. All directors and executive officers as a
group 324,104 shares. The shares in the table
also include shares of unvested restricted stock granted under
the 2003 Omnibus Incentive Compensation |
4
|
|
|
|
|
Plan, over which the executive officer or director has voting
control as of February 28, 2007, as follows:
Dr. Warner 29,400 shares,
Mr. Wrobel 10,200 shares,
Mr. Campbell 35,500 shares and
Mr. Mitchell 40,000 shares. All directors
and executive officers as a group
144,200 shares. The shares reflected in the table do not
include restricted stock units, which convey no voting control
prior to vesting. The following lists the restricted stock units
(not reflected in the table) held by the directors as of
February 28, 2007: each of Messrs. Hess and
Perez 15,000 units,
Mr. Tombros 16,000 units and Mr. Berg
Jacobsen 10,835 units. The shares reflected in
the table have not been pledged as security. |
|
(2) |
|
The source of this information is Schedule 13G dated
January 23, 2007, filed with the Securities and Exchange
Commission (the Commission) by Barclays Global
Investors, NA. (Barclays). Such Schedule 13G
reports that Barclays holds sole voting power as to
1,227,678 shares and sole dispositive power as to
1,374,915 shares. The Schedule 13G further reports
that an affiliate of Barclays, Barclays Global
Fund Advisors, holds sole voting power and sole dispositive
power as to 1,358,784 shares. The Schedule 13G further
reports that an affiliate of Barclays Global Investors, LRD,
holds sole voting power and sole dispositive power as to
24,246 shares. The address of Barclays and Barclays Global
Fund Advisors is 45 Fremont Street, San Francisco,
California 94105 and the address of Barclays Global Investors,
LP is 1 Royal Mint Court, London, EC3N4HHN, UK. |
|
(3) |
|
The source of this information is Amendment No. 3 to
Schedule 13G dated February 9, 2007, filed with the
Commission by Dimensional Fund Advisors LP
(Dimensional). Such Schedule 13G reports that
Dimensional, an investment adviser registered under
Section 203 of the Investment Advisers Act of 1940,
furnishes investment advice to four investment companies
registered under the Investment Company Act of 1940, and serves
as investment manager to certain other commingled group trusts
and separate accounts (the Funds). In its role as
investment adviser or manager, Dimensional possesses voting
and/or
investment power over the Company shares that are owned by the
Funds, and may be deemed to be the beneficial owner of these
shares. No one Fund, to Dimensionals knowledge, owns more
than 5% of the outstanding Class A Common Stock of the
Company. Dimensional disclaims beneficial ownership of the
shares owned by the Funds. The address of Dimensional is 1299
Ocean Ave.,
11th Floor,
Santa Monica, California 90401. |
|
(4) |
|
The source of this information is Schedule 13G dated
February 13, 2006, filed with the Commission by LSV Asset
Management (LSV). Such Schedule 13G reports that LSV
holds sole voting power as to 1,946,490 shares and sole
dispositive power as to 2,762,110 shares. The address of
LSV is 1 North Wacker Drive, Suite 4000, Chicago, Illinois
60606. |
|
(5) |
|
Includes 1,750 shares held by a private foundation of which
Mr. Hess is President; however he has no economic interest
in these shares. |
Section 16(a)
Beneficial Ownership Reporting Compliance
Section 16(a) of the Securities Exchange Act of 1934, as
amended, requires the Companys executive officers and
directors, and persons who own more than 10% of a registered
class of the Companys equity securities, to file reports
of ownership and changes in ownership of the Companys
stock on Forms 3, 4 and 5 with the Commission and the New
York Stock Exchange (the NYSE). Executive officers,
directors and greater than 10% beneficial stockholders are
required by Commission regulation to furnish the Company with
copies of all Forms 3, 4 and 5 that they file. The Company
is not aware of any late or missed filings (or other
noncompliance), during the 2006 fiscal year, by any of its
executive officers, directors and greater than 10% beneficial
stockholders with the Section 16(a) filing requirements.
5
ELECTION
OF DIRECTORS
Election
of Directors
The current terms of all of the Companys directors expire
at the Annual Meeting. Not standing for re-relection are
Ms. Wiik and Mr. Hess, who have each informed the
Board that they will retire from the Board at the end of their
current terms. The Board wishes to express its deepest gratitude
for the wisdom and significant contributions of Ms. Wiik
and Mr. Hess during their tenure.
The Board intends to cause the nomination of the nominees listed
below under Nominees for Directors and all proxies
received from holders of Class A Common Stock will be voted
FOR the election of such nominees as Directors, except to the
extent that persons giving such proxies withhold authority to
vote for such nominees. The Nominating and Corporate Governance
Committee recommended the nominees to the Board, which
subsequently approved the nominations. Each director is to be
elected to hold office until the next Annual Meeting of
Stockholders and until his or her successor is elected and
qualified. Mr. Ladell and Mr. UPrichard were recommended
to the Nominating and Corporate Governance Committee by a
third-party search firm.
Directors are elected by the affirmative vote of a plurality of
the votes cast at the Annual Meeting. Abstentions and broker
non-votes are not counted as votes cast in determining the
plurality required to elect directors. The Board of Directors
recommends that shareholders vote for such nominees for director.
Nominees
for Directors
The Company believes that each of the nominees for director will
be able to serve. If any of the nominees for Directors would be
unable to serve, the enclosed proxy confers authority to vote in
favor of such other person or persons as the Companys
Directors at the time recommend to serve in place of the person
or persons unable to serve. The name, age, principal business
experience during the last five years, and certain other
information regarding each of the persons proposed to be
nominated for election as a Director, are listed below
|
|
|
|
|
|
|
Name
|
|
Age
|
|
Principal Business Experience
|
|
Finn Berg Jacobsen
|
|
|
66
|
|
|
Director of the Company since
April 2005. Senior Advisor since 2005 with Bahr Law, the
Norwegian law firm. Among numerous recent consulting
engagements, was engaged by a Norwegian corporation traded on
the Oslo and NASDAQ Stock Exchanges to build an internal audit
function to be compliant with the Sarbanes-Oxley Act of 2002.
Served as Group Executive Vice President and Chief of Corporate
Staff of Aker Kvaerner ASA, the Norwegian oil services company,
from February 2002 to March 2005, and as Acting Chief Financial
Officer (from December 2003 to November 2004) and Chief
Financial Officer (from September 2001 to January 2002) for such
company. From 1967 to 2000, served in a variety of positions,
including Country Managing Partner in Norway (from 1977 to
1999), for Arthur Andersen & Co. Chairman and
subsequently member of the Accounting Advisory Council with the
Oslo Stock Exchange, from 1977 to 2000. Chairman and one of the
founders of the Norwegian Financial Accounting Standards Board,
from 1990 to 2000. Chairman of the Control Committee of the Oslo
Stock Exchange, from 2000 to 2004. Chairman of the
Companys Audit Committee. Member of the Companys
Compensation Committee and Nominating and Corporate Governance
Committee.
|
6
|
|
|
|
|
|
|
Name
|
|
Age
|
|
Principal Business Experience
|
|
Peter W. Ladell
|
|
|
63
|
|
|
Formerly Chief Operating Officer
of Hoechst Marion Roussel from 1997 until the companys
December 1999 merger with Rohne-Poulenc Rorer to form Aventis
Pharmaceuticals. Subsequently served as a member of the Aventis
Executive Committee until retirement in 2001. During 35 year
tenure at Hoechst Marion Roussel and its predecessors, served in
several other senior leadership positions, including President
and Chief Executive Officer, Hoechst Marion Roussel, North
America and President, Marion Merrell Dow Europe. Director of
Dendrite International, Inc., a provider of sales, marketing,
clinical and compliance solutions to the life sciences and
pharmaceuticals industries.
|
Dean J. Mitchell
|
|
|
51
|
|
|
President and Chief Executive
Officer of the Company since July 2006. From October 2005 to
June 2006 he was President of MGI, GP (the company that acquired
Guilford Pharmaceuticals). From December 2004 until October
2005, President and Chief Executive Officer of Guilford
Pharmaceuticals Inc. From 2001 until 2004 held various senior
management positions with Bristol-Myers Squibb Company,
including President, International Pharmaceuticals, President,
U.S. Primary Care, and Vice President, Strategy. From 1987
through 2001, employed with GlaxoSmithKline and its predecessor
business, most recently as Senior Vice President, Clinical
Development and Product Strategy. Director of MGI Pharma Inc., a
bio-pharmaceutical company focused in oncology and acute care,
since October 2005; and ISTA Pharmaceuticals, a specialty
pharmaceutical company focused on products for serious eye
conditions, since July 2004.
|
Ramon M. Perez
|
|
|
53
|
|
|
Director of the Company since May
2004. Managing Director of Vela Management Group, Ltd., a
consulting practice focused in the healthcare industry. Formerly
served in executive and senior management positions at Cardinal
Health Inc., a global provider of products and services to
healthcare providers and manufacturers, including President,
Specialty Pharmaceutical Products & Services from 2000
to 2003, Executive Vice President, Supply Chain Services from
1996 to 1999, and Senior Vice President, Purchasing from 1994 to
1995. Formerly served in senior management positions at Baxter
International, Inc., a global developer, manufacturer and
distributor of products and services for healthcare and related
fields, including Vice President, Reengineering Team from 1993
to 1994, Vice President, Corporate Alliances from 1991 to 1993,
Vice President, Purchasing, Hospital Supply Division from 1990
to 1991, Vice President, Marketing, Hospital Supply Division
from 1987 to 1990, and various other positions in its Dietary
Products Division from 1978 to 1987, including Director of
Marketing. Chairman of the Companys Compensation
Committee. Member of the Companys Audit Committee and
Nominating and Corporate Governance Committee.
|
7
|
|
|
|
|
|
|
Name
|
|
Age
|
|
Principal Business Experience
|
|
Peter G. Tombros
|
|
|
64
|
|
|
Chairman of the Board since March
2006. Director of the Company since August 1994. Commencing in
2005, Professor and Executive in Residence in the Eberly College
of Science BS/MBA Program at Pennsylvania State University. From
2001 to 2005, served as Chief Executive Officer of VivoQuest,
Inc., a private bio-pharmaceutical company. Former Director,
President and Chief Executive Officer of Enzon, Inc., a
developer and marketer of bio-pharmaceutical products, from
April 1994 to June 2001. Served in a variety of senior
management positions at Pfizer, Inc., the pharmaceutical
company, for 25 years, including Vice President of
Marketing, Senior Vice President and General Manager of the
Roerig Pharmaceuticals Division, Executive Vice President of
Pfizer Pharmaceuticals Division, Director, Pfizer
Pharmaceuticals Division, Vice President-Corporate Strategic
Planning, and Vice President-Corporate Officer of Pfizer, Inc.
Director of NPS Pharmaceuticals, Inc., a biotechnology company;
Cambrex Corp., a supplier of human health products to the life
sciences industry; Protalex Inc., a developer of
bio-pharmaceutical drugs, Dendrite International, Inc., a
provider of sales, marketing, clinical and compliance solutions
to the life sciences and pharmaceutical industries; and Pharma
Net Development Group, a global drug development company
providing a range of early and late stage clinical drug
development services to the pharmaceutical, biotechnology,
genetic drug, and medical device industries. Chairman of the
Companys Nominating and Corporate Governance Committee.
Member of the Companys Audit Committee and Compensation
Committee.
|
David C. UPrichard
|
|
|
58
|
|
|
Venture partner with Venture
partner for Care Capital LLC from 2004 to 2006. Red Abbey
Venture Partners, and President, Druid Consulting LLC. Venture
partner for Apax Partners Ltd from 2003 to 2004. Chief Executive
Officer of
3-Dimensional
Pharmaceuticals, Inc from 1999 to 2003. Served as Chairman,
Research & Development of SmithKline Beecham
Pharmaceuticals, Inc. from 1997 to 1999. Director of Cyclacel
Pharmaceuticals, Inc, a biopharmaceutical company that develops
and commercializes drugs to treat human cancers and other
serious disorders; and Invitrogen Corporation, a company
providing life science technology.
|
CORPORATE
GOVERNANCE
Board
Meetings, Annual Meeting and Attendance of Directors
The Board held 16 meetings in 2006. Other than
Mr. Sissener, each person who served as a director in 2006
attended at least 75% of the aggregate of (i) the total
number of meetings of the Board held while such person was a
member, and (ii) the total number of meetings held by all
committees of the Board on which such person served while a
member of such committee. The Company does not have a policy
requiring directors to attend its annual meeting of
Stockholders; however, the Company encourages the attendance of
all directors standing for reelection, and all of the current
directors attended the 2006 Annual Meeting of Stockholders held
on May 23, 2006.
8
Board and
Committee Independence
The Board complies with the independence criteria established by
the New York Stock Exchange and with the independence standards
of the Commission. In determining Board independence in
compliance with the NYSE rules, the Board considers whether
directors or director nominees have a material relationship with
the Company or any of its subsidiaries. When assessing
materiality, the Board weighs all relevant facts and
circumstances, using the following categorical standards to
determine director independence: (1) whether the director
or nominee, or his or her immediate family member, is currently
or has been within the last three years: (a) an employee or
executive officer of the Company; (b) received more than
$100,000 during any 12 month period in direct compensation
from the Company (other than director and committee fees and
pension or other forms of deferred compensation for prior
service unless such compensation is contingent in
any way on continued service); (c) affiliated with or
employed in a professional capacity by a present or former
internal or external auditor of the Company; (d) employed
as an executive officer of another company where any of the
Companys present executive officers serves as a member of
such other companys compensation committee; or (e) an
executive officer or an employee of another company that makes
payments to, or receives payments from, the Company for property
or services in an amount which, in any of the last three fiscal
years, exceeds the greater of $1 million or 2% of such
other companys consolidated gross revenues; and
(2) whether certain other factors or circumstances external
to the Company exist that would materially interfere with the
director or nominee making decisions without regard to such
factors or circumstances. The Board has reviewed all such
relationships of each outside director.
The current members of the Board are Peter G. Tombros
(Chairman), Dean J. Mitchell, Finn Berg Jacobsen, Glen E. Hess,
Ramon Perez and Ingrid Wiik. Mr. Einar Sissener served as a
director through June 29, 2006. Mr. William I. Jacobs,
Ms. Jill Karin-Lovers, Ms. Farah M. Walters and
Mr. Robert Thong served as directors through May 23,
2006. The Board affirmatively determined in May 2006 that the
following directors, constituting a majority of the Board,
qualify as independent members of the Board: Finn
Berg Jacobsen, Glen E. Hess, Ramon M. Perez and Peter G.
Tombros. The Board affirmatively determined in June 2005 that
Mr. William I. Jacobs, Ms. Jill Karin-Lovers,
Ms. Farah M. Walters and Mr. Robert Thong qualified as
independent members of the Board. The Board did not
analyze their independence in May 2006 due to the fact that they
were not standing for re-election to the Board.
None of the directors determined to be independent engaged in
any transaction, relationship or arrangement that might affect
the determination of their independence, or which required Board
review except for Mr. Tombros, who serves as a director of
one of the Companys suppliers.
In determining Audit Committee independence, the Board first
considers whether directors or director nominees qualify as
independent to serve on the Board (as set forth
above), and, if answered affirmatively, whether they satisfy two
additional independence requirements: (1) whether the
director or nominee currently receives (or in the past has
received), directly or indirectly, compensation of any kind
(including salary, legal fees, consulting fees and auditing
fees) from the Company or any of its subsidiaries, other than
directors compensation for prior service that is not
contingent in any way on continued service, and (2) whether
the director or nominee is an affiliated person of
the Company, in that he or she is either (a) an executive
officer or (b) a stockholder holding 10% or more of any
class of Company securities. Applying these standards, the Board
determined in May 2006 that the following directors,
constituting the entire Audit Committee, qualify as
independent to serve on the Boards Audit
Committee: Finn Berg Jacobsen, Ramon M. Perez and Peter G.
Tombros.
In determining Compensation Committee independence, the Board
first considers whether directors or director nominees qualify
as independent to serve on the Board (as set forth
above), and, if answered affirmatively, whether they satisfy two
additional independence requirements: (1) whether the
director or nominee
9
is a Non-Employee Director under
Rule 16b-3
of the Securities Exchange Act of 1934, which means a director
or nominee who: (a) is not currently an officer or employee
of the Company or its subsidiaries; (b) does not receive
more than $120,000 in compensation annually from the Company or
its subsidiaries for services rendered as a consultant or in any
capacity other than as a director; and (c) does not possess
a direct or indirect material interest in any transaction in
which the Company or its subsidiaries were or are to be
participants and the amount involved exceeds $120,000; and
(2) whether the director or nominee is an Outside
Director under Internal Revenue Service Code
Section 162(m), in that he or she: (a) is not
currently an officer or employee of the Company or its
subsidiaries; (b) is not a former employee of the Company
or its subsidiaries who is currently receiving remuneration from
the Company or its subsidiaries for prior services; (c) has
not been an officer of the Company or its subsidiaries; and
(d) is not currently receiving, directly or indirectly,
compensation of any kind from the Company other than
directors compensation. Applying these standards, the
Board determined in May 2006 that the following directors,
constituting the entire Compensation Committee, qualify as
independent to serve on the Boards
Compensation Committee: Ramon M. Perez (Chairman), Finn Berg
Jacobsen and Peter G. Tombros.
In determining Nominating and Corporate Governance Committee
independence, the Board considers whether directors or director
nominees qualify as independent to serve on the
Board (as set forth above). Applying these standards, the Board
determined in January 2007 that the following directors,
constituting the entire Nominating and Corporate Governance
Committee, qualify as independent to serve on the
Boards Nominating and Corporate Governance Committee:
Peter G. Tombros (Chairman), Finn Berg Jacobsen and Ramon M.
Perez.
Committees
of the Board
Pursuant to its by-laws, as amended, the Company has established
standing Audit, Nominating and Corporate Governance, and
Compensation Committees. The charters for each of these
committees are available on the Companys website at
www.Alpharma.com by clicking first on the About
Alpharma tab and then on the Our Business
Guidelines tab, and in print, without charge, to any
Stockholder requesting a copy in writing to Investor
Relations at the Companys offices located at 440
Route 22, Bridgewater, New Jersey 08807. On
January 29, 2007 the Company reorganized its Board
committee structure. Prior to January 29, 2007, the Company
had in place (i) an Audit and Corporate Governance
Committee, which handled the responsibilities now undertaken by
the Audit Committee and the Nominating and Corporate Governance
Committee, (ii) an Executive and Finance Committee and
(iii) a Compensation Committee. On January 29, 2007
the Company eliminated the Executive and Finance Committee,
maintained the Compensation Committee and bifurcated the Audit
and Corporate Governance Committee into the Audit Committee and
the Nominating and Corporate Governance Committee. Prior to
December 28, 2006 the Company was a controlled
company under the NYSE listing standards and was thus exempt
from the requirement that it maintain a nominating committee.
Except where specifically noted, the discussions regarding Board
committees herein refer to the new committee structure effective
January 29, 2007.
Nominating
and Corporate Governance Committee
Prior to December 28, 2006 the Company was a
controlled company under the NYSE listing standards
and was thus exempt from the requirement that it maintain a
nominating committee. The full Board held 16 meetings during
2006. The Nominating and Corporate Governance Committee was
established in January 2007 and is entrusted with the
responsibility to assist the Board in fulfilling its oversight
responsibility with respect to corporate governance principles,
directorship practices and the recommendation of qualified
candidates for election to the Board. The Nominating and
Corporate Governance Committee recommended the 2007 slate of
director nominees to the Board, which subsequently approved the
nominations. The Nominating and Corporate Governance Committee
also monitors the Companys Business Conduct Guidelines.
The Nominating and Corporate Governance
10
Committee has a charter which governs its operations, and
requires that the committee be comprised of at least three
directors, each of whom are independent directors.
(See Corporate Governance; Board and Committee
Independence above for a description of such independence
criteria). During 2006, the corporate governance
responsibilities of the Nominating and Corporate Governance
Committee were administered by the Audit and Corporate
Governance Committee, which held ten meetings during 2006. The
current members of the Nominating and Corporate Governance
Committee are Peter G. Tombros (Chairman), Ramon M. Perez and
Finn Berg Jacobsen.
Audit
Committee
The Audit Committee provides assistance to the Board in
fulfilling the Boards oversight responsibility to the
Stockholders, potential stockholders, the investment community,
and others relating to the Companys financial statements
and the financial reporting process, the systems of internal
accounting and financial controls, and the annual independent
audit of the Companys financial statements. In so doing,
it is the responsibility of the committee to maintain free and
open communications between the committee, independent auditors,
and management of the Company. In discharging its oversight
role, the committee is empowered to investigate any matter
brought to its attention with full access to all books, records,
facilities, and personnel of the Company and has the power to
retain outside counsel or other experts. The committee is
charged with taking the appropriate actions to set the overall
corporate tone for quality financial reporting,
sound business risk, corporate governance practices and ethical
behavior. In furtherance of this mission, the Audit Committee
ensured that the Board and the committees of the Board completed
their annual performance evaluations at their February 2007
meetings, to evaluate their effectiveness. The Audit Committee
has a charter which governs its operations, and requires that
the committee be comprised of at least three directors, each of
whom are independent directors. (See Corporate
Governance; Board and Committee Independence above for a
description of such independence criteria). All committee
members shall be financially literate, or shall become
financially literate within a reasonable period of time after
appointment to the committee, and at least one member shall have
accounting or related financial management expertise necessary
to be considered an audit committee financial expert
in accordance with the rules of the Commission. The Board
determined, in May 2006, that Mr. Finn Berg Jacobsen,
Chairman of the Audit Committee, qualifies as an Audit
Committee Financial Expert pursuant to these rules, based
on his attributes, education and experience. In addition, the
Board also determined, in May 2006, that all of the members of
the Audit Committee qualify as financially literate.
The current members of the Audit Committee are Finn Berg
Jacobsen (Chairman), Ramon M. Perez and Peter G. Tombros, none
of whom serves on more than three audit committees of public
companies. The Audit Committee, in its predecessor form, the
Audit and Corporate Governance Committee, held ten meetings in
2006.
Compensation
Committee
The Compensation Committee has the authority of the Board with
respect to the compensation, benefit and employment policies and
arrangements for directors, the CEO, executive officers and
other key employees of the Company. The committee leads the
processes for CEO succession planning and CEO performance
evaluation. The committee also has authority with respect to the
compensation and benefit plans generally applicable to the
Companys employees. The Compensation Committee has a
charter which governs its operations and requires that the
committee be comprised of at least three directors, each of whom
are independent directors. (See Corporate
Governance; Board and Committee Independence above for a
description of such independence criteria.) The current members
of the Compensation Committee are Ramon M. Perez (Chairman),
Peter G. Tombros, and Finn Berg Jacobsen. The Compensation
Committee held 16 meetings in 2006.
11
Compensation
Committee Processes and Procedures
Scope
of Authority
Generally, the Compensation Committee reviews, approves, and
modifies, as necessary, the Companys executive
compensation programs, plans and awards. It holds overall
responsibility for approving, evaluating, modifying,
terminating, and monitoring the compensation plans, policies,
and programs of the Company in regard to the CEO and members of
his senior management team, i.e., the Companys top
executives who regularly participate in management decisions
regarding the Company (referred to throughout this Proxy
Statement as the Leadership Team). The Compensation
Committee also maintains authority over all aspects of general
benefit plans of the Company, to the extent that such plans have
either a substantial financial impact on the Company, or provide
benefits intended primarily for the CEO or members of the
Leadership Team.
In carrying out its duties and responsibilities, the
Compensation Committee may delegate its authority to a
subcommittee of one or more Compensation Committee members. In
2006 the Compensation Committee retained all of its primary
duties and responsibilities, with the exception of:
|
|
|
|
|
Delegating duties relating to the search for a new CEO due to
the announced retirement of Ingrid Wiik. These duties were
delegated to the CEO Search Committee, a
sub-committee
of the Compensation Committee; and
|
|
|
|
Approving a resolution granting the Chairman of the Compensation
Committee the authority to approve employment arrangements or
other employment actions requiring Compensation Committee
approval under the Corporations Contract Policy.
|
In addition, the Board delegated to a Benefits Committee
(comprised of senior management members) duties pertaining to
administrative amendments to the Companys benefit plans.
Role
of Executives
The CEO and EVP, HR and Communications (EVP, HR)
attend all of the Compensation Committees meetings.
However, the Compensation Committee conducts an executive
session at the majority of these meetings without these
executives being present. Typically during executive sessions,
the Compensation Committees compensation consultant
remains to provide advice and counsel.
The CEO with the EVP, HR develop recommendations on compensation
for the Leadership Team which they present to the Compensation
Committee for consideration. During the development of these
recommendations, the executives interact with the Compensation
Committees compensation consultant to help frame the
proposals and to gain a better understanding of what the
Compensation Committees position might be on certain
compensation issues. As a result, while the Compensation
Committee generally does not develop its own compensation
proposals, it has taken steps to ensure that its point of view
is included in the compensation proposals put forward by
management.
The CEO with the EVP, HR have put forward recommendations to the
Committee on compensation matters, including:
|
|
|
|
|
Alignment of the Companys compensation philosophy with the
Companys strategy;
|
|
|
|
Composition of the Compensation Comparator Group (as defined
below), including defining the relevant market for talent;
|
12
|
|
|
|
|
Basic pay positioning of the Company versus the Compensation
Comparator Group, including base salary, bonus and long-term
incentives;
|
|
|
|
Specific pay levels for executives, and
|
|
|
|
Incentive design and long-term incentive vehicles.
|
Compensation
Consultant
The Compensation Committee has the authority to secure the
services of third party service providers (e.g.,
accountants, attorneys, compensation consultants and other
experts) in carrying out its duties. The Committee has retained
the services of a compensation consulting firm, Exequity LLP
(the Compensation Consultant), to assist it in
analyzing and considering compensation proposals.
The Compensation Consultant reports directly to the Chairman of
the Compensation Committee. Materials produced by the
Compensation Consultant are provided to the Chair. The Committee
has authorized the Compensation Consultant to work directly with
the Companys internal HR professionals to help develop
compensation philosophy and alternative design and benchmarking
approaches. All materials produced by the Compensation
Consultant and all recommendations of the Compensation
Consultant are provided to the Chairman of the Compensation
Committee prior to the Compensation Committee meetings at which
such issues are discussed.
The Compensation Consultant provides no services other than
executive compensation consulting services to the Company. The
Committee is copied on all final work product prepared by the
Compensation Consultant for management and receives copies of
all of the Compensation Consultants bills to the Company.
The Compensation Committee makes all decisions on the nature and
scope of the Compensation Consultants role and
interactions with the Company.
The scope and nature of the Compensation Consultants
assignments involving the Company cover the full range of
executive compensation issues. The Companys management
does not retain any compensation consultant. The Compensation
Committee, in discussion with the Companys management (to
the extent management wishes to also use the Compensation
Consultants services), determines the Compensation
Consultants assignments.
The Compensation Committee requested throughout 2006 that the
Compensation Consultant assist in conducting assessments of
market pay levels in order to help the Committee determine the
appropriate benchmark levels for various executive roles. In
addition, the Committee requested that the Compensation
Consultant help frame incentive design alternatives, and
participate in identifying alternative approaches to
compensation design and benchmarking. Further, the Compensation
Committee requested that the Compensation Consultant help in the
analysis and assessment of the appropriate compensation
philosophy applying to executive officers.
The Companys Compensation Consultant relied upon market
data provided by Hewitt Associates, primarily through its Total
Compensation Database. In this regard, Hewitt provided
competitive market data for specific executive roles in the
context of similar roles within the general pharmaceutical
industry and within general industry.
13
Corporate
Governance Principles, Business Conduct Guidelines and Code of
Ethics
The Board has adopted Corporate Governance Principles (which are
available on the Companys website at www.Alpharma.com
by clicking first on the About Alpharma tab and
then on the Our Business Guidelines tab, and in
print, without charge, to any Stockholder requesting a copy in
writing to Investor Relations at the Companys
offices in Bridgewater, New Jersey) to provide the general
framework for the governance of the Company. The Corporate
Governance Principles specifically address the role of the Board
and management, the functions of the Board, qualifications of
directors, independence of directors and committees, the
prohibition on making loans to directors and executive officers,
size of the Board and selection process, Board committees,
meetings of outside (non-management) directors, setting the
Board agenda, ethics and conflicts of interest, reporting of
concerns to the Audit Committee, Board compensation, access to
senior management and independent advisors, director orientation
and continuing education, succession planning, and the
Boards annual performance evaluation.
The Board has adopted Business Conduct Guidelines (which are
available on the Companys website at www.Alpharma.com
by clicking first on the About Alpharma tab and
then on the Our Business Guidelines tab, and in
print, without charge, to any Stockholder requesting a copy in
writing to Investor Relations at the Companys
offices in Bridgewater, New Jersey) that set forth principles
and standards to guide the business behavior of members of the
Board and Company employees worldwide. The Business Conduct
Guidelines specifically address compliance with laws (including
food and drug, environmental, copyright and competition laws),
fairness in employment, safety and health, reporting to
governmental agencies, confidentiality, the protection of
Company assets, conflicts of interest, political contributions,
the extended application of certain U.S. laws,
relationships with medical professionals, and fair dealings with
third parties.
The Board has adopted a Code of Ethics (which is available on
the Companys website at www.Alpharma.com by
clicking first on the About Alpharma tab and then on
the Our Business Guidelines tab, and in print,
without charge, to any Stockholder requesting a copy in writing
to Investor Relations at the Companys offices
in Bridgewater, New Jersey) that, in addition to the Business
Conduct Guidelines, applies to the Companys CEO, Chief
Financial Officer and Controller. The Code of Ethics requires
such officers to engage in and promote honest and ethical
conduct, protect the Companys and its customers
confidential information, produce full, fair, accurate, timely
and understandable disclosure in reports to the Commission and
other regulators and in other public communications, to comply
with applicable laws, rules and regulations of governments and
self-regulatory organizations, and to report promptly to the
Audit Committee violations of the Code of Ethics.
Director
Identification and Selection
In identifying acceptable potential director candidates, the
Nominating and Corporate Governance Committee seeks input from
Board members and other sources so that a variety of viewpoints
are considered. The Nominating and Corporate Governance
Committee may also engage independent search firms. However, the
Nominating and Corporate Governance Committee ultimately
determines which candidates are to be recommended to the Board
for approval. Board candidates are considered based on various
criteria which may change over time and as the composition of
the Board changes. At a minimum, the Nominating and Corporate
Governance Committee considers a candidates personal and
professional ethics, integrity and values, commitment to
representing the interests of the stockholders, demonstrated
wisdom and mature judgment and diversity of experience at
policy-making levels in business, government, education and
technology, and in other areas that are relevant to the
Companys global activities. The Board does not believe
that arbitrary term limits on directors service are
appropriate, nor does it believe that directors should expect to
be routinely re-nominated on an annual basis. The
14
Nominating and Corporate Governance Committee also considers
such other factors as may be appropriate including the current
composition of the Board and evaluations of prospective
candidates.
The Nominating and Corporate Governance Committee will consider
director candidates recommended by shareholders. Shareholders
wishing to submit a director candidate for consideration by the
Committee should submit the recommendation to Alpharma Inc.
Nominating and Corporate Governance Committee,
c/o Secretary, 440 Route 22, Bridgewater, New Jersey
08807 not less than 120 days nor more than 150 days
prior to the annual meeting date (determined based on the same
date as the previous years annual meeting). The request
must be in a writing setting forth the name of the person to be
nominated, the number and class of all shares of each class of
stock of the Company beneficially owned by such person, the
information regarding such person required by
paragraphs (a), (e) and (f) of Item 401
(director identification, business experience and involvement in
legal proceedings) of
Regulation S-K
adopted by the Securities and Exchange Commission (or the
corresponding provisions of any regulation subsequently adopted
by the Securities and Exchange Commission applicable to the
Company), such persons signed consent to serve as a
director of the Company if elected, such stockholders name
and address and the number and class of all shares of each class
of stock of the Company beneficially owned by such stockholder.
The Nominating and Corporate Governance Committee may also
request additional background or other information.
Executive
Sessions of Outside (Non-Management) Directors
The Chairman of the Board presides at executive sessions of
outside (non-management) directors, held at regularly scheduled
times throughout the year. Outside (non-management) directors
are those who are not Company officers. Except for
Mr. Mitchell, all of the Companys directors are
outside (non-management) directors. In addition, the independent
directors also meet periodically without the presence of
non-independent directors.
Communications
from Stockholders and Other Interested Parties
Stockholders and other interested parties may send
communications to the Board (and to individual directors)
through the Secretary of the Company, Mr. Robert F. Wrobel.
The Secretary will forward to the directors all communications
that, in his judgment, are appropriate for consideration by the
directors. The Secretary will consider most commercial
solicitations and other matters not relevant to the
Companys stockholders, the Board, or to the Company in
general, to be inappropriate for consideration by the directors.
Stockholders and other interested parties may communicate
directly with the Chairman of the Companys Audit Committee
by sending an
e-mail to
auditchair@alpharma.com. Stockholders and other
interested parties may communicate with outside (non-management)
directors, individually or as a group, by sending an
e-mail to
outsidedirectors@alpharma.com.
Compensation
Committee Interlocks and Insider Participation
During fiscal year 2006, Mr. Ramon Perez (Chairman),
Mr. Peter G. Tombros, and Mr. Finn Berg Jacobsen
served on the Compensation Committee. None of these directors
have ever been an officer or employee of the Company or any of
its subsidiaries or any other company for which an executive
officer of the Company serves as a director, nor have they
engaged during 2006 in any transaction, had any business
relationship, or incurred any indebtedness that would require
disclosure in this Proxy Statement.
15
COMPENSATION
COMMITTEE REPORT*
The Compensation Committee (we or the
Committee) has reviewed and discussed with
management the Compensation Discussion and Analysis included in
this proxy statement. Based on those reviews and discussions, we
recommended to the Board that the Compensation Discussion and
Analysis be included in this proxy statement for filing with the
Commission.
Compensation Committee
Ramon M. Perez, Chairman
Finn Berg Jacobsen
Peter G. Tombros
EXECUTIVE
COMPENSATION
Compensation
Discussion and Analysis
Activities
of the Compensation Committee in 2006
The Committee held 16 meetings in 2006. The Committee has a set
calendar for taking up routine compensation matters throughout
the year and adds items and meetings, as necessary, to address
non-routine compensation matters and developments.
At each meeting there is a standing agenda of discussion topics
to be addressed. As noted above, the Committee meetings are
generally attended by each Committee member, the CEO, the EVP,
HR, and the Compensation Consultant. In addition, in 2006 the
Committee requested that a member of the Companys Legal
Department attend each meeting in order to provide legal input
to the matters discussed during the meetings.
In addition to making all decisions on the compensation and
benefit arrangements covering the Companys Leadership
Team, the Committee in 2006 also:
|
|
|
|
|
Evaluated the overall executive compensation philosophy,
positioning, and benchmarking, and made changes as discussed
throughout this Compensation Discussion and Analysis;
|
|
|
|
Participated in the review of CEO candidates, and the hiring
decisions pertaining to the Companys new CEO, Dean
Mitchell, who started with the Company in July 2006;
|
|
|
|
Facilitated the transition between the Companys former
CEO, Ingrid Wiik, who retired in June 2006, and the new CEO;
|
|
|
|
Evaluated the succession needs and assessed pay positioning with
respect to executives who left during 2006 (Matthew Farrell,
EVP, Finance and CFO, and George Rose, EVP, Human Resources and
Communications), to those who announced their intent to retire
(Robert Wrobel, EVP, Chief Legal Officer and Secretary), and to
new hires (Stephan Aigner, EVP, Business Development);
|
* This Compensation Committee Report is not deemed
incorporated by reference by any general statement incorporating
by reference this Proxy Statement into any filing under the
Securities Act or the Securities Exchange Act, except to the
extent that the Company specifically incorporates this
information by reference, and shall not otherwise be deemed
filed under either of such Acts.
16
|
|
|
|
|
Reviewed the performance of the Companys Leadership Team,
and approved pay decisions commensurate with that performance;
|
|
|
|
Reviewed other aspects of the Companys relationship with
its top executives, such as share ownership by these
individuals, succession planning, severance plan design, and the
ability of the Company to recruit and retain the desired level
of executive talent;
|
|
|
|
Reviewed the treatment of outstanding equity-based awards with
respect to the impact of dividends paid on the Company stock;
|
|
|
|
Reviewed the regulatory influences on executive pay in
2006; and
|
|
|
|
Conducted a review and assessment of the Committees own
activities and performance.
|
Throughout early 2007, the Compensation Committee worked with
the CEO and EVP, HR to determine the appropriate terms of
transition of Mr. Campbell from interim Chief Financial
Officer to fully appointed Chief Financial Officer.
General
Compensation Philosophy
In 2006 the Compensation Committee undertook a study to help
foster tight alignment between the Companys new strategic
direction and the compensation programs that are made available
to the Companys executives. This study identified several
executive attributes that should be supported by prospective pay
arrangements:
|
|
|
|
|
A mindset focused on strategic corporate directives;
|
|
|
|
Orientation toward growth and the corporate actions necessary to
spur that growth;
|
|
|
|
Comfort with balanced business risk; and
|
|
|
|
Acceptance of leveraged compensation opportunities that deliver
targeted value only when strict performance expectations are
accomplished.
|
The Compensation Committee believes that the Companys
prospective strategic operating objectives will be best
supported by executives who exhibit the above attributes. The
Committee also believes that alignment of the Companys
executive pay programs with these attributes suggests the
advisability of making some changes in the design and
positioning of current executive compensation programs. In
particular, the Companys pay programs should:
|
|
|
|
|
Be supportive of a high-performance culture;
|
|
|
|
Offer competitive levels of pay opportunities, when evaluated
against executive positions within similar organizations and
operations;
|
|
|
|
Introduce a significant degree of variability of pay outcome,
consistent with business results over the period that each
incentive opportunity is outstanding;
|
|
|
|
Reward contributions to Company growth and shareholder value
creation; and
|
|
|
|
Reward teamwork and individual excellence.
|
The above considerations indicate a shift in emphasis toward a
higher degree of variable pay. In addition, the Committee
believes that executive pay opportunities should focus in a more
tailored way on each executives
line-of-sight
authority and accountabilities. Accordingly, the Committee is
receptive to allowing some variance
17
between internal pay positioning, with the objective of crafting
appropriate opportunities based on each executives
specific contributions and potential. At the same time, the
Committee desires to maintain a significant degree of internal
parity in order to encourage teamwork across functions.
Specific
Pay Positioning
The principles outlined above contributed to some changes in
2006 with respect to the positioning of executive pay. Because
the parameters that were applied to pay decisions in early 2006
(Pre-Transition Positioning) were different than
those that were applied toward the end of 2006
(Post-Transition Positioning), the following
discussion provides details regarding the pay positioning
principles during each of these periods:
Pre-Transition
Positioning
The sale of the Generics division of the Company in December
2005 resulted in significant changes in the size and operational
mix of the Company. Soon after close of the sale, the Company
announced that it was considering strategic
alternatives for the remaining business, introducing
uncertainty and potentially fueling talent flight at a critical
juncture in the Companys history.
This all occurred at the same time that 2006 pay decisions were
being made. In order to help promote stability through this
period, the Compensation Committee elected in 2006 to maintain
the basic pay positioning that applied in 2005 and earlier
years. Accordingly, the pay positioning in the Pre-Transition
period applied the following principles that guided pay
decisions in 2005 and earlier (note that the following
description provides the rationale behind the overall decisions
that were made by the Committee on executive pay, but that
certain exceptions were made in the case of top executives who
departed during the year (Ingrid Wiik and Matthew Farrell), as
well as the Companys new CEO who was hired during 2006
(Dean Mitchell) and the then interim CFO (Jeffrey Campbell);
these exceptions are discussed separately below and within the
section of this proxy entitled Potential Payments upon
Termination or Change in Control):
|
|
|
|
|
Peer Companies: The same companies used as a
reference in 2005 for executive pay levels and design were used
during this period. Due to varying degrees of data availability
for certain executive positions, as well as data sources that
were more relevant for some segments of the Companys
employee population, the peer groups that were used as primary
and secondary market references varied somewhat by executive
position. Details on the three primary data sources and their
use in the Pre-Transition period are as follows:
|
|
|
|
|
|
CEO and CFO Positions: Publicly disclosed data
on the pay of similarly situated executives among the targeted
peer organizations is readily available, so proxy disclosures of
the peer companies were used as a primary reference point for
determining the market pay for the CEO and CFO roles. A list of
comparable
|
18
|
|
|
|
|
specialty pharmaceuticals was compiled in
consultation between management and the Compensation Committee.
These companies were:
|
|
|
|
Axcan
|
|
Medicis
|
Biovail
|
|
MGI
|
Cephalon
|
|
Noven
|
Connetics
|
|
Pharmion
|
Endo
|
|
QLT
|
First Horizon
|
|
Salix
|
Forest
|
|
Shire
|
King
|
|
Watson
|
KOS
|
|
|
In addition, data from Hewitt Associates Total
Compensation Measurement DataBase (TCM) was
referenced in cases in which the TCM system included data from
companies involved in the specialty pharmaceutical industry.
These companies included:
|
|
|
Allergan
|
|
Mylan
|
Barr
|
|
Perrigo
|
Forest
|
|
Valeant
|
Ivax
|
|
Watson
|
King
|
|
|
|
|
|
|
|
Business Unit Heads and Top Corporate Staff Positions: The
available proxy disclosures described above provide less robust
data for executive positions other than the CEO and CFO roles.
Accordingly, a more comprehensive source of data for these
positions was needed. In addition, since the relevant talent
market includes large pharmaceuticals, pay data from these
companies was viewed by the Committee as relevant in determining
appropriate pay levels at the Company.
|
The Committee determined the appropriate market levels of pay
for these positions through primary reference to TCM, with
specific focus on comparable positions within the pharmaceutical
companies participating in TCM. The companies included within
Hewitts TCM system that were referenced as part of large
pharmaceutical organizations were:
|
|
|
Abbott
|
|
Merck
|
Alcon
|
|
Mylan
|
Allergan
|
|
Novartis
|
Amgen
|
|
Novo Nordisk
|
AstraZenica
|
|
Pfizer
|
Bristol-Myers Squibb
|
|
Schering-Plough
|
CIBA Vision
|
|
Takeda
|
Eli Lilly
|
|
TAP
|
J&J
|
|
Wyeth
|
In cases in which this data required supplementation, the
Committee also received data on general industry practices from
Hewitts TCM. This data set provides a more comprehensive
source of pay
19
information, albeit from broader industry sources than pure
pharmaceuticals. The Committee deemed this information to be
important not only for purposes of supplementing the available
data from pharmaceutical companies, but also due to the fact
that general industry serves as a source of executive talent.
Representative companies from Hewitts general industry TCM
database include:
|
|
|
Advo
|
|
Medtronic
|
Allergan
|
|
Quest Diagnostics
|
ALLTEL
|
|
Rayonier
|
Anadarko
|
|
Tribune Co
|
Clorox
|
|
Viad
|
Ecolab
|
|
Vulcan Materials
|
Fortune Brands
|
|
Waters Corp
|
Kohls
|
|
Williams-Sonoma
|
|
|
|
|
|
Other Executive Positions: The Committee
relied upon data from both general industry and pharmaceutical
cuts from Hewitts TCM, depending upon the degree of
relevance of each talent pool for each given executive role, as
well as the degree to which each role had sufficient data
references available.
|
|
|
|
|
|
Pay Level Benchmarking: Throughout 2005,
each major element of pay (base pay, targeted bonus, and
long-term incentive grant-date values), as well as the total
value of the compensation program for each executive, was
targeted at the median pay levels among the identified peer
group. Pay decisions for 2006 were addressed during the period
in which the sale of Generics was completed, as well as during
the period that the Company had announced that it was pursuing
strategic alternatives.
|
In order to minimize disruption through this period, the
Compensation Committee sought to maintain as much stability
through the pay program as possible. With this goal, the
Committee decided to leave in place all levels of pay and the
general pay design applying to executive pay opportunities.
Accordingly, base pay levels, targeted bonus opportunities, and
long-term incentive award grant values for 2006 were set at
levels equal to 2005 levels. Benchmarking of competitive pay
opportunities among the peer companies was done by regressing
the peer company data to the 2005 revenue level of the Company.
The Committee also determined that the general pay positioning
principles that existed before the Generics sale would be
continued indefinitely for executives whose employment with the
Company pre-dated the sale. In contrast, for executives hired
after the Generics sale, the new pay positioning (described
below under Post-Transition Positioning) principles
would apply.
The Companys pay positioning generally resulted in total
compensation opportunities (other than for the two CEOs who
served during 2006, discussed below in this section) that
approximate
50th percentile
levels when measured against companies of a similar size prior
the Companys sale of the Generics business unit. When
measured against companies having similar revenues to the
Company after the Generics sale, the total targeted compensation
opportunities of the Companys top executives generally
exceeded
50th percentile
levels by 50%-60%. However, actual bonuses paid in 2006 (for
2005 performance) were significantly below median levels,
drawing total compensation actually delivered closer to
50th percentile
levels when regressing to the post-Generics sale revenues.
20
Ingrid Wiiks total targeted compensation was 5% above the
50th percentile
level when measured against the Companys post-Generics
sale revenue size. Ms. Wiiks total compensation
delivered was 4% above the 50th percentile level of the
Specialty Pharmaceutical peer group.
Dean Mitchell was offered sign-on inducements to recruit him to
serve as the Companys CEO after Ingrid Wiiks
retirement. These sign-on awards resulted in total compensation
opportunities for Mr. Mitchell in 2006 which fell slightly
below the
50th percentile
levels of the Specialty Pharmaceutical peer group (even when
allocating the entire value of the sign-on awards to 2006). The
total pay package offered to Mr. Mitchell in 2006 exceeded
the
50th percentile
of the general industry peer group (regressed to the
Companys post-Generics sale size) by 65%, but was 14% over
the median of this peer comparison when excluding the value of
the sign-on award.
|
|
|
|
|
Incentive Opportunities: The Companys
incentive arrangements for executives consist of annual bonus
and long-term incentive opportunities. These incentives align
management with critical Company goals, helping promote the
accomplishment of near-term and long-term performance along the
lines deemed important by the Committee. In addition, the design
and operation of these arrangements are generally consistent
with marketplace practices, and the Committee feels it
appropriate to provide overall pay opportunities that make the
Companys compensation program competitive with those of
the Companys competitors for talent.
|
In 2006, the Committee provided for the following incentive
arrangements:
|
|
|
|
|
Annual Bonus in 2006: As noted above, the targeted bonus
opportunities for 2006 were established at the same levels as
existed in 2005, before the sale of Generics. In order to
further maintain consistency of the pay program between 2005 and
2006 (and thereby further promote stability in the wake of the
Generics sale), the basic operation of the program was retained
for 2006.
|
Further, since the Companys financial operating objectives
in 2006 were similar to 2005, the performance metrics in 2006
were the same as those used in the executive bonus program in
2005 (Operating Income and Cash Flow). With respect to the
corporate-wide performance goals, these metrics were measured at
the consolidated corporation level. In cases in which an
executive is head of an operating unit, the Operating Income and
Cash Flow metrics were also measured at the business unit level.
The Committee believes that in 2006 these metrics continued to
best reflect the executive teams success in contributing
to disciplined company growth. In addition, these metrics are
widely understood and accepted among the executive team, and are
representative of typical annual bonus program design, and
thereby contribute to the degree of conformity with market
practice.
The relationship between targeted bonus amounts and base pay for
Leadership Team members in 2006 was also the same as that in
2005 (targeted bonus of 100% of base pay for the CEO and 50% of
base pay for the other members of the Leadership Team). The
Committee feels it is important to maintain the consistency of
this relationship across the members of the Leadership Team in
order to encourage a common focus and teamwork among these top
executives.
Consistent with the notion of maintaining the general design and
operation of the 2005 Leadership Team bonus opportunities into
2006, the Committee established the same relative performance
metric weightings for top executives in 2006 as was the case in
2005. Specifically, the members of the Leadership Team had 70%
of their total annual bonus opportunity tied to the achievement
of corporate results at the consolidated corporation level, and
30% of the opportunity tied to the accomplishment of goals
relating to each executives business unit or function, as
appropriate. The Committee believes that
21
this created the appropriate
line-of-sight
accountability for each executive, based on relative
contribution to overall corporate results vs. line of business
or functional results.
The performance-payout relationship for the 2006 annual bonus
opportunity for members of the Leadership Team also continued
the 2005 design, as follows:
|
|
|
Percentage of Corporate/Business Unit
|
|
Funding Percentage (Percent of Total
|
Operating Income and Cash Flow Goals
|
|
Target Payouts for Combined Operating
|
Achieved
|
|
Income and Cash Flow Components)
|
|
Less than 80%
|
|
Some funding may be available at
senior leaderships discretion to reward top performers
|
80%
|
|
40%
|
90%
|
|
80%
|
100% (target)
|
|
100%
|
110%
|
|
120%
|
120%
|
|
150%
|
Above 120%
|
|
Discretionary
|
The Committee believes that the above performance-payout
relationships appropriately reward performance above targeted
levels, and provides for significantly reduced payouts when
performance falls short of goals. The Committee feels the steep
performance-payout slope is properly reflective of the desired
performance-based culture sought at the Company.
Application of the payout formula, which the Compensation
Committee believes was set both individually and
collectively at aggressive levels in order to
motivate superior performance, yielded average incentive
payments ranging from approximately 92% to 110% of target levels.
|
|
|
|
|
Long-Term Incentive Awards in 2006: In 2006 the
Committee also desired to maintain general incentive
opportunities in 2006 along lines consistent with 2005
practices. This called for a balance of highly leveraged
opportunities in the form of stock options and vehicles that
would help promote retention of key employees through the
announced review of strategic alternatives (restricted stock).
This award mix served the dual roles of linking executives
tightly with the return of shareholders and invoking retention
incentives to preserve the executive team through a period of
substantial change.
|
The above considerations resulted in awards of equity-based
long-term incentives in 2006 having the following
characteristics:
|
|
|
|
|
Grant-date values of the aggregate awards to each top executive
equal to the grant-date values of long-term incentive vehicles
granted in 2005;
|
|
|
|
50% of the grant-date value being delivered in the form of stock
options and the remaining 50% being delivered in the form of
restricted shares; and
|
|
|
|
Vesting and other terms of the awards being consistent with
awards made in 2005 stock options vest on a graded
basis over the four-year period after grant, and restricted
stock granted to members of the Leadership Team vests 100% at
the end of the three-year period following grant.
|
Consistent with past practice, regular annual awards of
equity-based incentives in 2006 were generally made in late
February and early March. Dean Mitchell was granted equity-based
long-term incentives on July 3, 2006, the first business
day after his employment commencement date with the Company.
22
As has been the Companys practice in past years, all
options were granted with an exercise price equal to the
Companys closing stock price on the date of grant. The
Committee believes that this is the most appropriate benchmark
for stock price on the date of grant.
|
|
|
|
|
Conversion of Performance Units: Due to the impact of the sale
of the Generics business in 2005, the operation of the
performance metrics associated with outstanding performance
units (initially granted in 2004) was dramatically changed.
Originally, the degree of earning of these performance units was
based on the Companys total shareholder return vs. that of
a group of identified peer companies. The peer group of
companies was identified significantly before the sale of the
Generics business, and reflected a group of large diversified
pharmaceuticals that were much more representative of the
Companys mix of business operations prior to the Generics
sale than after.
|
The scope of the changes brought about by the Generics sale made
it inappropriate to continue to track the pre-selected peer
group of companies. In the Committees opinion, the
Generics sale so changed the basic operation of the performance
metrics under the performance unit program that the outstanding
awards had to be revised to more appropriately motivate behavior
within the post-sale organization. Therefore, the Compensation
Committee determined that because the peer group of companies
was no longer applicable, each outstanding performance unit
should be valued at the
60th percentile,
which equals $100 per unit. The vesting of performance
units awards remains unchanged (i.e., at the end of the
scheduled three-year performance period), and if a holder of an
award were to voluntarily terminate employment prior to vesting,
the entire unpaid balance would be forfeited. Specifically,
performance units granted in 2004 vested on December 31,
2006 and performance units granted in 2005 will vest on
December 31, 2007.
|
|
|
|
|
Retention Incentives: The sale of Generics and the following
announcement that strategic alternatives by the Company would be
reviewed created a significant risk to retention of key
executive talent. In order to help minimize the potential talent
flight, at the end of 2005 the Company extended cash-based
retention opportunities to the Leadership Team and selected
other individuals, contingent on continued employment through
specified vesting dates. The value of these retention incentives
was established by reference to median market practices in the
context of retention awards during a period of corporate
restructuring. These retention arrangements were incorporated
within contracts that also provide the terms of severance
protections associated with any possible future change in
control of the Company.
|
Specifically, the retention incentives of each of the top
executives listed in this proxy as a named executive officer
(and who was employed by the Company immediately after the close
of the Generics sale in December 2005) except Ms. Wiik
and Mr. Campbell had a total potential value equal to the
executives then current annual base salary plus target
bonus. The retention incentives vested one-third on
June 30, 2006, one-third on December 29, 2006, and the
final one-third will vest on June 29, 2007. However, if an
executive voluntarily terminates employment prior to a vesting
date, all unvested amounts of the retention incentive are
forfeited at that point.
Post-Transition
Positioning
As noted above, the Companys pay positioning and
benchmarking was revised in 2006 in the aftermath of the sale of
Generics. The Generics sale significantly reduced the overall
size of the organization and changed the mix of operations.
While this change had a substantial impact on executives at the
corporate level, the impact on executives within the surviving
operating units was less significant, as these operations
generally are run fairly autonomously.
23
In addition to the operational changes brought about by the sale
of Generics, the composition of the Compensation Committee was
substantially changed mid-year (due to the overall reduction in
Board seats), and Mr. Mitchell was hired as the new CEO
after the retirement of Ms. Wiik. Further, the Company
undertook a review of the organizations strategy, which
indicated certain directional changes in 2006 and beyond. These
events all contributed to a fresh review in 2006 of the general
pay positioning and benchmarking, as well as a review of the
peer groups of companies against which compensation comparisons
are made.
It is important to note in this regard that, while the
directional changes in compensation positioning were agreed upon
by management and the Compensation Committee in 2006, the impact
of these new principles on actual pay decisions will not occur
until 2007, and will be phased-in over multiple years. This
portion of the Compensation Discussion and Analysis describes
the changes in compensation design and targeting that occurred
in 2006 as a result of these events:
|
|
|
|
|
Peer Companies: The same basic principles will
be applied in 2007 to the composition of compensation peer
groups as were applied in 2006. However, given the changes in
the Companys operational mix and size, the actual
companies in the peer groups will change somewhat, as follows:
|
|
|
|
|
|
Leadership Team Members: The primary reference for pay
benchmarking of Leadership Team members in 2007 is top executive
pay among specialty pharmaceutical companies. Given the
Companys increasing alignment with strategic operational
directions among specialty pharmaceutical companies, the
Committee feels it is most appropriate to reward top executives
in line with prevalent practices within this industry.
|
The new strategic focus will require executive leadership that
has a skill set and mindset consistent with top leaders of
companies in the specialty pharmaceutical industry. Accordingly,
the most relevant talent pool for executive leadership will
increasingly be the specialty pharmaceutical industry.
The Compensation Committee, in conjunction with top management,
has identified a group of specialty pharmaceutical companies
that best represent the Companys strategic positioning
within this industry. The specialty pharmaceutical companies
used as a peer group in this regard for 2007 are:
|
|
|
Allergan
|
|
KOS
|
Axcan
|
|
Medicis
|
Biovail
|
|
MGI
|
Cephalon
|
|
Noven
|
Connetics
|
|
Pharmion
|
Endo
|
|
QLT
|
First Horizon (now Sciete)
|
|
Salix
|
Forest
|
|
Shire
|
King
|
|
Valeant
|
Because this peer group of companies has been specially
identified for this purpose, the Committee is limited in its
review of executive pay practices among these companies to
disclosures included within public filings. Further, because of
the necessary reliance on proxy statement disclosures of pay
(which are generally limited to a companys top five
highest-paid executives), information from this source is
necessarily limited.
Accordingly, the Committee has reviewed the pay practices among
these companies with respect to the three top executive
positions that are commonly included among the top five
highest-paid the CEO,
24
the CFO, and the General Counsel positions. The pay data for
these positions within the selected group of specialty
pharmaceutical companies is relatively robust, and the Committee
has made primary reference to these practices when evaluating
the appropriate pay positioning for 2007. However, the Committee
also feels it is advisable to further review the pay practices
among general pharmaceutical companies, and has evaluated the
pay of top leaders among these peer companies as well.
Although information on specific pay levels of executives below
the CEO, CFO, and General Counsel positions is sparse,
significant information on general incentive design among these
companies is available through proxy filings. Accordingly, while
tailored pay benchmarking below the CEO, CFO, and General
Counsel positions is not possible, the Committee has evaluated
general pay design and relative levels, and has applied these
general precepts to the pay design and relative pay levels
of Leadership Team members in general.
In order to help fill in some of the information gap arising as
a result of the sparse publicly available data pertaining to top
executive pay among specialty pharmaceutical companies, the
Committee also reviewed pay data from more robust sources of
information. In particular, the Hewitt TCM database provides
substantial pay level and design information relating to
companies within the general pharmaceutical industry, as well as
companies more broadly within general industry. Due to the fact
that the Companys location plays a significant role in
defining the available talent pool, when evaluating companies in
general industry, the Committee placed particular emphasis on
pay practices among manufacturing companies within the
Northeastern United States.
For purposes of compiling a compensation peer group reflecting
the general pharmaceutical industry, the same basic
pharmaceutical companies will be referenced in 2007 as were
referenced for Business Unit Heads and top corporate staff
positions in 2006 (described above in the Compensation
Discussion and Analysis under Pre-Transition
Positioning). There may be some minor changes due to data
availability within Hewitts TCM system, but the same group
will be referenced, to the extent available.
There will be a change in 2007 to the secondary set of peer
companies referenced for purposes of gaining insight into pay
practices among companies involved in general industry (beyond
pure pharmaceuticals). Specifically, this secondary reference
will be made to industrial companies within Hewitts TCM
system, but only with respect to such companies that have
significant employee populations in the Northeast United States.
This focus will help tailor pay comparisons to regional norms,
thus helping tailor comparisons more narrowly to the
Companys talent pool.
|
|
|
|
|
Other Executive Positions: As was the case in 2006, the
Committee will primarily refer to the general pharmaceutical
company and general industry peer groups for purposes of
benchmarking market pay for these positions. The Committee feels
that these peer groups provide the most relevant data set in
determining competitive pay levels for these roles. As is the
case with executives within the business units, the Committee
will apply general design principles and will reference general
pay alignment among companies within the specialty
pharmaceutical industry. In this regard, the Committee feels it
is important to maintain a significant amount of internal
parity both in terms of general design of
compensation arrangements, and in terms of relative pay levels.
|
In addition to referring to the competitive data sources
described above, the Compensation Committee will apply
subjective discretion in determining the specific pay of
individual executives. In this regard, the Committee desires to
engender general internal parity among comparable roles within
the Company, but also preserves the discretion to deviate from a
pure focus on market pay levels when necessary to recruit
25
and/or
retain the right executive talent. Accordingly, exceptions to
the general market positioning will exist where the Committee
deems it advisable to secure the services of key executive
talent.
|
|
|
|
|
Pay Level Benchmarking: The Compensation
Committee has established general prospective competitive pay
benchmarking objectives as follows:
|
|
|
|
|
|
Base Pay:
50th percentile
levels among the relevant peer organizations;
|
|
|
|
Targeted Bonus: In general,
50th percentile
levels among the relevant peer organizations, but also provide
continuity with respect to the existing parity of bonus targets
among Leadership Team members (100% of base pay for the CEO as
required by contract, and 50% of base pay for other members of
the Leadership Team);
|
|
|
|
Long-Term Incentives: Grant-date targeted values established at
50th-75th percentile
levels among the relevant peer organizations in 2007, with the
goal of phasing-in alignment with 75th percentile levels
over a
two-to-three-year
period; and
|
|
|
|
Resulting Overall Targeted Pay:
50th-75th percentile
levels when compared to the relevant peer organizations.
Alignment with the targeted total pay objective is scheduled to
occur over a
two-to-
three-year transition period, with the understanding that
Leadership Team total pay in 2007 will generally fall below the
ultimate targeted benchmark levels. The Committee preserves the
flexibility to make exceptions to the above general principles
in order to respond to competitive market forces impacting
selected individuals, and in order to properly adjust to
specific talent needs that may merit individualized arrangements.
|
The Committee believes that the above benchmarks most
appropriately support the prospective strategic objectives of
the Company, as articulated above in this Compensation
Discussion and Analysis. In particular, a heightened focus on
growth and strategic advances in 2007 and ensuing years, as well
as the recruitment and retention of executives who embrace
leveraged opportunities tied to stretch performance objectives,
will be supported by the elevated emphasis on long-term
incentive opportunities.
|
|
|
|
|
Incentive Opportunities: As was the case in
2006, the Companys incentive opportunities in 2007 will
consist of annual bonus and long-term incentive arrangements.
The Committee has established the split between the equity and
non-equity components of compensation in a manner consistent
with typical market practices among the peer companies. In 2006,
this relationship was aligned with typical practices among
companies within the general pharmaceutical industry. For 2007,
the proportion of total pay opportunities associated with
equity-based incentives will increase, consistent with prevalent
practices among specialty pharmaceutical companies.
|
|
|
|
|
|
The basic operation of the annual bonus program will be similar
to that employed in 2006, with the following differences:
|
|
|
|
|
|
The mix of performance metrics will emphasize each
executives specific
line-of-sight
responsibilities and accountabilities to a greater extent. For
example, the percentage influence of overall corporate results
for Leadership Team members will increase from 70% (in
2006) to 80% (in 2007). Similarly, leaders within the
business units will have a larger percentage of their bonus
opportunity tied to the achievement of business unit results.
The Committee believes that execution on the Companys
prospective strategic plans will be supported by this
fine-tuning of the performance metrics.
|
|
|
|
The
pay-for-performance
curve will be steeper, with more quickly escalating payouts for
performance above target. In addition, the maximum payout
opportunity for Leadership Team members will be increased from
150% of target to 200%, predicated on the achievement of
performance levels at least
|
26
|
|
|
|
|
135% of targeted objectives. The Committee believes that this
more steeply-sloped performance-payout relationship better
supports the Companys strategic goals for 2007 and beyond.
|
|
|
|
|
|
Revenue Growth will be added as a performance metric. The
Companys heightened emphasis on growth will be supported
by the addition of this factor.
|
The Companys evolving strategic operating goals also
suggest the need to refine the mix of long-term incentives
granted to executives. The Committee believes that the
Companys move toward a more growth-oriented strategy
suggests that more leverage should be introduced into the
long-term incentive program.
Accordingly, top executives in 2007 will receive a mix of
options (representing 75% of the overall grant value), and
performance-based restricted stock units (representing 25% of
the overall grant value). This award mix will promote a steeper
performance-payout relationship, thereby adding more leverage to
the long-term incentive than existed in 2005 and 2006, when the
award mix was 50% options and 50% restricted shares. This
steeper slope is consistent with the general incentive move
toward more leveraged incentive opportunities.
Elements
of Compensation
The Committee has approved each element of compensation
delivered to named executive officers, and has applied the
principals described above to arrive at the established pay
levels and designs. Some of the rationale underlying the choices
with respect to which elements of pay are offered were:
|
|
|
|
|
Base Pay: The Committee views competitive base
pay as an essential part of recruiting and retaining the talent
necessary to drive the Companys goals. The Committee
believes that the Companys position of providing
50th percentile base pay levels helps establish the
foundation of a competitive compensation program that
facilitates the Companys recruiting and retention efforts.
|
|
|
|
Annual Bonus: As is the case with base pay,
the Committee believes that competitive targeted bonus
opportunities are a necessary part of offering a compensation
program that will attract and retain the desired executive
talent. In this regard, the Committee feels that establishing
targeted bonus opportunities at the 50th percentile levels
fosters this goal in an appropriate fashion.
|
As noted above in this Compensation Discussion and Analysis, the
Committee seeks to drive its pay-for performance culture goals
by establishing bonus opportunities that have a steep
pay-for-performance
slope. This sort of leveraged relationship attracts executives
who are confident in their ability to drive superior
performance, and also are accepting of the fact that
above-median bonus payouts are inappropriate in years in which
targeted performance is not achieved.
|
|
|
|
|
Long-Term Incentives: The Committees
beliefs with respect to engendering a
pay-for-performance
culture apply equally in the case of long-term incentive
opportunities. In addition to attracting executives with the
desired
pay-for-performance
mindset, competitive long-term incentive opportunities are a
critical part of the establishment of a compensation program
that offers competitive overall compensation opportunities.
|
As noted above in this Compensation Discussion and Analysis, the
Committee seeks to increase the role of long-term incentive
opportunities at the Company. The Committee believes that the
Companys evolving strategic direction is best supported
through a greater emphasis on incentives tied to the performance
of the Companys stock over
three-to-four-year
periods. Accordingly, in addition to employees at the Vice
President and Director levels having the opportunity to receive
long-term incentives, in 2007 the Committee
27
authorized the allocation of 25,000 shares of Restricted
Stock to a special CEO award pool which will be primarily
targeted toward Managers to acknowledge special contributions
and to retain high potential individuals.
|
|
|
|
|
Change in Control/General Severance
Coverage: The section of this proxy entitled
Change in Control/Termination Payments provides a
comprehensive description of the various severance benefits
offered by the Company to its executive officers. The Committee
believes that offering termination protection along the lines
provided in the Companys severance programs is an
important element of providing total compensation and benefits
that is competitive with the Companys competitors for
executive talent.
|
Consistent with general market practice, and in line with the
objective of offering compensation arrangements aligned with
median practices, the vesting of equity-based incentives that
are outstanding at the time of a Change in Control is
accelerated upon consummation of the transaction. The Committee
believes that, in addition to providing market-competitive
coverage, this single trigger activation provision
appropriately protects incentive values that have been earned up
to the point of a transaction. In addition, the vesting
activation encourages the successor entity to implement new
arrangements aligned with post-change in control objectives
following the close of the transaction.
In order to further align with competitive market practices,
cash severance protections associated with a qualifying
termination following a change in control become activated only
upon the employment termination (i.e., double
trigger activation). The Committee believes that, in
addition to aligning with prevalent practices, this design helps
encourage executive retention following a transaction.
|
|
|
|
|
Retirement, Savings, and Deferred Compensation
Programs: The Committee believes that a
contemporary retirement program is essential to help eligible
employees accumulate financial resources for retirement. In this
regard, the Committee feels that the 401(k) Savings Plan, the
Supplemental Savings Plan and the Employee Stock Purchase Plan
achieve this goal.
|
|
|
|
Health, Life Insurance, Disability, and Similar
Benefits: The Committee recognizes that the
Companys greatest resource is its employees, and therefore
feels that it is appropriate to offer comprehensive and
affordable health and welfare benefits to eligible employees and
their eligible family members.
|
|
|
|
Other Benefits and Perquisites: As is the case
with Retirement, Savings, and Health and Welfare Benefits, the
Committee believes that additional benefits such as paid time
off and tuition assistance are a necessary part of offering
eligible employees a competitive and comprehensive benefits
package.
|
Certain employees are also eligible to receive an Executive
Allowance, including the CEO ($35,000 per annum), the Leadership
Team ($28,600 per annum) and Vice Presidents
($23,400 per annum). The Executive Allowance is delivered
in lieu of executive perquisites. This arrangement provides
comparable value to executives to executive perquisites commonly
offered to similarly situated officers.
|
|
|
|
|
Impact of Regulatory and Similar
Requirements: Section 162(m) of the Internal
Revenue Code of 1986, as amended, places a limit of $1,000,000
on the annual amount of compensation (other than compensation
that qualifies as qualified performance-based
compensation) that publicly held companies may deduct for
federal income tax purposes for certain executive officers.
|
The Committee believes that tax deductibility is an important
factor, but only one factor, to be considered in evaluating a
compensation program. Thus, while our performance-based
incentive plans have generally been designed and administered to
maintain tax deductibility, including shareholder approval of
the plans, the Company believes competitive and other
circumstances may require, in some instances, that the interests
28
of the Company and its shareholders are best served by providing
compensation that is not fully tax deductible. Accordingly, the
Committee may continue to exercise discretion to provide base
salaries or other compensation that may not be fully tax
deductible to the Company.
Many other tax code requirements, SEC regulations and accounting
rules affect the delivery of executive pay and are generally
taken into consideration as programs are designed and developed.
The Companys goal is to create and maintain plans that are
in full compliance with these requirements, and that provide for
the most efficient delivery of compensation, both with respect
to payment by the Company and receipt by the employee. These
include but are not limited to FAS 123R and IRC 409A, and
Section 16 of the Securities and Exchange Act.
Appointment
of Jeffrey S. Campbell to Chief Financial Officer Role
In early 2007, the Compensation Committee worked with the CEO
and EVP, HR to establish the appropriate employment terms
associated with the transition of Mr. Campbell from VP,
Finance and interim Chief Financial Officer to Executive Vice
President and Chief Financial Officer. The pay decisions were
based on alignment of Mr. Campbells total
compensation opportunities with the pay benchmarking principals
described above, under Post-Transition Positioning.
29
SUMMARY
COMPENSATION TABLE
The following table provides information concerning the
compensation of the Chief Executive Officer, the Chief Financial
Officer, the former Chief Executive Officer, the former Chief
Financial Officer, and the three other most highly compensated
executive officers (the named executive officers) for fiscal
2006.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Change in
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Pension
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Value and
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Nonqualified
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stock
|
|
|
Option
|
|
|
Non-equity
|
|
|
Deferred
|
|
|
All Other
|
|
|
|
|
|
|
|
|
|
Salary
|
|
|
Bonus
|
|
|
Awards
|
|
|
Awards
|
|
|
Incentive Plan
|
|
|
Compensation
|
|
|
Compensation
|
|
|
Total
|
|
|
|
Year
|
|
|
($)
|
|
|
($)
|
|
|
($)
|
|
|
($)
|
|
|
Compensation ($)
|
|
|
Earnings ($)
|
|
|
($)
|
|
|
($)
|
|
Name and Principal (a)
|
|
(b)
|
|
|
(c)
|
|
|
(d)
|
|
|
(e)
|
|
|
(f)
|
|
|
(g)
|
|
|
(h)
|
|
|
(i)
|
|
|
(j)
|
|
|
Dean J. Mitchell
|
|
|
2006
|
|
|
$
|
300,481
|
|
|
$
|
100,000
|
|
|
$
|
158,200
|
|
|
$
|
135,927
|
|
|
$
|
625,000
|
|
|
$
|
|
|
|
$
|
92,635
|
|
|
$
|
1,412,244
|
|
President & Chief
Executive Officer
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Ingrid Wiik
|
|
|
2006
|
|
|
$
|
368,443
|
|
|
$
|
|
|
|
$
|
579,910
|
|
|
$
|
640,105
|
|
|
$
|
|
|
|
$
|
899,287
|
|
|
$
|
5,370,162
|
|
|
$
|
7,857,907
|
|
Former Vice Chairman of the Board
President &
Chief Executive Officer
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Jeffrey S. Campbell
|
|
|
2006
|
|
|
$
|
291,554
|
|
|
$
|
320,500
|
|
|
$
|
192,390
|
|
|
$
|
67,293
|
|
|
$
|
|
|
|
$
|
10,691
|
|
|
$
|
39,534
|
|
|
$
|
921,962
|
|
Executive Vice President &
Chief Financial Officer
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Matthew T. Farrell
|
|
|
2006
|
|
|
$
|
311,538
|
|
|
$
|
234,533
|
|
|
$
|
(164,743
|
)
|
|
$
|
97,440
|
|
|
$
|
|
|
|
$
|
11,746
|
|
|
$
|
57,260
|
|
|
$
|
800,321
|
|
Former Executive Vice President,
Finance &
Chief Financial Officer
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Ronald N. Warner
|
|
|
2006
|
|
|
$
|
400,000
|
|
|
$
|
619,067
|
|
|
$
|
228,539
|
|
|
$
|
132,844
|
|
|
$
|
225,000
|
|
|
$
|
14,664
|
|
|
$
|
70,384
|
|
|
$
|
1,690,499
|
|
President,
Pharmaceuticals & Executive Vice President,
Compliance & Intellectual Property
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
George Rose
|
|
|
2006
|
|
|
$
|
294,231
|
|
|
$
|
575,978
|
|
|
$
|
(90,996
|
)
|
|
$
|
37,367
|
|
|
$
|
125,000
|
|
|
$
|
15,257
|
|
|
$
|
384,848
|
|
|
$
|
1,481,013
|
|
Executive Vice President, Human
Resources & Communications
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Robert F. Wrobel
|
|
|
2006
|
|
|
$
|
410,000
|
|
|
$
|
429,067
|
|
|
$
|
126,020
|
|
|
$
|
178,272
|
|
|
$
|
200,000
|
|
|
$
|
35,236
|
|
|
$
|
54,067
|
|
|
$
|
1,432,661
|
|
Executive Vice President, Chief
Legal Officer & Secretary
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Footnotes:
|
|
|
Column (d) |
|
Includes the following bonuses paid or earned during 2006:
Mr. Mitchell $100,000 signing bonus;
Mr. Campbell $220,500 guaranteed bonus for his
continued service as interim CFO through year end 2006, and
performance units valued at $100,000;
Mr. Farrell retention incentive of $234,533;
Mr. Warner retention incentive of $419,067, and
performance units valued at $200,000; Mr. Rose
retention incentive of $319,067, payment of $76,911 related to
an option forfeiture, and performance units valued at $180,000;
and Mr. Wrobel retention incentive of $429,067. |
|
Column (e) |
|
Reflects Stock Awards valued in accordance with SFAS 123R,
which requires recognition of the fair value of stock-based
compensation in net earnings, including the impact of
compensation reversals due to award forfeitures. Compensation
for restricted stock is recorded based on the market value of
the stock on the grant date. The Company recognizes stock-based
compensation expense over the |
30
|
|
|
|
|
requisite period of individual grants, which generally equals
the vesting period of the grant (ref.
Form 10-K,
Notes to Consolidated Financial Statements). The following
restricted stock awards were forfeited in 2006: Mr. Farrell
40,610 shares with negative impact of $252,546, and
Mr. Rose 20,800 shares with negative impact of
$139,328. The impact of these forfeitures is reflected in the
values shown. Ms. Wiiks stock award value includes
compensation cost associated with a grant of 5,000 restricted
shares, which she received as a Director following her
retirement on June 30, 2006. |
|
Column (f) |
|
Reflects Option Awards valued in accordance with SFAS 123R,
which requires recognition of the fair value of stock-based
compensation in net earnings, including the impact of
compensation reversals due to award forfeitures. The Company
estimated the fair value, as of the date of grant, of options
outstanding in the plan using the Black-Scholes option pricing
model. The Company recognizes stock-based compensation expense
over the requisite period of individual grants, which generally
equals the vesting period of the grant (ref.
Form 10-K,
Notes to Consolidated Financial Statements). The following stock
option awards were forfeited in 2006: Mr. Farrell
49,150 shares and Mr. Rose 15,180 shares. These
forfeitures had no impact on the reported values. |
|
Column (g) |
|
Reflects the annual target bonuses earned under the Alpharma
Inc. Executive Bonus Plan, calculated as a percentage of annual
base salary as follows, and adjusted based on individual and
company performance: 100% for CEO, 50% for named executive
officers other than CEO. Ms. Wiiks target bonus is
disclosed in Col (i); Mr. Campbell was not awarded a target
bonus in addition to a guaranteed bonus disclosed in Col (d);
and Mr. Farrell was not awarded a target bonus, since his
employment terminated in September 2006. Mr. Campbell was
also granted an incentive payment of $285,246, which was earned
in 2005, in connection with the sale of the Global Generics
business, and paid in June 2006. |
|
Column (h) |
|
Reflects the change in pension value for each named executive
officer. There were no nonqualified deferred compensation
earnings for the named executive officers. |
|
Column (i) |
|
Includes the following items, other than perquisites or personal
benefits, whose value exceeds $10,000:
Mr. Mitchell $26,764 for reimbursement of tax
gross-ups;
Ms. Wiik matching contributions under the
Companys Savings Plan of $12,000, $173,943 for
reimbursement of tax
gross-ups,
pro-rata bonus for 2006 of $355,000, special award of
$1,475,000, retention payment of $1,456,547 including interest,
performance unit payout of $854,780 including interest, vacation
payout of $40,962, an amount of $742,424 as reimbursement for
the Companys failure to execute a pre-established 10b5-1
option exercise election, in accordance with
Ms. Wiiks written instructions, and board of director
fees of $26,025; Mr. Farrell vacation payout of
$22,500; Mr. Warner $11,168 for reimbursement
of tax
gross-ups;
George Rose severance payment of $328,600, and
vacation payout of $17,308. Includes the following perquisites
or personal benefits, whose value exceeds $25,000:
Ms. Wiik $185,021 for tax advice arising from
her status as a Norwegian citizen resident in the U.S., and
shifting her residence from the U.S. to Norway;
Mr. Warner executive allowance of $28,600;
Mr. Rose executive allowance of $28,050;
Mr. Wrobel executive allowance of $28,600. The
Company also provided the following perquisites or personal
benefits, whose value was less than $25,000: executive
allowances for each of Messrs. Mitchell, Campbell and Farrell;
holiday gift of wine for each named executive officer;
Mr. Mitchell reimbursement for legal fees,
permanent residence sponsorship, and supplemental disability
insurance; Ms. Wiik reimbursement of relocation
and telephone costs, an automobile allowance and retirement
gifts; Mr. Farrell unreimbursable medical
expenses, and departure gifts; and Mr. Warner
unreimbursable medical expenses, and sales award gift. |
31
Employment
Agreements
The named executive officers are parties to employment
agreements. For a discussion of the material terms of these
employment agreements please see Potential Payments upon
Termination or Change in Control of the Company on
page 44.
Retention
Agreements
In December 2005, the Company entered into retention agreements
with Mr. Farrell, Dr. Warner, Mr. Rose and
Mr. Wrobel providing for payments and other incentives and
protections intended to encourage these executive officers to
continue their employment with the Company after the significant
changes anticipated as a result of the December 19, 2005
sale of the Generics Business to Actavis Group Hf. Pursuant to
the retention agreements, each of these executive officers
received a retention payment equal to his or her annual base
salary and target annual bonus opportunity payable in one-third
increments on each of June 30, 2006, December 29,
2006, and June 29, 2007, provided the executive officer
remained employed by us on the applicable payment date. These
payments may be accelerated upon (i) termination of the
executives employment as a result of death or by the
Company without cause or due to disability, (ii) a change
of control of the Company under the Change in Control Plan, or
(iii) for Dr. Warner, six months after a sale of the
executive officers business segment.
The retention agreements provide further that if a change of
control occurs or, for Dr. Warner, if there is a sale of
his business segment, then the executive officer will be
entitled to the following benefits in lieu of benefits (equal to
two times the sum of the executive officers annual rate of
base salary and target bonus opportunity) under Severance or
Change in Control Plans:
|
|
|
|
|
Payment of a pro rated annual bonus, on terms described in the
retention agreements.
|
|
|
|
Accelerated vesting of stock options, restricted stock and
restricted stock units (subject to specified limitations for
Dr. Warner).
|
|
|
|
Severance payments equal to two times the sum of the executive
officers annual rate of base salary and target annual
bonus opportunity.
|
|
|
|
Continued coverage under our medical, dental and life insurance
benefits for two years after termination and outplacement
services.
|
The severance payments, insurance coverage and outplacement
services are only available if the executive officers cease to
be employed by us, without cause or due to a constructive
termination, subject to specified limitations described in the
retention agreements.
The retention agreements contain non-competition obligations,
pursuant to which the executive officers agreed to not engage in
specified business activities that compete with the Company for
a one-year period following a change of control or, for
Dr. Warner, a sale of his business segment. The Company has
also agreed to pay certain tax obligations of the executive
officers under Section 4999 of the Internal Revenue Code of
1986, as amended.
On June 24, 2005 the Company entered into a retention
agreement with Mr. Campbell providing for payments and
other incentives and protections intended to encourage
Mr. Campbell to continue employment with the Company after
the significant changes anticipated as a result of the
December 19, 2005 sale of the Generics Business to Actavis
Group Hf. Pursuant to the retention agreements, in June 2006
Mr. Campbell received a retention payment equal to 100% of
his base salary in effect on June 24, 2005.
32
Executive
Termination Payments
Former
Vice Chairman of the Board, President and Chief Executive
Officer
As presented in Column (i) of the Summary Compensation
Table above, in connection with her retirement and pursuant to
her amended and restated employment agreement, Ms. Wiik was
awarded (i) a pro rata bonus for 2006 in an amount equal to
$355,000, paid on June 30, 2006, (ii) a special award
of $1,475,000, paid on June 30, 2006, (iii) vacation
pay equal to $40,962 and (iv) $2,253,333, payable in
January 2007 (with interest on such amount between June 30,
2006 and the payment date).
Executive
Vice President, Human Resources &
Communications
As presented in Column (i) of the Summary Compensation
Table above, in connection with his termination of employment,
Mr. Rose was awarded (i) a severance payment of
$328,600 and (ii) vacation pay of $17,308. These payments
were made or accrued in accordance with the terms of
Mr. Roses agreement.
GRANTS OF
PLAN-BASED AWARDS
The following table provides information concerning the grants
made to each of our named executive officers in fiscal 2006
under the Alpharma Inc. Executive Bonus Plan and the 2003
Omnibus Incentive Compensation Plan.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
All Other
|
|
|
All Other
|
|
|
|
|
|
Grant
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stock
|
|
|
Option
|
|
|
|
|
|
Date
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Awards:
|
|
|
Awards:
|
|
|
Exercise
|
|
|
Fair
|
|
|
|
|
|
|
Estimated Future Payouts
|
|
|
Estimated Future Payouts
|
|
|
Number
|
|
|
Number
|
|
|
or Base
|
|
|
Value of
|
|
|
|
|
|
|
Under Non-Equity Incentive
|
|
|
Under Equity Incentive
|
|
|
of Shares
|
|
|
of Securities
|
|
|
Price of
|
|
|
Stock
|
|
|
|
|
|
|
Plan Awards
|
|
|
Plan Awards
|
|
|
of Stock
|
|
|
Underlying
|
|
|
Option
|
|
|
and
|
|
|
|
Grant
|
|
|
Threshold
|
|
|
Target
|
|
|
Maximum
|
|
|
Threshold
|
|
|
Target
|
|
|
Maximum
|
|
|
or Units
|
|
|
Options
|
|
|
Awards
|
|
|
Option
|
|
Name
|
|
Date
|
|
|
($)
|
|
|
($)
|
|
|
($)
|
|
|
($)
|
|
|
($)
|
|
|
($)
|
|
|
(#)
|
|
|
(#)
|
|
|
($/Sh)
|
|
|
Awards
|
|
(a)
|
|
(b)
|
|
|
(c)
|
|
|
(d)
|
|
|
(e)
|
|
|
(f)
|
|
|
(g)
|
|
|
(h)
|
|
|
(i)
|
|
|
(j)
|
|
|
(k)
|
|
|
(l)
|
|
|
Dean J. Mitchell
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Alpharma Inc. Executive Bonus Plan
|
|
|
|
|
|
$
|
|
|
|
$
|
625,000
|
|
|
$
|
937,500
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2003 Omnibus Incentive Compensation
Plan
|
|
|
7/3/2006
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
40,000
|
|
|
|
|
|
|
|
|
|
|
$
|
949,200
|
|
2003 Omnibus Incentive Compensation
Plan
|
|
|
7/3/2006
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
100,000
|
|
|
$
|
23.73
|
|
|
$
|
1,096,430
|
|
Ingrid Wiik
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Alpharma Inc. Executive Bonus Plan
|
|
|
|
|
|
$
|
|
|
|
$
|
710,000
|
|
|
$
|
1,065,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2003 Omnibus Incentive Compensation
Plan
|
|
|
7/1/2006
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
5,000
|
|
|
|
|
|
|
|
|
|
|
$
|
120,200
|
|
Jeffrey S. Campbell
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Alpharma Inc. Executive Bonus Plan
|
|
|
|
|
|
$
|
|
|
|
$
|
102,900
|
|
|
$
|
154,350
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2003 Omnibus Incentive Compensation
Plan
|
|
|
2/27/2006
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3,500
|
|
|
|
|
|
|
|
|
|
|
$
|
110,670
|
|
2003 Omnibus Incentive Compensation
Plan
|
|
|
2/27/2006
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
7,000
|
|
|
$
|
31.62
|
|
|
$
|
108,338
|
|
2003 Omnibus Incentive Compensation
Plan
|
|
|
9/20/2006
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
20,000
|
|
|
|
|
|
|
|
|
|
|
$
|
453,000
|
|
Matthew T. Farrell
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Alpharma Inc. Executive Bonus Plan
|
|
|
|
|
|
$
|
|
|
|
$
|
225,000
|
|
|
$
|
337,500
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2003 Omnibus Incentive Compensation
Plan
|
|
|
2/27/2006
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
5,400
|
|
|
|
|
|
|
|
|
|
|
$
|
170,748
|
|
2003 Omnibus Incentive Compensation
Plan
|
|
|
2/27/2006
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
12,650
|
|
|
$
|
31.62
|
|
|
$
|
195,783
|
|
Ronald N. Warner
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Alpharma Inc. Executive Bonus Plan
|
|
|
|
|
|
$
|
|
|
|
$
|
200,000
|
|
|
$
|
300,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2003 Omnibus Incentive Compensation
Plan
|
|
|
2/27/2006
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
5,400
|
|
|
|
|
|
|
|
|
|
|
$
|
170,748
|
|
2003 Omnibus Incentive Compensation
Plan
|
|
|
2/27/2006
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
12,650
|
|
|
$
|
31.62
|
|
|
$
|
195,783
|
|
George Rose
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Alpharma Inc. Executive Bonus Plan
|
|
|
|
|
|
$
|
|
|
|
$
|
150,000
|
|
|
$
|
225,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2003 Omnibus Incentive Compensation
Plan
|
|
|
2/27/2006
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3,600
|
|
|
|
|
|
|
|
|
|
|
$
|
113,832
|
|
2003 Omnibus Incentive Compensation
Plan
|
|
|
2/27/2006
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
8,430
|
|
|
$
|
31.62
|
|
|
$
|
130,470
|
|
Robert F. Wrobel
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Alpharma Inc. Executive Bonus Plan
|
|
|
|
|
|
$
|
|
|
|
$
|
200,000
|
|
|
$
|
300,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2003 Omnibus Incentive Compensation
Plan
|
|
|
2/27/2006
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2,700
|
|
|
|
|
|
|
|
|
|
|
$
|
85,374
|
|
2003 Omnibus Incentive Compensation
Plan
|
|
|
2/27/2006
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
6,330
|
|
|
$
|
31.62
|
|
|
$
|
97,969
|
|
33
Footnotes:
|
|
|
Column (d) |
|
Target Bonus is defined under the SEC Proxy regulations as the
amount payable if the specified performance target(s) are
reached. Target Bonus is defined under the EBP as the targeted
amount of bonus award established for each eligible employee,
expressed as a percentage of the employees base salary
corresponding to the employees position at the end of the
applicable incentive year; assuming his or her individual goals
are achieved at the 100% level established by the Compensation
Committee. |
|
Column (e) |
|
Maximum Bonus is defined under the SEC Proxy regulations as the
maximum payout possible under the plan. Maximum Bonus is defined
under the EBP as an amount equal to 150% of a Participants
Target Bonus. |
Plan
Award Terms
Plan awards for the 2006 fiscal year were made under our 2003
Omnibus Incentive Compensation Plan and our Executive Bonus
Plan. As more fully discussed in the CD&A (see page 16
above), awards under the Executive Bonus Plan may be made to
executive officers and key employees performing services for the
Company in the form of a cash bonus at a target level. Target
levels for each named executive officer are set as a percentage
of base salary. Each of the named executive officers may receive
more or less than his or her target level bonus, based upon the
Companys ability to achieve certain operating income, cash
flow and revenue growth targets for 2007. In addition, for
executive officers who are responsible for a specific business
segment, a portion of his or her bonus depends on such business
segments achievement of certain income, cash flow and
revenue targets for 2007. As provided in the Executive Bonus
Plan, the Compensation Committee has the discretion to vary any
individual bonus award from the amount derived by the
application of the criteria described above.
Plan awards under our 2003 Omnibus Incentive Compensation Plan
were made in the form of stock options and restricted stock.
Stock option awards vest at the rate of 25% on each of the first
four anniversaries of the date of grant. Restricted stock awards
granted in 2006 generally vest 100% three years from the date of
grant.
34
OUTSTANDING
EQUITY AWARDS AT FISCAL YEAR-END
The following table provides information concerning the current
holdings of unexercised and unvested stock options and unvested
restricted stock awards for each of the named executive officers
as of the end of fiscal 2006.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Option Awards
|
|
|
Stock Awards
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Equity
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Incentive
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Plan
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Equity
|
|
|
Awards:
|
|
|
|
|
|
|
|
|
|
Equity
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Incentive
|
|
|
Market
|
|
|
|
|
|
|
|
|
|
Incentive
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Plan
|
|
|
or Payout
|
|
|
|
|
|
|
|
|
|
Plan
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Awards:
|
|
|
Value of
|
|
|
|
|
|
|
|
|
|
Awards:
|
|
|
|
|
|
|
|
|
|
|
|
Market
|
|
|
Number of
|
|
|
Unearned
|
|
|
|
|
|
|
|
|
|
Number
|
|
|
|
|
|
|
|
|
|
|
|
Value of
|
|
|
Unearned
|
|
|
Shares,
|
|
|
|
Number of
|
|
|
Number of
|
|
|
of
|
|
|
|
|
|
|
|
|
Number
|
|
|
Shares or
|
|
|
Shares,
|
|
|
Units or
|
|
|
|
Securities
|
|
|
Securities
|
|
|
Securities
|
|
|
|
|
|
|
|
|
of Shares
|
|
|
Units
|
|
|
Units or
|
|
|
Other
|
|
|
|
Underlying
|
|
|
Underlying
|
|
|
Underlying
|
|
|
|
|
|
|
|
|
or Units
|
|
|
of Stock
|
|
|
Other
|
|
|
Rights
|
|
|
|
Unexercised
|
|
|
Unexercised
|
|
|
Unexercised
|
|
|
Option
|
|
|
|
|
|
of Stock
|
|
|
That Have
|
|
|
Rights That
|
|
|
That Have
|
|
|
|
Options
|
|
|
Options
|
|
|
Unearned
|
|
|
Exercise
|
|
|
Option
|
|
|
That Have
|
|
|
Not
|
|
|
Have Not
|
|
|
Not
|
|
|
|
(#)
|
|
|
(#)
|
|
|
Options
|
|
|
Price
|
|
|
Expiration
|
|
|
Not Vested
|
|
|
Vested
|
|
|
Vested
|
|
|
Vested
|
|
Name
|
|
Exercisable
|
|
|
Unexercisable
|
|
|
(#)
|
|
|
($)
|
|
|
Date
|
|
|
(#)
|
|
|
($)
|
|
|
(#)
|
|
|
($)
|
|
(a)
|
|
(b)
|
|
|
(c)
|
|
|
(d)
|
|
|
(e)
|
|
|
(f)
|
|
|
(g)
|
|
|
(h)
|
|
|
(i)
|
|
|
(j)
|
|
|
Dean J. Mitchell
|
|
|
|
|
|
|
100,000
|
|
|
|
|
|
|
$
|
23.730
|
|
|
|
7/3/2016
|
|
|
|
40,000
|
|
|
$
|
964,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Ingrid Wiik
|
|
|
37,500
|
|
|
|
37,500
|
|
|
|
|
|
|
$
|
19.800
|
|
|
|
3/8/2014
|
|
|
|
5,000
|
|
|
$
|
120,500
|
|
|
|
|
|
|
|
|
|
|
|
|
12,500
|
|
|
|
37,500
|
|
|
|
|
|
|
$
|
11.170
|
|
|
|
5/12/2015
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Jeffrey S. Campbell
|
|
|
|
|
|
|
3,750
|
|
|
|
|
|
|
$
|
19.800
|
|
|
|
3/8/2014
|
|
|
|
3,500
|
|
|
$
|
84,350
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
5,625
|
|
|
|
|
|
|
$
|
11.170
|
|
|
|
5/12/2015
|
|
|
|
5,000
|
|
|
$
|
120,500
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
7,000
|
|
|
|
|
|
|
$
|
31.620
|
|
|
|
2/27/2016
|
|
|
|
3,500
|
|
|
$
|
84,350
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3,500
|
|
|
$
|
84,350
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
20,000
|
|
|
$
|
482,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Matthew T. Farrell
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Ronald N. Warner
|
|
|
20,000
|
|
|
|
|
|
|
|
|
|
|
$
|
12.760
|
|
|
|
12/4/2012
|
|
|
|
9,000
|
|
|
$
|
216,900
|
|
|
|
|
|
|
|
|
|
|
|
|
9,000
|
|
|
|
9,000
|
|
|
|
|
|
|
$
|
19.800
|
|
|
|
3/8/2014
|
|
|
|
15,000
|
|
|
$
|
361,500
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
12,650
|
|
|
|
|
|
|
$
|
31.620
|
|
|
|
2/27/2016
|
|
|
|
5,400
|
|
|
$
|
130,140
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
George Rose
|
|
|
20,000
|
|
|
|
|
|
|
|
|
|
|
$
|
30.813
|
|
|
|
1/30/2007
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Robert F. Wrobel
|
|
|
15,000
|
|
|
|
|
|
|
|
|
|
|
$
|
32.250
|
|
|
|
1/7/2007
|
|
|
|
7,500
|
|
|
$
|
180,750
|
|
|
|
|
|
|
|
|
|
|
|
|
10,000
|
|
|
|
|
|
|
|
|
|
|
$
|
35.000
|
|
|
|
2/24/2007
|
|
|
|
2,700
|
|
|
$
|
65,070
|
|
|
|
|
|
|
|
|
|
|
|
|
20,000
|
|
|
|
|
|
|
|
|
|
|
$
|
30.110
|
|
|
|
2/23/2011
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
5,000
|
|
|
|
|
|
|
|
|
|
|
$
|
14.437
|
|
|
|
4/2/2012
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
5,000
|
|
|
|
|
|
|
|
|
|
|
$
|
9.480
|
|
|
|
10/31/2012
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
12,500
|
|
|
|
12,500
|
|
|
|
|
|
|
$
|
19.800
|
|
|
|
3/8/2014
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
6,330
|
|
|
|
|
|
|
$
|
31.620
|
|
|
|
2/27/2016
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Footnotes:
|
|
|
Column (b) |
|
Ms. Wiiks option award of 37,500 shares vested
50% each on March 8, 2005 and March 8, 2006. |
|
|
|
|
|
Ms. Wiiks option award of 12,500 shares vested
on May 12, 2006. |
35
|
|
|
|
|
Mr. Warners option award of 20,000 shares vested
50% each on December 4, 2005 and December 4, 2006. |
|
|
|
Mr. Warners option award of 9,000 shares vested
50% each on March 8, 2005 and March 8, 2006. |
|
|
|
Mr. Roses option award of 20,000 shares became
fully vested on September 4, 2005. |
|
|
|
Mr. Wrobels option award of 15,000 shares became
fully vested on January 7, 2004. |
|
|
|
Mr. Wrobels option award of 10,000 shares became
fully vested on February 24, 2004. |
|
|
|
Mr. Wrobels option award of 20,000 shares became
fully vested on February 23, 2005. |
|
|
|
Mr. Wrobels option award of 5,000 shares vested
on April 2, 2006. |
|
|
|
Mr. Wrobels option award of 5,000 shares vested
on October 31, 2006. |
|
|
|
Mr. Wrobels option award of 12,500 shares vested
50% each on March 8, 2005 and March 8, 2006. |
|
Column (c) |
|
Mr. Mitchells option award of 100,000 shares
will vest 25% on each of the four anniversaries following its
grant date on July 3, 2006. |
|
|
|
Ms. Wiiks option award of 37,500 shares will
vest 50% each on March 8, 2007 and March 8, 2008. |
|
|
|
Ms. Wiiks option award of 37,500 shares will
vest 1/3rd each on May 12, 2007, May 12, 2008 and
May 12, 2009. |
|
|
|
Mr. Campbells option award of 3,750 shares will
vest 50% each on March 8, 2007 and March 8, 2008. |
|
|
|
Mr. Campbells option award of 5,625 shares will
vest 1/3rd each on May 12, 2007, May 12, 2008 and
May 12, 2009. |
|
|
|
Mr. Campbells option award of 7,000 shares will
vest 25% on each of the four anniversaries following its grant
date on February 27, 2006. |
|
|
|
Mr. Warners option award of 9,000 shares will
vest 50% each on March 8, 2007 and March 8, 2008. |
|
|
|
Mr. Warners option award of 12,650 shares will
vest 25% on each of the four anniversaries following its grant
date on February 27, 2006. |
|
|
|
Mr. Wrobel will retire from the Company no earlier than
January 15, 2007 and no later than June 30, 2007, at
which time all option awards outstanding shall immediately
become fully vested. |
|
|
|
Mr. Wrobels option award of 12,500 shares, set
to vest 50% each on March 8, 2007 and March 8, 2008,
will 100% vest on retirement. |
|
|
|
Mr. Wrobels option award of 6,330 shares, set to
vest 25% on each of the four anniversaries following its grant
date on February 27, 2006, will 100% vest on retirement. |
|
Column (g) |
|
Mr. Mitchells stock award of 40,000 shares will
100% vest on July 3, 2009. |
|
|
|
Ms. Wiiks stock award of 5,000 shares which she
received as a Director following her retirement on
6/30/2006,
will 100% vest on July 1, 2007. |
|
|
|
Mr. Campbells stock award of 3,500 shares will
100% vest on March 8, 2009. |
|
|
|
Mr. Campbells stock award of 5,000 shares 100%
vested on March 8, 2007. |
|
|
|
Mr. Campbells stock award of 3,500 shares will
100% vest on May 12, 2010. |
|
|
|
Mr. Campbells stock award of 3,500 shares will
100% vest on February 27, 2009. |
|
|
|
Mr. Campbells stock award of 20,000 shares will
100% vest on December 31, 2007, or earlier under certain
circumstances. |
36
|
|
|
|
|
Mr. Warners stock award of 9,000 shares will
100% vest on March 8, 2009. |
|
|
|
Mr. Warners stock award of 15,000 shares will
100% vest on May 12, 2007. |
|
|
|
Mr. Warners stock award of 5,400 shares will
100% vest on February 27, 2009. |
|
|
|
Mr. Wrobel will retire from the Company no earlier than
January 15, 2007 and no later than June 30, 2007, at
which time all stock awards outstanding shall immediately become
fully vested. |
|
|
|
Mr. Wrobels stock award of 7,500 shares will
100% vest on May 12, 2007, will 100% vest on retirement. |
|
|
|
Mr. Wrobels stock award of 2,700 shares will
100% vest on February 27, 2009, will 100% vest on
retirement. |
OPTION
EXERCISES AND STOCK VESTED
The following table provides information concerning stock option
exercises and the vesting of restricted stock awards for each of
the named executive officers during fiscal 2006.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Option Awards
|
|
|
Stock Awards
|
|
|
|
Number of
|
|
|
Value
|
|
|
Number of
|
|
|
Value
|
|
|
|
Shares
|
|
|
Realized
|
|
|
Shares
|
|
|
Realized
|
|
|
|
Acquired on
|
|
|
on
|
|
|
Acquired
|
|
|
on
|
|
|
|
Exercise
|
|
|
Exercise
|
|
|
on Vesting
|
|
|
Vesting
|
|
Name
|
|
(#)
|
|
|
($)
|
|
|
(#)
|
|
|
($)
|
|
(a)
|
|
(b)
|
|
|
(c)
|
|
|
(d)
|
|
|
(e)
|
|
|
Dean J. Mitchell
|
|
|
|
|
|
$
|
|
|
|
|
|
|
|
$
|
|
|
Ingrid Wiik
|
|
|
|
|
|
$
|
|
|
|
|
45,000
|
|
|
$
|
1,012,500
|
|
Jeffrey S. Campbell
|
|
|
32,625
|
|
|
$
|
509,839
|
|
|
|
5,000
|
|
|
$
|
142,550
|
|
Matthew T. Farrell
|
|
|
174,000
|
|
|
$
|
1,691,079
|
|
|
|
15,000
|
|
|
$
|
370,050
|
|
Ronald N. Warner
|
|
|
20,000
|
|
|
$
|
292,120
|
|
|
|
15,000
|
|
|
$
|
370,050
|
|
George Rose
|
|
|
54,750
|
|
|
$
|
643,181
|
|
|
|
10,000
|
|
|
$
|
246,700
|
|
Robert F. Wrobel
|
|
|
57,334
|
|
|
$
|
834,696
|
|
|
|
7,500
|
|
|
$
|
185,025
|
|
37
PENSION
BENEFITS
The following table provides information as of fiscal year end
2006 for each of the named executive officers with respect to
the Companys pension plans.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Payments
|
|
|
|
|
|
|
|
|
During
|
|
|
|
|
Number of
|
|
Present Value
|
|
Last
|
|
|
|
|
Years Credited
|
|
of Accumulated
|
|
Fiscal
|
Name
|
|
Plan Name
|
|
Service (#)
|
|
Benefit ($)
|
|
Year ($)
|
(a)
|
|
(b)
|
|
(c)
|
|
(d)
|
|
(e)
|
|
Dean J. Mitchell
|
|
|
N/A
|
|
|
|
|
|
|
$
|
|
|
|
$
|
|
|
Ingrid Wiik(1)
|
|
|
Contractual Pension
|
|
|
|
N/A
|
|
|
$
|
|
|
|
$
|
5,288,276
|
|
|
|
|
Alpharma AS Defined Benefit Plan
|
|
|
|
23
|
|
|
$
|
|
|
|
$
|
174
|
|
Jeffrey S. Campbell
|
|
|
Alpharma Inc. Pension Plan
|
|
|
|
4
|
|
|
$
|
39,729
|
|
|
$
|
|
|
|
|
|
Alpharma Inc. Supplemental Pension Plan
|
|
|
|
3
|
|
|
$
|
7,260
|
|
|
$
|
|
|
Matthew T. Farrell
|
|
|
Alpharma Inc. Pension Plan
|
|
|
|
5
|
|
|
$
|
53,143
|
|
|
$
|
|
|
|
|
|
Alpharma Inc. Supplemental Pension Plan
|
|
|
|
4
|
|
|
$
|
10,562
|
|
|
$
|
|
|
Ronald N. Warner
|
|
|
Alpharma Inc. Pension Plan
|
|
|
|
4
|
|
|
$
|
52,776
|
|
|
$
|
|
|
|
|
|
Alpharma Inc. Supplemental Pension Plan
|
|
|
|
3
|
|
|
$
|
8,787
|
|
|
$
|
|
|
George Rose
|
|
|
Alpharma Inc. Pension Plan
|
|
|
|
5
|
|
|
$
|
66,648
|
|
|
$
|
|
|
|
|
|
Alpharma Inc. Supplemental Pension Plan
|
|
|
|
4
|
|
|
$
|
12,795
|
|
|
$
|
|
|
Robert F. Wrobel
|
|
|
Alpharma Inc. Pension Plan
|
|
|
|
9
|
|
|
$
|
209,426
|
|
|
$
|
|
|
|
|
|
Alpharma Inc. Supplemental Pension Plan
|
|
|
|
8
|
|
|
$
|
39,178
|
|
|
$
|
|
|
Footnotes:
|
|
|
(1) |
|
Ms. Wiiks Contractual Pension value settled in 2006.
Payments shown for 2006 include the following: periodic payments
totaling approximately $160,000, which represents six payments
of NOK170,400 converted to $US using a conversion rate of
NOK1=$US0.1564, representing the average exchange rate over the
six payment period; and one single settlement payment of
$5,128,276, which was paid to Vital Forsikring ASA, the
Norwegian insurer, who will provide all future payments due to
Ms. Wiik. |
Alpharma
Inc. Pension Plan
Eligibility. Prior to January 1, 2007, an
eligible employee became a participant in the Alpharma Inc.
Pension Plan (the Pension Plan) on the first
July 1 or January 1 coincident with or next following the
date he had completed 3 months of continuous service with
an Alpharma company, and attained age 18 years.
Effective as of January 1, 2007, participation in the
Pension Plan is frozen. Jeffrey Campbell, Matthew Farrell,
Ronald Warner, Robert Wrobel and George Rose are participants in
the Pension Plan.
Vesting. A participant shall be fully vested
after completing five years of service. Notwithstanding the
foregoing, a participant who was employed by Alpharma on
December 31, 2006, is fully vested in his accrued benefit
as of such date regardless of his number of years of service.
Thus, Jeffrey Campbell, Ronald Warner, Matthew Farrell, Robert
Wrobel and George Rose are vested in their benefits under the
Pension Plan.
Actuarial Assumptions. For purposes of
determining benefits under the Pension Plan, except lump-sum
payments, the following actuarial assumptions are used:
38
Mortality Table 1971 Group Annuity Mortality Table
for Males
Interest 8.0%
For purposes of determining lump sum payments, the actuarial
assumptions prescribed under Section 417(e) of the Code,
the Pension Funding Equity Act and Pension Protection Act of
2006 are used.
Normal Retirement Benefit. The annual
retirement benefit payable to a participant on his normal
retirement date (age 65) in the form of a single life
annuity is equal to:
0.8% of his final average earnings up to covered compensation,
plus 1.45% percent of his final
average earnings in excess of covered compensation
times
years of benefit service
(not to exceed 30).
Effective as of December 31, 2006, benefit accruals under
the Pension Plan ceased.
Early Retirement Benefit. A participant who
terminates employment after attaining age 55 and having at
least 5 years of service is eligible for an early
retirement benefit. A participants normal retirement
benefit will be reduced by 7% for each year payments commence
before he attains age 65 and an additional 4% for each year
payments commence before he attains age 65 between the ages
of 55 and 60. Matthew Farrell and George Rose have terminated
employment but are not eligible for an early retirement benefit
because they have not attained age 55.
Deferred Vested Benefit. A participant who
terminates employment and is vested in his benefit is eligible
to receive a monthly deferred vested benefit commencing on his
normal retirement date. A participant may commence payment of
his benefit as early as age 55. If payments commence before
the participant attains age 65, his benefit will be reduced
by 7% for each year payments commence before age 65 (down
to age 60) and 4% for each year his age at the time
payments begin precedes age 60 (down to age 55).
Matthew Farrell and George Rose are eligible for deferred vested
benefit.
Compensation. The final average earnings of a
participant shall be the annual average of the earnings paid
during the 5 consecutive plan years for which his earnings were
highest within the last 10 plan years immediately preceding his
termination of employment. If a participant has less than
5 years of employment, then his final average earnings
shall be the average annual earnings paid during his employment.
Generally, with respect to the above-named participants,
earnings mean base compensation.
Forms of Benefit. The normal form of benefit
for a married participant is a qualified joint and survivor
annuity (QJSA). The normal form of benefit for an
unmarried participant is a single life annuity. In lieu of the
normal form of benefit, a participant may elect to have his
benefit paid as a joint and (50% or 100%) survivor annuity or a
ten year certain life annuity. If a participants benefit
is paid in a form other than a single life annuity, his monthly
benefit will be reduced to reflect the fact that benefits will
be paid over two lifetimes (or, in the case of a ten year
certain annuity, for a period certain).
Alpharma
Inc. Supplemental Pension Plan
Eligibility. Prior to January 1, 2006,
the Committee appointed highly compensated employees or key
management employees to participate in the Alpharma Inc.
Supplemental Pension Plan (the SPP). Effective as of
January 1, 2006, participation in the SPP was frozen.
Jeffrey Campbell, Matthew Farrell, Ronald Warner, Robert Wrobel
and George Rose are participants in the Plan. Matthew Farrell
and George Rose have terminated employment.
39
Vesting. A participant shall be fully vested
after completing five years of service. Robert Wrobel is vested
in his benefit under the SPP. Jeffrey Campbell and Ronald Warner
are not yet vested in their benefits. At the time that Matthew
Farrell and George Rose terminated employment, they were vested
in their benefits.
Benefit. The benefit payable to a participant
is equal to the difference that the participant would have
received under the Pension Plan if his compensation was not
limited by Section 401(a)(17) of the Code less his actual
benefit under the Pension Plan. The amount of compensation (as
defined under the Pension Plan) that is considered under the SPP
is limited to $235,840, and compensation earned after the last
payroll period ending in 2005 is not taken into account.
Actuarial Assumptions. The actuarial
assumptions used to determine benefits under the SPP are the
same as those used to determine benefits under the Pension Plan.
Forms of Benefit. A participants benefit
under the SPP will be paid in a lump sum as soon as
administratively practicable following the date that is six
months after his termination from employment. Matthew Farrell
and George Rose are eligible for lump sum distributions from the
SPP in March 2007 and July 2007, respectively.
Alpharma
AS Defined Benefit Plan
The Alpharma AS Defined Benefit Plan (the AS Plan)
terminated on December 31, 2006. Ingrid Wiik terminated her
employment with Alpharma on June 30, 2006. During
Ms. Wiiks employment period, Ms. Wiik was an
active participant in the AS Plan. During this time, premiums
were paid towards a
paid-up
policy through Vital Forskiring ASA. Generally, the amount of
the paid-up
policy represents the value of Ms. Wiiks benefit
under the AS Plan. Upon Ms. Wiiks attainment of
normal retirement age, 67, she will begin to receive payments
from the
paid-up
policy through Vital Forskiring ASA. Ms. Wiik will not
receive any benefit payments directly from the AS Plan.
Normal Retirement Age. The normal retirement
age under the AS Plan is 67.
Pension Benefit. The retirement pension
payable to a participant for life is equal to:
15% of his salary in excess of 3.67 times the National Insurance
base rate, plus
30% of his salary in excess of 8 times the National
Insurance,
plus the sum of 45% of the pensionable salary between 1 and 8
times the National Insurance base rate and
15% of the pensionable salary between 8 and 12 times the
National Insurance base rate,
less assumed pension from Social Security.
Compensation. Generally, compensation means
base salary.
Alpharma
Inc. 2007 Supplemental Savings Plan
Eligibility. The Committee appoints highly
compensated employees or key management employees as eligible to
participate in the Alpharma Inc. 2007 Supplemental Savings Plan
(the 2007 SSP). Dean Mitchell, Jeffrey Campbell,
Robert Wrobel and Ronald Warner are not participants in the 2007
SSP.
Vesting. A participant is immediately vested
in his deferrals to the 2007 SSP.
Contributions. Participants may elect to defer
up to 75% of their compensation, as described below. There are
no matching contributions under the 2007 SSP.
Compensation. Compensation means base salary,
including amounts deferred under the 2007 SSP and the Alpharma
Inc. Savings Plan, and bonus under the Alpharma Inc. Executive
Bonus Plan.
40
Forms of Benefit. A participants benefit
under the Plan will be paid in a lump sum as soon as
administratively practicable following the date that is six
months after his termination from employment.
Alpharma
Inc. 2005 Supplemental Savings Plan
Eligibility. The Committee appointed highly
compensated employees or key management employees as eligible to
participate in the Alpharma Inc. 2005 Supplemental Savings Plan
(the 2005 SSP). The 2005 SSP was frozen effective as
of December 31, 2005. Jeffrey Campbell, Matthew Farrell,
Ronald Warner, George Rose, Robert Wrobel and Ingrid Wiik are
participants in the 2005 SSP. Matthew Farrell, George Rose and
Ingrid Wiik have terminated employment.
Vesting. A participant is immediately vested
in his deferrals to the 2005 SSP. A participant is vested in his
matching contributions after three years of service.
Contributions. Participants could have elected
to defer up to 25% of their compensation, as described below.
The Company credited matching contributions to a
participants account in an amount up to six percent (6%)
of the amount of compensation deferred under the 2005 SSP.
Compensation. Compensation means base salary,
including amounts deferred under the 2005 SSP and the Alpharma
Inc. Savings Plan.
Forms of Benefit. A participants benefit
under the Plan will be paid in accordance with the distribution
election made by the participant at the time that the deferral
election was made, however such distribution cannot be made
earlier than the date that is six months after his termination
from employment. Matthew Farrell and Ingrid Wiik are entitled to
distributions from the 2005 SSP in 2007. George Rose is entitled
to a distribution from the 2005 SSP in annual installments over
five years to commence five years after his termination from
employment.
Alpharma
Inc. Supplemental Savings Plan
Eligibility. The Committee appointed highly
compensated employees or key management employees as eligible to
participate in the Alpharma Inc. Supplemental Savings Plan (the
SSP). The SSP was frozen effective as of
December 31, 2004. Jeffrey Campbell, Matthew Farrell,
Ronald Warner, George Rose, Robert Wrobel and Ingrid Wiik are
participants in the SSP. Matthew Farrell, George Rose and Ingrid
Wiik have terminated employment.
Vesting. A participant is fully vested in his
deferrals to the SSP. A participant is vested in his matching
contributions after three years of service.
Contributions. Participants could have elected
to defer a potion of their compensation, as described below. In
no event could a participants deferrals under the SSP and
the Alpharma Inc. Savings Plan exceed more than 10% of his
compensation. A participant was permitted to defer a portion of
their bonus to the SSP. The Company credited matching
contributions to a participants account in an amount up to
six percent (6%) of the amount of compensation deferred under
the SSP.
Compensation. Compensation means base salary,
including amounts deferred under the SSP and the Alpharma Inc.
Savings Plan.
Forms of Benefit. A participants benefit
under the Plan will be paid in a lump sum as soon as
administratively practicable following the date that is six
months after his termination from employment. Matthew Farrell,
George Rose and Ingrid Wiik are entitled to distributions from
the SSP in 2007.
41
Ingrid
Wiik Contractual Pension
Ingrid Wiiks employment agreement provided that she was
entitled to an annual retirement benefit equal to:
30% of base compensation, plus an inflationary adjustment (same
adjustment for inflation as in the Norwegian Pension Plan)
less
Other retirement benefits (retirement benefits, excluding
benefits
under any 401(k) plan or deferred compensation plan).
The retirement benefit is payable in Norwegian Kroner in equal
monthly installments. Ingrid Wiiks monthly payments
commenced in July 2006. Alpharma made the payments to Ingrid
Wiik for the period July 2006 though December 2006. On or about
December 28, 2006, Alpharma purchased an annuity contract
from Vital Forsikring ASA to pay Ingrid Wiiks retirement
benefits.
NONQUALIFIED
DEFERRED COMPENSATION
The following table provides information for fiscal 2006 with
respect to the non-qualified defined contribution and
compensation deferral plans of the Company for each of the named
executive officers.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Aggregate
|
|
|
|
|
|
Aggregate
|
|
|
|
Executive
|
|
|
Registrant
|
|
|
Earnings
|
|
|
Aggregate
|
|
|
Balance
|
|
|
|
Contributions
|
|
|
Contributions in
|
|
|
in Last
|
|
|
Withdrawals/
|
|
|
at Last
|
|
|
|
in Last FY
|
|
|
Last FY
|
|
|
FY
|
|
|
Distributions
|
|
|
FYE
|
|
Name
|
|
($)
|
|
|
($)
|
|
|
($)
|
|
|
($)
|
|
|
($)
|
|
(a)
|
|
(b)
|
|
|
(c)
|
|
|
(d)
|
|
|
(e)
|
|
|
(f)
|
|
|
Dean J. Mitchell
|
|
|
N/A
|
|
|
|
N/A
|
|
|
|
N/A
|
|
|
|
N/A
|
|
|
|
N/A
|
|
Ingrid Wiik
|
|
$
|
|
|
|
$
|
53,918
|
|
|
$
|
74,804
|
|
|
$
|
|
|
|
$
|
482,120
|
|
Jeffrey S. Campbell
|
|
$
|
|
|
|
$
|
|
|
|
$
|
9,728
|
|
|
$
|
|
|
|
$
|
82,560
|
|
Matthew T. Farrell
|
|
$
|
|
|
|
$
|
|
|
|
$
|
77,685
|
|
|
$
|
|
|
|
$
|
489,011
|
|
Ronald N. Warner
|
|
$
|
|
|
|
$
|
|
|
|
$
|
4,520
|
|
|
$
|
|
|
|
$
|
37,139
|
|
George Rose
|
|
$
|
|
|
|
$
|
|
|
|
$
|
54,244
|
|
|
$
|
|
|
|
$
|
417,619
|
|
Robert F. Wrobel
|
|
$
|
|
|
|
$
|
|
|
|
$
|
29,440
|
|
|
$
|
|
|
|
$
|
280,404
|
|
Footnotes:
|
|
|
Column (c) |
|
Reflects an adjustment to Ms. Wiiks Alpharma Inc.
Supplemental Savings Plan account for prior years employer
matching contribution formulas that were adjusted to take into
account Ms. Wiiks correct years of service with
the Company. |
42
DIRECTOR
COMPENSATION
The table below summarizes the compensation paid by the Company
to non-employee directors for fiscal 2006.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Change in
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Pension
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Value and
|
|
|
|
|
|
|
|
|
|
Fees
|
|
|
|
|
|
|
|
|
|
|
|
Nonqualified
|
|
|
|
|
|
|
|
|
|
Earned or
|
|
|
|
|
|
|
|
|
Non-Equity
|
|
|
Deferred
|
|
|
|
|
|
|
|
|
|
Paid in
|
|
|
Stock
|
|
|
Option
|
|
|
Incentive Plan
|
|
|
Compensation
|
|
|
All Other
|
|
|
|
|
Name
|
|
Cash ($)
|
|
|
Awards ($)
|
|
|
Awards ($)
|
|
|
Compensation ($)
|
|
|
Earnings
|
|
|
Compensation ($)
|
|
|
Total ($)
|
|
(a)
|
|
(b)
|
|
|
(c)
|
|
|
(d)
|
|
|
(e)
|
|
|
(f)
|
|
|
(g)
|
|
|
(h)
|
|
|
Peter G. Tombros
|
|
$
|
139,557
|
|
|
$
|
50,807
|
|
|
$
|
|
|
|
$
|
|
|
|
$
|
|
|
|
$
|
|
|
|
$
|
190,364
|
|
Glen E. Hess
|
|
$
|
51,600
|
|
|
$
|
48,001
|
|
|
$
|
|
|
|
$
|
|
|
|
$
|
|
|
|
$
|
|
|
|
$
|
99,601
|
|
Finn Berg Jacobsen
|
|
$
|
101,754
|
|
|
$
|
30,824
|
|
|
$
|
|
|
|
$
|
|
|
|
$
|
|
|
|
$
|
|
|
|
$
|
132,578
|
|
Ramon M. Perez
|
|
$
|
108,954
|
|
|
$
|
48,001
|
|
|
$
|
|
|
|
$
|
|
|
|
$
|
|
|
|
$
|
|
|
|
$
|
156,955
|
|
Einar W. Sissener (former director)
|
|
$
|
77,767
|
|
|
$
|
64,986
|
|
|
$
|
|
|
|
$
|
|
|
|
$
|
52,106
|
|
|
$
|
231,609
|
|
|
$
|
527,986
|
|
William I. Jacobs (former director)
|
|
$
|
30,332
|
|
|
$
|
33,970
|
|
|
$
|
|
|
|
$
|
|
|
|
$
|
|
|
|
$
|
|
|
|
$
|
64,302
|
|
Jill Kanin-Lovers (former director)
|
|
$
|
29,679
|
|
|
$
|
33,970
|
|
|
$
|
|
|
|
$
|
|
|
|
$
|
|
|
|
$
|
|
|
|
$
|
63,649
|
|
Robert Thong
(former director)
|
|
$
|
22,586
|
|
|
$
|
33,970
|
|
|
$
|
|
|
|
$
|
|
|
|
$
|
|
|
|
$
|
|
|
|
$
|
56,556
|
|
Farrah M. Walters (former director)
|
|
$
|
27,386
|
|
|
$
|
33,970
|
|
|
$
|
|
|
|
$
|
|
|
|
$
|
|
|
|
$
|
|
|
|
$
|
61,356
|
|
Footnotes:
|
|
|
Column (c) |
|
Reflects Stock Awards valued in accordance with SFAS 123R,
which requires recognition of the fair value of stock-based
compensation in net earnings, including the impact of
compensation reversals due to award forfeitures. Compensation
for restricted stock is recorded based on the market value of
the stock on the grant date. The Company recognizes stock-based
compensation expense over the requisite period of individual
grants, which generally equals the vesting period of the grant
(ref.
Form 10-K,
Notes to Consolidated Financial Statements). The fair value of
equity awards computed in accordance with SFAS 123R at
fiscal year end 2006 are: Mr. Tombros $138,660,
Mr. Hess $115,550, Mr. Jacobsen $115,550,
Mr. Perez $115,550, Mr. Sissener $115,550. The
aggregate number of stock awards outstanding at fiscal year end
2006 are: Mr. Tombros 16,000; Mr. Hess 15,000;
Mr. Jacobsen 10,835; Mr. Perez 15,000;
Mr. Sissener 15,000; Mr. Jacobs 10,000;
Ms. Kanin-Lovers 10,000; Mr. Thong 10,000; and
Ms. Walters 10,000. |
|
Column (d) |
|
Reflects Option Awards valued in accordance with SFAS 123R,
which requires recognition of the fair value of stock-based
compensation in net earnings, including the impact of
compensation reversals due to award forfeitures. The Company
estimated the fair value, as of the date of grant, of options
outstanding in the plan using the Black-Scholes option pricing
model. The Company recognizes stock-based compensation expense
over the requisite period of individual grants, which generally
equals the vesting period of the grant (ref.
Form 10-K,
Notes to Consolidated Financial Statements). The aggregate
number of option awards outstanding at fiscal year end 2006 are:
Mr. Tombros 31,500; Mr. Hess 31,500; Mr. Sissener
27,500; Mr. Jacobs 17,500; Ms. Kanin-Lovers 11,800;
Mr. Thong 11,800; and Ms. Walters 11,800. |
43
|
|
|
Column (g) |
|
Includes the following items, other than perquisites or
personal benefits, whose value exceeds $10,000:
Mr. Sissener chairmanship fees of $66,667,
consulting fees of $167,681, and $22,653 for reimbursement of
tax
gross-ups.
Includes no perquisites or personal benefits, whose value
exceeds $25,000. The Company provided the following perquisites
and personal benefits, whose value was less than $25,000: auto
allowance in Norway; housing expenses in U.S. including
apartment lease, furniture rental, gas and electric utilities,
telephone and cable; telephone, fax and newspaper reimbursements
in Norway; and chairman retirement gift. |
During 2006, directors received an annual directors fee of
$30,000. In addition each director received a grant of 5,000
restricted stock units pursuant to the Companys 2003
Omnibus Incentive Compensation Plan. Further, each director
received $1,200 for each Board meeting and $1,200 for each
Committee meeting attended in person or by telephone. The
Chairman of each of the Audit and Corporate Governance and
Compensation Committees received an additional payment of
$7,500. Mr. Tombros received an additional annual fee of
$50,000 and 1,000 restricted stock units for his service as
Chairman of the Board.
Pursuant to an agreement between the Company and
Mr. Sissener dated July 1, 1999, as amended in March
2004, in 2006 Mr. Sissener received $66,667 for serving as
Chairman of the Board (and as a director of certain of the
Companys subsidiaries) through June 29, 2006. In
addition, Mr. Sissener received 5,000 restricted stock
units pursuant to the Companys 2003 Omnibus Incentive
Compensation Plan and meeting fees of $11,100
Until January 1, 2007, directors had the ability to
participate in the Companys Deferred Compensation Plan, as
amended and restated on January 1, 2005, through which they
were able to defer receipt of cash compensation, and earn
interest quarterly on such deferred amounts, at the rate of two
percentage points below the prime rate (as published in the Wall
Street Journal), provided such amount did not exceed 12% or be
less than 4%. Effective January 1, 2006, the Companys
Deferred Compensation Plan was frozen, prohibiting participants
from making future deferrals of cash compensation.
Potential
Payments upon Termination or Change in Control of the
Company
Ingrid Wiik. Ms. Wiik retired from the
Company on June 30, 2006. As part of the plan of CEO
succession, Ms. Wiik agreed to remain as CEO through the
hiring and start date of the new CEO. The Company formalized the
terms of Ms. Wiiks retention and contribution to this
process, as well as the payments and benefits to be provided to
Ms. Wiik after retirement through an agreement executed
June 29, 2006. This agreement was disclosed publicly
through a
Form 8-K,
filed with the SEC on July 6, 2006.
The material terms of Ms Wiiks agreement are as follows:
|
|
|
|
|
Ms. Wiik agreed to remain as CEO through June 30,
2006. The general terms of her base pay and bonus were
maintained through this date (annual base pay of $710,000 and
target bonus of 100% of base pay). No new equity-based long-term
incentive award was granted to Ms. Wiik for her service
during 2006. Ms. Wiik has continued to serve as a director
of the Company and receives the standard director compensation.
In 2006 for serving as a non-executive director she received
fees totaling $26,025 and 5,000 shares of restricted stock
units.
|
|
|
|
The agreement requires compliance with the terms of restrictive
covenants, including:
|
|
|
|
|
|
A one-year prohibition on competing with the Company;
|
|
|
|
Restrictions on conveying or making use of confidential
information of the Company; and
|
|
|
|
A two-year prohibition on making disparaging comments about the
Company.
|
44
|
|
|
|
|
In connection with her agreement Ms. Wiik entered into a
waiver of legal claims against the Company.
|
|
|
|
In exchange for continued employment through the CEO succession
process, the Company paid Ms. Wiik a lump sum payment of
$1,456,547 (a retention payment equal to $1,420,000 plus
interest).
|
|
|
|
Ms. Wiik was paid a $355,000 pro rata annual bonus for the
portion of 2006 worked.
|
|
|
|
Settlement of Ms. Wiiks outstanding equity-based
long-term incentives occurred as follows:
|
|
|
|
|
|
Stock Options: Upon Ms. Wiiks
retirement on June 30, 2006, 25,000 unvested options were
accelerated and vested. The aggregate spread on June 30,
2006 of these unvested options was $189,500. On June 30,
2006, the aggregate spread of vested options was $319,875 and
the aggregate spread of unvested options was $641,625.
|
|
|
|
Restricted Stock: The majority of
Ms. Wiiks outstanding restricted shares were
forfeited upon her retirement. The remaining outstanding
restricted shares, having a total value of $120,200 on
June 30, 2006, will vest on July 1, 2007.
|
|
|
|
Performance Units: Ms. Wiiks
outstanding Performance Units were vested on a pro rata basis
(based on the amount of time employed during the three-year
performance cycle as a percentage of the total three-year
cycle), assuming targeted levels of performance. The value of
this payout was $854,780 (which was the value of the Performance
Units plus interest), and was paid six months and one day after
Ms. Wiiks retirement.
|
|
|
|
|
|
Ms. Wiik had filed a
Section 10b5-1
stock option exercise program, and 164,500 of
Ms. Wiiks options were scheduled to be exercised on
August 28, 2006. The Company failed to properly execute on
this predetermined exercise program, and the covered options
expired without having been exercised. As a settlement to this
issue, the Company paid Ms. Wiik the
in-the-money
value of the option spread that would have been realized on
August 28, 2006, assuming that the options had been
exercised as intended, according to the terms of the
Section 10b5-1
plan.
|
|
|
|
Ms. Wiik was paid an additional award of $1,475,000 in
connection with her retirement.
|
|
|
|
Ms. Wiiks retirement and deferred compensation
arrangements were paid according to their pre-existing terms.
The details of these programs and the amounts paid or payable to
Ms. Wiik are described in the Pension Benefits and
Nonqualified Deferred Compensation sections of this proxy
statement.
|
|
|
|
Consistent with the terms of Ms. Wiiks prior
employment agreement, the new agreement provided for
reimbursement of tax and financial planning assistance. This
included tax assistance in moving back to Norway, as well as a
tax gross up on the payments. The aggregate payments for these
arrangements were $352,612.
|
|
|
|
The Company reimbursed Ms. Wiik for the cost of moving her
residency back to Norway, and also
grossed-up
this amount for the impact of income taxes. The cost of this
arrangement was $8,965.
|
|
|
|
The value of Ms. Wiiks accrued vacation that was paid
to her after termination was $40,962.
|
Matthew Farrell: Mr. Farrell voluntarily
resigned from the Company effective on September 8, 2006.
Consistent with the terms of Mr. Farrells retention
agreement executed in December 2005, the Company did not make
any severance or other termination-related payments to
Mr. Farrell in connection with his resignation. All
outstanding stock options and restricted shares that were
unvested as of Mr. Farrells termination date lapsed
with no value.
45
George Rose: Mr. Rose voluntarily
resigned from the Company effective December 31, 2006. The
separation agreement with Mr. Rose was disclosed publicly
through the Companys
10-K, filed
with the SEC on March 1, 2007. The material terms of
Mr. Roses separation agreement were as follows:
|
|
|
|
|
Mr. Rose was paid a bonus relating to performance in 2006
based on actual results during the year, according to the normal
operation of the bonus program. This amount was $125,000, and
has been paid to Mr. Rose.
|
|
|
|
Mr. Rose was paid the installment of his retention
arrangement that vested on December 31, 2006. This amount
is approximately $160,000 and has been paid to Mr. Rose.
|
|
|
|
All outstanding stock options and restricted shares that were
unvested as of December 31, 2006 terminated on that date.
The exercise price of Mr. Roses vested options all
exceeded the Companys share price on December 31,
2006, and therefore had no intrinsic value on that date.
|
|
|
|
Mr. Roses performance units vested according to their
own terms on December 31, 2006, with no changes related to
Mr. Roses termination. The value of these performance
units was $180,000.
|
|
|
|
Mr. Rose was paid severance equal to one years base
salary plus executive allowance. This amount was $328,600, and
will be paid to him in a lump sum six months after his
termination date.
|
|
|
|
As part of Mr. Roses Separation Agreement,
Mr. Rose could have requested that the Company waive his
COBRA premiums for the 12 months following termination.
However, Mr. Rose chose not to enroll in COBRA coverage and
therefore derived no benefit from this option.
|
|
|
|
Mr. Rose was paid $17,308 for accrued vacation time.
|
|
|
|
As part of Mr. Roses separation, he entered into a
non-disparagement and confidentiality arrangement with the
Company which are not limited in duration. In addition,
Mr. Rose executed a waiver of legal claims.
|
Robert Wrobel: Mr. Wrobel entered into an
agreement with the Company spelling out the terms of
Mr. Wrobels retirement from active service as Chief
Legal Officer. This arrangement was disclosed publicly through a
Form 8-K,
filed with the SEC on September 26, 2006. The material
terms of the arrangement are as follows:
|
|
|
|
|
Mr. Wrobel will retire from the Company between
January 15, 2007 and June 30, 2007.
|
|
|
|
Mr. Wrobel will receive the last scheduled installment of
his retention arrangement (approximately $215,000) having a
vesting date of June 29, 2007 (this arrangement was
disclosed publicly through a
Form 8-K,
filed with the SEC on December 19, 2005). This amount shall
be paid in a lump sum on Mr. Wrobels retirement date.
|
|
|
|
Mr. Wrobel will be paid his annual bonus at the targeted
level, pro rated based on the length of time worked during 2007
(estimated at $102,500, based on the assumption that
Mr. Wrobels retirement date will be June 30,
2007). This amount shall be paid in a lump sum on
Mr. Wrobels retirement date.
|
|
|
|
Mr. Wrobel will be paid a lump sum amount equal to his
severance coverage under the Alpharma Inc. Severance Plan
(approximately $965,400 plus accrued interest for six months in
the amount of $28,962, totaling $994,362). In the event a
binding agreement for a change in control event is executed by
the Company prior to Mr. Wrobels retirement date, he
will be paid the benefits set forth under the Companys
Change in Control Plan in lieu of the severance described above
(this change in control-related severance is estimated at
$1,230,000) as modified by his retention agreement.
|
46
|
|
|
|
|
Health and welfare coverage for Mr. Wrobel and his spouse
will be continued for 18 months at the active-employee
rate. For 2007, the active-employee rate for
Mr. Wrobels elected level of medical and dental
coverage is $267.58 per month; the 2008 active employee
rate is not yet known. In addition, Mr. Wrobel will be paid
an amount equal to the employer-paid premiums paid by
Mr. Wrobel for the first six months of coverage (in order
to comply with Section 409A of the IRC) of $4,772 plus
$4,124 for tax gross ups. For the remaining 12 months of
Mr. Wrobels and his spouses coverage, the
Company will pay the employer-paid premiums. Additionally,
Mr. Wrobel is entitled to $40,000 plus $34,557 for tax
gross up representing the estimated actuarial equivalent of
providing continued health and welfare benefit coverage for
Mr. Wrobels spouse from the date that her coverage
ends, pursuant to COBRA, through April 22, 2012.
|
|
|
|
Upon Mr. Wrobels retirement date, the vesting of all
outstanding options and restricted shares then held by
Mr. Wrobel will be accelerated. The value of these unvested
awards is estimated to be $91,945, based on an assumed stock
price of $24.10 (measured as a function of the
in-the-money
spread of options and the full value of restricted shares). The
aggregate estimated
in-the-money
spread value of outstanding options that will be exercisable on
the assumed June 30, 2007 retirement date is $202,040.
|
|
|
|
Mr. Wrobel will remain eligible for his vested benefits
under the Companys retirement plans.
|
|
|
|
Mr. Wrobel has agreed to abide by the terms of a
non-disparagement and confidentiality agreement which are not
limited in duration. In addition, Mr. Wrobel has agreed to
execute a waiver of legal claims.
|
Dean Mitchell: Mr. Mitchell has entered
into an employment agreement with the Company providing the
terms that would apply to various forms of employment
termination. This agreement was disclosed publicly through a
Form 8-K,
filed with the SEC on June 5, 2006. The material terms of
the agreement are as follows:
|
|
|
|
|
Service as President and CEO at a beginning base salary of
$625,000.
|
|
|
|
A sign-on bonus of $100,000.
|
|
|
|
A targeted annual bonus opportunity of 100% of base pay. The
2006 annual bonus will be paid as if Mr. Mitchell worked
for the Company throughout all of 2006.
|
|
|
|
The right to participate in any equity or long-term incentive
plans of the Company.
|
|
|
|
Mr. Mitchell was granted an option to purchase
100,000 shares of the Company stock at the exercise price
on the date of grant ($23.73). The options vest 25% on each of
the first four anniversaries of the grant date. Regardless of
cause or reason, Mr. Mitchell would have 90 days after
termination of employment to exercise any vested options (except
that if termination is for Cause (as defined below) the period
would be 30 days. In addition, he was awarded 40,000
restricted shares that vest on the third anniversary of the
grant. This restricted stock grant will vest on an accelerated
basis in the event Mr. Mitchells employment with the
Company terminated without Cause or in the event of
Mr. Mitchells death, disability or retirement with
the Company for Good Reason.
|
|
|
|
An annual executive allowance of $35,000, paid in equal
installments on a bi-weekly basis.
|
|
|
|
Participation in general health and welfare benefits
commensurate with Mr. Mitchells position with the
Company, including life insurance coverage with a maximum
benefit level of $1,000,000.
|
|
|
|
Except as provided below in the case of a change in
control-related termination, in the event of an involuntary
termination without Cause (generally defined as conviction of a
felony or substantial and willful neglect of duties having a
material impact on the Company) or a voluntary termination for
Good Reason (generally defined as any of the following, provided
the Company fails to cure the event upon 10 days written
|
47
|
|
|
|
|
notice, (i) a reduction in base salary or targeted bonus
opportunity; (ii) a forced relocation of greater than
50 miles; (iii) a material reduction in health or
welfare benefits; (iv) a material diminution of
Mr. Mitchells job responsibilities, duties, or status
within the Company; (v) removal as President or CEO;
(vi) failure to appoint Mr. Mitchell to the Board;
(vii) a change in Mr. Mitchells direct reporting
relationship with the Board, (viii) a material breach by
the Company of Mr. Mitchells employment agreement or
(ix) the failure of the Company to obtain the assumption in
writing of its obligations under Mr. Mitchells
agreement by any successor entity), Mr. Mitchells
severance would be as follows:
|
|
|
|
|
|
Cash severance equal to 24 months of base salary plus two
times his target annual bonus, all paid in equal annual
installments over the 24 months after termination;
|
|
|
|
Pro rata payment of the annual bonus for the year of
termination, based on the length of time worked during the year
prior to termination, and determined based on actual results;
|
|
|
|
Accelerated vesting of unvested restricted shares;
|
|
|
|
Continuation of health and welfare benefits for 24 months
after termination of employment.
|
|
|
|
|
|
Qualifying Event: If Mr. Mitchells
employment termination occurs in connection with a change in
control of the Company (i.e., if the termination occurs within
the period starting three months before a change in control and
ending two years after the change in control),
Mr. Mitchells severance would be as follows:
|
|
|
|
|
|
Cash severance equal to 36 months of base salary plus three
times his target annual bonus. These amounts would be paid in
cash, in one lump sum, as follows:
|
|
|
|
|
|
If the termination occurs within three months before or
concurrent with the change in control, the payment would be made
upon the effective date of the change in control;
|
|
|
|
If the termination occurs after the change in control, the
payment would be made upon the effective date of the termination.
|
|
|
|
|
|
Pro rata payment of the annual bonus for the year of
termination, based on the length of time worked during the year
prior to termination, and determined based on actual results;
|
|
|
|
Accelerated vesting of unvested stock options upon the effective
date of the change in control (all options would remain
exercisable for the remainder of the original term of the
option);
|
|
|
|
Accelerated vesting of unvested restricted shares (and
restricted stock units) upon an involuntary termination without
Cause or a voluntary termination for Good Reason (both as
defined above) and accelerated vesting of unvested restricted
shares upon the acquisition of all or substantially all of the
Companys issued and outstanding common stock by the
acquiring company involved in the change in control;
|
|
|
|
Continuation of health and welfare benefits for 36 months
after termination of employment;
|
|
|
|
In the event parachute excise taxation would be triggered by the
above payments and benefits, the Company would gross up
Mr. Mitchells severance to offset the impact of the
excise taxes.
|
All of the above change in control-related severance benefits
are contingent upon Mr. Mitchell executing a release of
legal claims against the Company. Mr. Mitchell is also
subject to a non-disclosure agreement which is unlimited in
duration, and a non-competition, non-solicitation and
non-interference with business relationships agreement, which is
effective for a period of 12 months following
Mr. Mitchells termination for any reason.
48
The following table reflects the estimated payments and benefits
associated with various types of possible employment
terminations:
Dean
Mitchell Potential Payments upon Termination or a Change in
Control
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Change in
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Control
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Voluntary for
|
|
|
|
|
|
Followed by
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Involuntary
|
|
|
Involuntary
|
|
|
Good
|
|
|
Change in
|
|
|
Qualifying
|
|
|
|
Voluntary
|
|
|
Retirement
|
|
|
Disability
|
|
|
Death
|
|
|
for Cause
|
|
|
without Cause
|
|
|
Reason
|
|
|
Control
|
|
|
Event
|
|
|
Amounts Vested Prior to
Termination
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
DB Pension Present Value
|
|
$
|
|
|
|
$
|
|
|
|
$
|
|
|
|
$
|
|
|
|
$
|
|
|
|
$
|
|
|
|
$
|
|
|
|
$
|
|
|
|
$
|
|
|
DB Supplemental Pension Present
Value
|
|
$
|
|
|
|
$
|
|
|
|
$
|
|
|
|
$
|
|
|
|
$
|
|
|
|
$
|
|
|
|
$
|
|
|
|
$
|
|
|
|
$
|
|
|
Savings Plan Balance
|
|
$
|
9,163
|
|
|
$
|
9,163
|
|
|
$
|
9,163
|
|
|
$
|
9,163
|
|
|
$
|
9,163
|
|
|
$
|
9,163
|
|
|
$
|
9,163
|
|
|
$
|
9,163
|
|
|
$
|
9,163
|
|
Supplemental Savings Balance
|
|
$
|
|
|
|
$
|
|
|
|
$
|
|
|
|
$
|
|
|
|
$
|
|
|
|
$
|
|
|
|
$
|
|
|
|
$
|
|
|
|
$
|
|
|
Deferred Compensation Balance
|
|
$
|
|
|
|
$
|
|
|
|
$
|
|
|
|
$
|
|
|
|
$
|
|
|
|
$
|
|
|
|
$
|
|
|
|
$
|
|
|
|
$
|
|
|
Accrued Vacation
|
|
$
|
48,077
|
|
|
$
|
48,077
|
|
|
$
|
48,077
|
|
|
$
|
48,077
|
|
|
$
|
48,077
|
|
|
$
|
48,077
|
|
|
$
|
48,077
|
|
|
$
|
48,077
|
|
|
$
|
48,077
|
|
Vested Option Spread Value
|
|
$
|
|
|
|
$
|
|
|
|
$
|
|
|
|
$
|
|
|
|
$
|
|
|
|
$
|
|
|
|
|
|
|
|
$
|
|
|
|
$
|
|
|
Disability Pay
|
|
$
|
|
|
|
$
|
|
|
|
$
|
|
|
|
$
|
|
|
|
$
|
|
|
|
$
|
|
|
|
|
|
|
|
$
|
|
|
|
$
|
|
|
Bonus for Year of Termination
|
|
$
|
|
|
|
$
|
625,000
|
|
|
$
|
625,000
|
|
|
$
|
625,000
|
|
|
$
|
|
|
|
$
|
625,000
|
|
|
$
|
625,000
|
|
|
$
|
625,000
|
|
|
$
|
625,000
|
|
Sign-on Bonus
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$
|
100,000
|
|
|
$
|
100,000
|
|
|
|
|
|
|
|
|
|
Total Pre-Termination Vested
Value
|
|
$
|
57,239
|
|
|
$
|
682,239
|
|
|
$
|
682,239
|
|
|
$
|
682,239
|
|
|
$
|
57,239
|
|
|
$
|
782,239
|
|
|
$
|
782,239
|
|
|
$
|
682,239
|
|
|
$
|
682,239
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Amounts Vested at or After
Termination
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash Severance
|
|
$
|
|
|
|
$
|
|
|
|
$
|
|
|
|
$
|
|
|
|
$
|
|
|
|
$
|
2,500,000
|
|
|
$
|
2,500,000
|
|
|
$
|
|
|
|
$
|
3,750,000
|
|
Unvested Option Value
|
|
$
|
|
|
|
$
|
37,000
|
|
|
$
|
37,000
|
|
|
$
|
37,000
|
|
|
$
|
|
|
|
$
|
|
|
|
|
|
|
|
$
|
37,000
|
|
|
$
|
37,000
|
|
Restricted Stock/Unit Value
|
|
$
|
|
|
|
$
|
964,000
|
|
|
$
|
964,000
|
|
|
$
|
964,000
|
|
|
$
|
|
|
|
$
|
964,000
|
|
|
$
|
964,000
|
|
|
|
|
|
|
$
|
964,000
|
|
Health and Welfare
|
|
$
|
|
|
|
$
|
|
|
|
$
|
|
|
|
$
|
|
|
|
$
|
|
|
|
$
|
27,575
|
|
|
|
|
|
|
|
|
|
|
$
|
41,362
|
|
Perquisites
|
|
$
|
|
|
|
$
|
|
|
|
$
|
|
|
|
$
|
|
|
|
$
|
|
|
|
$
|
|
|
|
|
|
|
|
$
|
|
|
|
$
|
|
|
Outplacement
|
|
$
|
|
|
|
$
|
|
|
|
$
|
|
|
|
|
|
|
|
$
|
|
|
|
$
|
20,000
|
|
|
|
|
|
|
$
|
|
|
|
$
|
20,000
|
|
Excise Tax
Gross-Up
|
|
$
|
|
|
|
$
|
|
|
|
$
|
|
|
|
$
|
|
|
|
$
|
|
|
|
$
|
|
|
|
|
|
|
|
$
|
|
|
|
$
|
1,478,104
|
|
Total Value Vested at or After
Termination
|
|
$
|
|
|
|
$
|
1,001,000
|
|
|
$
|
1,001,000
|
|
|
$
|
1,001,000
|
|
|
$
|
|
|
|
$
|
3,511,575
|
|
|
$
|
3,464,000
|
|
|
$
|
37,000
|
|
|
$
|
6,290,466
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total Value
|
|
$
|
57,239
|
|
|
$
|
1,683,239
|
|
|
$
|
1,683,239
|
|
|
$
|
1,683,239
|
|
|
$
|
57,239
|
|
|
$
|
4,293,814
|
|
|
$
|
4,246,239
|
|
|
$
|
719,239
|
|
|
$
|
6,972,705
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Jeffrey Campbell: In 2006 Mr. Campbell
entered into an employment agreement with the Company providing
the terms that would apply to his position as Interim Chief
Financial Officer. This agreement was disclosed publicly through
a
Form 8-K,
filed with the SEC on September 26, 2006. The material
terms of the agreement were as follows:
|
|
|
|
|
Mr. Campbell agreed to serve as Interim Chief Financial
Officer at a continued base salary rate of $294,000.
|
|
|
|
Mr. Campbells 2006 annual bonus was guaranteed at an
amount equal to at least $220,500, contingent on continued
employment through the year.
|
|
|
|
For any portion of the 2007 year employed as Interim Chief
Financial Officer, Mr. Campbell was guaranteed a bonus
equal to at least 75% of his base salary, provided that he has
not voluntarily terminated his employment with the Company or
been terminated by the Company for Cause while serving as
Interim Chief Financial Officer.
|
49
|
|
|
|
|
Mr. Campbell was awarded 20,000 restricted shares that are
scheduled to vest on December 31, 2007. In the event
Mr. Campbells employment is terminated by the Company
other than for Cause prior to December 31, 2007, the
restricted shares will vest on an accelerated basis.
|
|
|
|
For the period of his service as Interim Chief Financial
Officer, and for six months following such period, the Company
agreed to cover Mr. Campbell under the Companys
Change in Control Plan and Severance Plan on terms generally
applicable to members of the Companys Senior Executive
Leadership Team. With respect to a qualifying termination
following a change in control of the Company, Mr. Campbell
would be covered by the following severance provisions:
|
|
|
|
|
|
All of Mr. Campbells unvested stock options would
immediately vest.
|
|
|
|
Qualifying Event: In the event of a qualifying
termination within two years of the change in control of the
Company, Mr. Campbell would be paid severance equal to
30 months of his base salary and target annual bonus
opportunity, payable in installments over 30 months. The
vesting of all outstanding unvested restricted shares (and
restricted stock units) would be accelerated upon the qualifying
employment termination (or earlier in the event that the
acquiring company purchases all or substantially all of the
Companys issued and outstanding common stock).
|
|
|
|
Mr. Campbells health and welfare benefit coverage
would be continued for 30 months.
|
|
|
|
For purposes of this change in control severance, a qualifying
termination would be deemed to exist in either of the following
circumstances:
|
|
|
|
|
|
An involuntary termination without Cause (generally
defined as conviction of a felony or substantial and willful
neglect of duties having a material impact on the
Company); or
|
|
|
|
A Constructive Termination (generally defined as
(i) a reduction in base salary or targeted bonus
opportunity; (ii) a forced relocation of greater than
50 miles; (iii) a material reduction in health or
welfare benefits; or (iv) a substantial diminution of
Mr. Campbells job responsibilities, duties, or status
within the Company).
|
|
|
|
|
|
If a qualifying termination, as described above, occurs, or if
the entity effecting the change in control purchases or acquires
all or substantially all of the Companys common stock,
then:
|
|
|
|
|
|
The vesting of all outstanding unvested restricted shares (and
restricted stock units) would be accelerated; and
|
|
|
|
All Performance Units would be valued on a date as close as
practicable to the date on which either event was first
satisfied and the sum due would be paid to Mr. Campbell.
|
|
|
|
|
|
In the event that any of the above amounts would result in
excise taxes under Tax Code Section 4999, the payments
would be reduced to the point at which no excise taxes would
apply; provided that, if uncapping the payments would result in
Mr. Campbell receiving greater after-tax benefits (after
paying his own excise taxes), the amounts would be uncapped. As
reflected in the table appearing below, the calculations
associated with an assumed change in control on
December 29, 2006 indicate that no excise taxes would have
been owed by Mr. Campbell.
|
50
|
|
|
|
|
On April 16, 2007, the Company entered into a new
employment agreement with Jeffrey Campbell, documenting the
terms of his transition from interim CFO to fully appointed CFO.
This new agreement provides for the following:
|
|
|
|
|
|
Base salary at an annual rate of $400,000, starting immediately
after execution of the new agreement;
|
|
|
|
Executive allowance of $28,600 per year;
|
|
|
|
Targeted annual bonus equal to 50% of base pay, applicable to
the portion of 2007 after the execution of the new agreement,
through December 31, 2007. For the portion of 2007 between
January 1, 2007 and the execution of the new contract,
Mr. Campbells bonus will be paid at the annual rate
of $220,500, prorated for the portion of 2007 prior to the
execution of the new contract and subject to increase at the
discretion of the Company;
|
|
|
|
An option to purchase 14,000 Company shares, with the exercise
price equal to the Companys closing stock price on the
date of grant of the option (May 15, 2007), and vesting
25% per year;
|
|
|
|
A performance-based restricted stock unit award of 3,100
restricted units, to be granted May 15, 2007. Vesting will
be based on the achievement of performance goals; and
|
|
|
|
Coverage under the Companys Severance and Change in
Control Plans.
|
51
Jeffrey
Campbell Potential Payments upon Termination or a Change in
Control
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Change in
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Control
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Involuntary
|
|
|
|
|
|
Followed by
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Involuntary
|
|
|
without
|
|
|
Change in
|
|
|
Qualifying
|
|
|
|
Voluntary
|
|
|
Retirement
|
|
|
Disability
|
|
|
Death
|
|
|
for Cause
|
|
|
Cause
|
|
|
Control
|
|
|
Event
|
|
|
Amounts Vested Prior to
Termination
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
DB Pension Present Value
|
|
$
|
39,729
|
|
|
$
|
39,729
|
|
|
$
|
39,729
|
|
|
$
|
19,864
|
|
|
$
|
39,729
|
|
|
$
|
39,729
|
|
|
$
|
39,729
|
|
|
$
|
39,729
|
|
DB Supplemental Pension Present
Value
|
|
$
|
|
|
|
$
|
|
|
|
$
|
|
|
|
$
|
|
|
|
$
|
|
|
|
$
|
|
|
|
$
|
|
|
|
$
|
|
|
Savings Plan Balance
|
|
$
|
79,952
|
|
|
$
|
79,952
|
|
|
$
|
79,952
|
|
|
$
|
79,952
|
|
|
$
|
79,952
|
|
|
$
|
79,952
|
|
|
$
|
79,952
|
|
|
$
|
79,952
|
|
Supplemental Savings Balance
|
|
$
|
82,560
|
|
|
$
|
82,560
|
|
|
$
|
82,560
|
|
|
$
|
82,560
|
|
|
$
|
82,560
|
|
|
$
|
82,560
|
|
|
$
|
82,560
|
|
|
$
|
82,560
|
|
Deferred Compensation Balance
|
|
$
|
76,703
|
|
|
$
|
76,703
|
|
|
$
|
76,703
|
|
|
$
|
76,703
|
|
|
$
|
76,703
|
|
|
$
|
76,703
|
|
|
$
|
76,703
|
|
|
$
|
76,703
|
|
Accrued Vacation
|
|
$
|
22,615
|
|
|
$
|
22,615
|
|
|
$
|
22,615
|
|
|
$
|
22,615
|
|
|
$
|
22,615
|
|
|
$
|
22,615
|
|
|
$
|
22,615
|
|
|
$
|
22,615
|
|
Vested Option Spread Value
|
|
$
|
121,162
|
|
|
$
|
121,162
|
|
|
$
|
121,162
|
|
|
$
|
121,162
|
|
|
$
|
|
|
|
$
|
121,162
|
|
|
$
|
121,162
|
|
|
$
|
121,162
|
|
Disability Pay
|
|
$
|
|
|
|
$
|
|
|
|
$
|
|
|
|
$
|
|
|
|
$
|
|
|
|
$
|
|
|
|
$
|
|
|
|
$
|
|
|
Bonus for Year of Termination
|
|
$
|
|
|
|
$
|
220,500
|
|
|
$
|
220,500
|
|
|
$
|
220,500
|
|
|
$
|
|
|
|
$
|
220,500
|
|
|
$
|
220,500
|
|
|
$
|
220,500
|
|
Performance Unit Payout
|
|
$
|
|
|
|
$
|
|
|
|
$
|
100,000
|
|
|
$
|
100,000
|
|
|
$
|
|
|
|
$
|
100,000
|
|
|
$
|
100,000
|
|
|
$
|
100,000
|
|
Total Pre-Termination Vested
Value
|
|
$
|
422,721
|
|
|
$
|
643,221
|
|
|
$
|
743,221
|
|
|
$
|
723,357
|
|
|
$
|
301,559
|
|
|
$
|
743,221
|
|
|
$
|
743,221
|
|
|
$
|
743,221
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Amounts Vested at or After
Termination
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash Severance
|
|
$
|
|
|
|
$
|
|
|
|
$
|
|
|
|
$
|
|
|
|
$
|
|
|
|
$
|
322,600
|
|
|
$
|
|
|
|
$
|
1,286,250
|
|
Unvested Option Value
|
|
$
|
|
|
|
$
|
88,856
|
|
|
$
|
88,856
|
|
|
$
|
88,856
|
|
|
$
|
|
|
|
$
|
|
|
|
$
|
88,856
|
|
|
$
|
88,856
|
|
Restricted Stock/Unit Value
|
|
$
|
|
|
|
$
|
855,550
|
|
|
$
|
855,550
|
|
|
$
|
855,550
|
|
|
$
|
|
|
|
$
|
855,550
|
|
|
$
|
|
|
|
$
|
855,550
|
|
Health and Welfare
|
|
$
|
|
|
|
$
|
|
|
|
$
|
|
|
|
$
|
|
|
|
$
|
|
|
|
$
|
13,514
|
|
|
|
|
|
|
$
|
20,270
|
|
Perquisites
|
|
$
|
|
|
|
$
|
|
|
|
$
|
|
|
|
$
|
|
|
|
$
|
|
|
|
$
|
|
|
|
$
|
|
|
|
$
|
|
|
Outplacement
|
|
$
|
|
|
|
$
|
|
|
|
$
|
|
|
|
|
|
|
|
$
|
|
|
|
$
|
20,000
|
|
|
$
|
|
|
|
$
|
20,000
|
|
Excise Tax
Gross-Up
|
|
$
|
|
|
|
$
|
|
|
|
$
|
|
|
|
$
|
|
|
|
$
|
|
|
|
$
|
|
|
|
$
|
|
|
|
$
|
|
|
Total Value Vested at or After
Termination
|
|
$
|
|
|
|
$
|
944,406
|
|
|
$
|
944,406
|
|
|
$
|
944,406
|
|
|
$
|
|
|
|
$
|
1,211,664
|
|
|
$
|
88,856
|
|
|
$
|
2,270,926
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total Value
|
|
$
|
422,721
|
|
|
$
|
1,587,627
|
|
|
$
|
1,687,627
|
|
|
$
|
1,667,763
|
|
|
$
|
301,559
|
|
|
$
|
1,954,884
|
|
|
$
|
832,077
|
|
|
$
|
3,014,147
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Ronald Warner: Mr. Warner has entered
into an employment agreement with the Company providing the
terms that would apply to various forms employment termination.
This agreement was disclosed publicly through a
Form 8-K,
filed with the SEC on December 22, 2005. The material terms
of the agreement are as follows:
|
|
|
|
|
In connection with the sale of the Generics business in December
2005, top executives, including Mr. Warner, entered into
retention arrangements to help ensure the continuity of the
management team through the post-transaction transition period.
As part of these arrangements, the executives were offered
retention incentives that vested over the 18 months after
the Generics sale. In the event of a change in control of the
Company, or certain qualifying employment terminations, the
unvested portion of the retention incentive would be accelerated
and paid. This amount would be paid in cash, in one lump sum.
|
The chart below details the types of employment termination that
would qualify for the accelerated payment, as well as the value
of the payment that would occur in the event the qualifying
termination or event were to have occurred on December 29,
2006. The payment reflected in the chart includes two-thirds of
the total retention incentive value, however, one-third of the
total retention value was scheduled to be paid on
December 29, 2006, regardless of whether a qualifying event
or termination occurred on that date. Accordingly, the portion
of the payment that actually would have been additive due to a
qualifying event or termination on December 29, 2006 is
shown in the bottom section of the chart (under Amounts
Vested at or
52
After Termination), whereas the portion that would have
been paid regardless of a qualifying event or termination (due
to full vesting on December 29, 2006) is shown in the
top section of the chart (under Amounts Vested Prior to
Termination).
|
|
|
|
|
The balance relating to outstanding Performance Units would have
been pain in cash, in one lump sum. The Performance Units would
be paid at targeted levels of performance. This amount would be
paid in cash, in one lump sum.
|
The chart below details the types of employment termination that
would qualify for the accelerated payment, as well as the value
of the payment that would occur in the event the qualifying
termination or event were to have occurred on December 29,
2006. Since this amount was fully vested on December 29,
2006, regardless of whether a qualifying event or termination
occurred, it is reflected in the top section of the chart (under
Amounts Vested Prior to Termination).
|
|
|
|
|
In the event of a qualifying sale of the Pharmaceuticals
business (Pharmaceuticals), or a change in control
of the Company, certain additional amounts would become vested
and paid. In particular:
|
|
|
|
|
|
If the triggering event is a qualifying sale of Pharmaceuticals
occurring after
June 30th
of the applicable calendar year, Mr. Warners annual
bonus award would be paid in cash, at the actual earned amount,
based on performance during the year. Because the assumption
underlying this disclosure is that the qualifying event occurred
on December 29, 2006, this bonus payout would represent the
full-year value of the bonus. This amount would have been vested
as of December 29, 2006, and therefore the chart below
reflects the value within the top section of the chart (under
Amounts Vested Prior to Termination).
|
If the triggering event is a change in control of the Company
(or had the hypothetical qualifying sale occurred before
June 30th of the applicable calendar year), the annual
bonus would be paid at the targeted level of performance.
|
|
|
|
|
In the event of a qualifying sale of Pharmaceuticals, all of
Mr. Warners unvested stock options, restricted
shares, and restricted stock units would immediately vest.
However, if the transaction is a change in control of the
Company, unvested restricted shares and restricted stock units
would vest upon the earlier to occur of any of the following
Qualifying Events: (1) the scheduled vesting
date; (2) the termination of Mr. Warners
employment within two years after the consummation of the change
in control; or (3) the acquisition of all or substantially
all of the Companys issued and outstanding common stock by
the acquiring company.
|
|
|
|
In the event of a qualifying termination within two years of the
sale of Pharmaceuticals or change in control of the Company,
Mr. Warner would be paid severance in monthly installments
over 24 months equal to two times the sum of his base
salary and target annual bonus opportunity. In addition,
Mr. Warners health and welfare benefit coverage would
be continued for two years.
|
For purposes of this severance, a qualifying termination would
be deemed to exist in either of the following circumstances:
|
|
|
|
|
An involuntary termination without Cause (generally
defined as conviction of a felony or substantial and willful
neglect of duties having a material impact on the
Company); or
|
|
|
|
A Constructive Termination (generally defined as
(i) a reduction in base salary or targeted bonus
opportunity; (ii) a forced relocation of greater than
50 miles; (iii) a material reduction in health or
welfare benefits; or (iv) a substantial diminution of
Mr. Warners job responsibilities, duties, or status
within the Company).
|
53
In the event that any of the above amounts would result in
excise taxes under tax code section 4999, the Company would
gross up the payments in order to offset the impact to
Mr. Warner of the excise taxes. As reflected in the table
appearing below, the calculations associated with an assumed
change in control on December 29, 2006 indicate that no
excise taxes would have been owed by Mr. Warner, and
therefore no gross up payment would have been required to be
made.
Mr. Warner would also be entitled to outplacement services.
|
|
|
|
|
The payments and benefits provided under Mr. Warners
employment contract are all subject to restrictive covenants
that prohibit (i) competition with the Company for a period
of
12-months,
(ii) interference with the Companys business for a
period of 24 months and (iii) solicitation of the
Companys employees for a period of 24 months.
|
Ronald
Warner Potential Payments upon Termination or a Change in
Control
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Sale of
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Change in
|
|
|
|
|
|
Branded
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Control
|
|
|
Sale of
|
|
|
Pharma
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Involuntary
|
|
|
Involuntary
|
|
|
|
|
|
Followed by
|
|
|
Branded
|
|
|
Followed by
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
for
|
|
|
without
|
|
|
Change in
|
|
|
Qualifying
|
|
|
Pharma
|
|
|
Qualifying
|
|
|
|
Voluntary
|
|
|
Retirement
|
|
|
Disability
|
|
|
Death
|
|
|
Cause
|
|
|
Cause
|
|
|
Control
|
|
|
Termination
|
|
|
Business
|
|
|
Event
|
|
|
Amounts Vested Prior to
Termination
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
DB Pension Present Value
|
|
$
|
52,776
|
|
|
$
|
52,776
|
|
|
$
|
52,776
|
|
|
$
|
26,388
|
|
|
$
|
52,776
|
|
|
$
|
52,776
|
|
|
$
|
52,776
|
|
|
$
|
52,776
|
|
|
$
|
52,776
|
|
|
$
|
52,776
|
|
DB Supplemental Pension Present
Value
|
|
$
|
|
|
|
$
|
|
|
|
$
|
|
|
|
$
|
|
|
|
$
|
|
|
|
$
|
|
|
|
$
|
|
|
|
$
|
|
|
|
$
|
|
|
|
$
|
|
|
Savings Plan Balance
|
|
$
|
76,556
|
|
|
$
|
76,556
|
|
|
$
|
76,556
|
|
|
$
|
76,556
|
|
|
$
|
76,556
|
|
|
$
|
76,556
|
|
|
$
|
76,556
|
|
|
$
|
76,556
|
|
|
$
|
76,556
|
|
|
$
|
76,556
|
|
Supplemental Savings Balance
|
|
$
|
37,139
|
|
|
$
|
37,139
|
|
|
$
|
37,139
|
|
|
$
|
37,139
|
|
|
$
|
37,139
|
|
|
$
|
37,139
|
|
|
$
|
37,139
|
|
|
$
|
37,139
|
|
|
$
|
37,139
|
|
|
$
|
37,139
|
|
Deferred Compensation Balance
|
|
$
|
34,637
|
|
|
$
|
34,637
|
|
|
$
|
34,637
|
|
|
$
|
34,637
|
|
|
$
|
34,637
|
|
|
$
|
34,637
|
|
|
$
|
34,637
|
|
|
$
|
34,637
|
|
|
$
|
34,637
|
|
|
$
|
34,637
|
|
Accrued Vacation
|
|
$
|
30,769
|
|
|
$
|
30,769
|
|
|
$
|
30,769
|
|
|
$
|
30,769
|
|
|
$
|
30,769
|
|
|
$
|
30,769
|
|
|
$
|
30,769
|
|
|
$
|
30,769
|
|
|
$
|
30,769
|
|
|
$
|
30,769
|
|
Vested Option Spread Value
|
|
$
|
265,500
|
|
|
$
|
265,500
|
|
|
$
|
265,500
|
|
|
$
|
265,500
|
|
|
$
|
|
|
|
$
|
265,500
|
|
|
$
|
265,500
|
|
|
$
|
265,500
|
|
|
$
|
265,500
|
|
|
$
|
265,500
|
|
Disability Pay
|
|
$
|
|
|
|
$
|
|
|
|
$
|
|
|
|
$
|
|
|
|
$
|
|
|
|
$
|
|
|
|
$
|
|
|
|
$
|
|
|
|
$
|
|
|
|
$
|
|
|
Bonus for Year of Termination
|
|
$
|
|
|
|
$
|
200,000
|
|
|
$
|
200,000
|
|
|
$
|
200,000
|
|
|
$
|
|
|
|
$
|
200,000
|
|
|
$
|
200,000
|
|
|
$
|
200,000
|
|
|
$
|
225,000
|
|
|
$
|
225,000
|
|
Vested Retention Award Value
|
|
|
|
|
|
|
|
|
|
$
|
200,000
|
|
|
$
|
200,000
|
|
|
|
|
|
|
$
|
200,000
|
|
|
$
|
200,000
|
|
|
$
|
200,000
|
|
|
$
|
200,000
|
|
|
$
|
200,000
|
|
Performance Unit Payout
|
|
$
|
|
|
|
$
|
|
|
|
$
|
200,000
|
|
|
$
|
200,000
|
|
|
$
|
|
|
|
$
|
200,000
|
|
|
$
|
200,000
|
|
|
$
|
200,000
|
|
|
$
|
200,000
|
|
|
$
|
200,000
|
|
Total Pre-Termination Vested
Value
|
|
$
|
497,377
|
|
|
$
|
697,377
|
|
|
$
|
1,097,377
|
|
|
$
|
1,070,990
|
|
|
$
|
231,877
|
|
|
$
|
1,097,377
|
|
|
$
|
1,097,377
|
|
|
$
|
1,097,377
|
|
|
$
|
1,122,377
|
|
|
$
|
1,122,377
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Amounts Vested at or After
Termination
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Unvested Retention Award Value
|
|
$
|
|
|
|
$
|
|
|
|
$
|
219,067
|
|
|
$
|
219,067
|
|
|
$
|
|
|
|
$
|
219,067
|
|
|
$
|
219,067
|
|
|
$
|
219,067
|
|
|
$
|
219,067
|
|
|
$
|
219,067
|
|
Cash Severance
|
|
$
|
|
|
|
$
|
|
|
|
$
|
|
|
|
$
|
|
|
|
$
|
|
|
|
$
|
428,600
|
|
|
$
|
|
|
|
$
|
1,200,000
|
|
|
$
|
|
|
|
$
|
1,200,000
|
|
Unvested Option Value
|
|
$
|
|
|
|
$
|
38,700
|
|
|
$
|
38,700
|
|
|
$
|
38,700
|
|
|
$
|
|
|
|
$
|
|
|
|
$
|
38,700
|
|
|
$
|
38,700
|
|
|
$
|
38,700
|
|
|
$
|
38,700
|
|
Restricted Stock/Unit Value
|
|
$
|
|
|
|
$
|
756,740
|
|
|
$
|
756,740
|
|
|
$
|
756,740
|
|
|
$
|
|
|
|
$
|
756,740
|
|
|
$
|
|
|
|
$
|
756,740
|
|
|
$
|
756,740
|
|
|
$
|
756,740
|
|
Health and Welfare
|
|
$
|
|
|
|
$
|
|
|
|
$
|
|
|
|
$
|
|
|
|
$
|
|
|
|
$
|
27,523
|
|
|
|
|
|
|
$
|
27,523
|
|
|
|
|
|
|
$
|
27,523
|
|
Perquisites
|
|
$
|
|
|
|
$
|
|
|
|
$
|
|
|
|
$
|
|
|
|
$
|
|
|
|
$
|
|
|
|
$
|
|
|
|
$
|
|
|
|
$
|
|
|
|
$
|
|
|
Outplacement
|
|
$
|
|
|
|
$
|
|
|
|
$
|
|
|
|
|
|
|
|
$
|
|
|
|
$
|
20,000
|
|
|
$
|
|
|
|
$
|
20,000
|
|
|
$
|
|
|
|
$
|
20,000
|
|
Excise Tax
Gross-Up
|
|
$
|
|
|
|
$
|
|
|
|
$
|
|
|
|
$
|
|
|
|
$
|
|
|
|
$
|
|
|
|
$
|
|
|
|
$
|
|
|
|
$
|
|
|
|
$
|
|
|
Total Value Vested at or After
Termination
|
|
$
|
|
|
|
$
|
795,440
|
|
|
$
|
1,014,507
|
|
|
$
|
1,014,507
|
|
|
$
|
|
|
|
$
|
1,451,930
|
|
|
$
|
257,767
|
|
|
$
|
2,262,030
|
|
|
$
|
1,014,507
|
|
|
$
|
2,262,030
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total Value
|
|
$
|
497,377
|
|
|
$
|
1,492,817
|
|
|
$
|
2,111,884
|
|
|
$
|
2,085,497
|
|
|
$
|
231,877
|
|
|
$
|
2,549,307
|
|
|
$
|
1,355,144
|
|
|
$
|
3,359,407
|
|
|
$
|
2,136,884
|
|
|
$
|
3,384,407
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
54
PROPOSAL TO
RATIFY APPOINTMENT OF
BDO SEIDMAN, LLP AS THE COMPANYS ACCOUNTANTS
The Audit Committee of the Board of Directors and the full Board
of Directors has approved BDO Seidman, LLP as the Companys
independent registered public accounting firm to audit its
consolidated financial statements for the 2007 fiscal year.
During the 2006 fiscal year, BDO Seidman, LLP served as the
Companys independent registered public accounting firm and
also provided certain tax consulting and other accounting
services. The Company is not required to seek Stockholder
ratification for the appointment of its independent accountants,
however, the Board of Directors believes it to be sound
corporate practice to seek such ratification.
Ratification of the appointment of the independent registered
public accounting firm for fiscal 2007 requires the affirmative
vote of holders of a majority of the shares of the
Companys Class A Common Stock present in person or by
proxy and entitled to vote at the Annual Meeting. Abstentions
would have the same effect as a vote against ratification. If
the appointment is not ratified, the Audit Committee will
investigate the reasons for Stockholder rejection and the Board
of Directors will reconsider the appointment.
PRINCIPAL
ACCOUNTANT FEES AND SERVICES
The following table sets forth the aggregate fees billed or
expected to be billed by BDO Seidman, LLP, the Companys
independent accountants for fiscal years ended December 31,
2006 and 2005, for professional services rendered in connection
with the audits of the Companys financial statements and
reports for fiscal years 2006 and 2005 and for other services
rendered during fiscal years 2006 and 2005 on behalf of the
Company and its subsidiaries, as well as all
out-of-pocket
costs incurred in connection with these services, which have
been or will be billed to the Company:
|
|
|
|
|
|
|
|
|
|
|
2006
|
|
|
2005
|
|
|
Audit Fees(1)
|
|
|
2,085,980
|
|
|
|
2,079,000
|
|
Audit-Related Fees(2)
|
|
|
0
|
|
|
|
2,607,500
|
|
Tax Fees
|
|
|
0
|
|
|
|
0
|
|
All Other Fees
|
|
|
0
|
|
|
|
0
|
|
Total(3)
|
|
|
2,085,980
|
|
|
|
4,686,500
|
|
|
|
|
(1) |
|
Audit Fees for fiscal years 2006 and 2005 were for
professional services rendered by the auditor for the audit of
the Companys annual and quarterly financial statements and
services provided in connection with statutory and regulatory
filings or engagements. |
|
(2) |
|
Audit-Related Fees for fiscal year 2005 were for
assurance and related services rendered by the auditor that were
reasonably related to the performance of the audit or review of
the Companys financial statements, but not included in
Audit Fees above. These services related primarily to
providing assistance with the Companys debt placement
filings, auditing of employee benefit plans and auditing of
carve-out financial statements of a business segment. |
|
(3) |
|
With the adoption of its Audit & Non-Audit Services
Pre-Approval Policy in May 2004, the Audit Committee commenced
pre-approval of fees and services included within the scope of
its policy. During 2006, the Audit Committee did not utilize the
de minimis exception to pre-approval offered by the Commission. |
55
Audit &
Non-Audit Services Pre-Approval Policy
Pursuant to its charter (available on the Companys website
and in print See Corporate Governance;
Committees of the Board above), the Audit Committee
adopted its Audit & Non-Audit Services
Pre-Approval Policy in May 2004 to establish procedures by
which it pre-approves all audit and non-audit services provided
by its independent auditor. Through this policy, the Audit
Committee ensures that the audit and non-audit services provided
by its independent auditor are compatible with maintaining the
independence of such auditor and maximizing efficiency overall.
The Companys policy sets forth a list of those types of
audit, audit-related and tax services that its independent
auditor is permitted to provide, and therefore have the general
pre-approval of the Audit Committee. If a type of service has
not received such general pre-approval, it will
require specific pre-approval by the Audit
Committee, based on a review of facts and circumstances, before
such service may be provided by the independent auditor. Any
proposed services exceeding pre-approved cost levels or budgeted
amounts will also require specific pre-approval by the Audit
Committee. The policy also sets forth those non-audit services
that the Companys independent auditor is prohibited from
providing, based upon legal requirements.
AUDIT
COMMITTEE REPORT
The Audit Committee reviews and makes recommendations to the
Board regarding internal accounting and financial controls and
accounting principles and auditing practices, and it is
responsible for the engagement of the independent registered
public accounting firm, the scope of the audits to be undertaken
by such accountants, administration of the Companys
Related Persons Transactions Policy and internal auditing. (See
Corporate Governance; Committees of the Board above
for further information.)
The Audit Committee reviews with the Companys independent
registered public accounting firm the results of its audit and
of its interim quarterly reviews and the overall quality of the
Companys accounting policies. The Companys
independent registered public accounting firm assists
management, as necessary, in updating the Audit Committee
concerning new accounting developments and their potential
impact on the Companys financial reporting. The Audit
Committee also meets regularly with the Companys
independent registered public accounting firm without management
present. The Audit Committee reviews and discusses with
management the Companys annual audited financial
statements and quarterly financial statements, including the
Companys disclosures under Managements Discussion
and Analysis of Financial Condition and Results of Operations.
The Audit Committee also meets with Company management, without
the Companys independent registered public accounting firm
present, to discuss managements evaluation of the
performance of the independent registered public accounting firm.
The Audit Committee also meets regularly with the Companys
internal audit staff to discuss the Companys internal
audit process and the results of ongoing or recently completed
internal audits.
With respect to fiscal 2006, the Audit Committee:
|
|
|
|
|
reviewed and discussed the Companys audited financial
statements with BDO Seidman, LLP and with management;
|
|
|
|
discussed with BDO Seidman, LLP the scope of its services,
including its audit plan;
|
|
|
|
reviewed the Companys internal control processes and
procedures;
|
|
|
|
discussed with BDO Seidman, LLP the matters required to be
discussed by Statement on Auditing Standards No. 61,
Communication with Audit Committees, as amended;
|
56
|
|
|
|
|
reviewed the written disclosures and confirmation from BDO
Seidman, LLP required by Independence Standards Board Standard
No. 1, Independence Discussions with Audit Committees, and
discussed with BDO Seidman, LLP their independence from
management and the Company; and
|
|
|
|
approved the audit and non-audit services provided by BDO
Seidman, LLP during fiscal 2006.
|
Based on the foregoing review and discussions, the Audit
Committee recommended to the Board of Directors that the audited
financial statements be included in the Companys Annual
Report on
Form 10-K
for fiscal 2006. The Audit Committee also evaluated and
recommended to the Board of Directors the reappointment of BDO
Seidman, LLP as the Companys independent registered public
accounting firm for fiscal 2007.
Pursuant to Section 404 of the Sarbanes-Oxley Act,
management is required to prepare as part of the Companys
2006 Annual Report on
Form 10-K
a report by management on its assessment of the Companys
internal control over financial reporting, including
managements assessment of the effectiveness of such
internal control. BDO Seidman, LLP has issued an audit report
relative to internal control over financial reporting. During
the course of fiscal 2006, management regularly discussed the
internal control review and assessment process with the Audit
Committee, including the framework used to evaluate the
effectiveness of such internal controls, and at regular
intervals updated the Audit Committee on the status of this
process and actions taken by management to respond to issues
identified during this process. The Audit Committee also
discussed this process with BDO Seidman, LLP. Managements
assessment report and the auditors audit report are
included as part of the 2006 Annual Report on
Form 10-K.
This report of the Audit Committee shall not be deemed
incorporated by reference into any filing under the Securities
Act of 1933, as amended, or the Securities Exchange Act of 1934,
as amended, except to the extent that the Company specifically
incorporates this information by reference.
By the Audit Committee:
Finn Berg Jacobsen (Chairman)
Ramon M. Perez
Peter G. Tombros
CERTAIN
RELATIONSHIPS AND RELATED TRANSACTIONS
Until December 28, 2006, A. L. Industrier owned 100% of the
Companys Class B Common Stock (which at the time was
approximately 22% of the Companys outstanding stock and
51% of the Companys voting stock). During that time
Mr. Einar Sissener, who until June 29, 2006 was a
Class B Director of the Companys Board and until
March 31, 2006 was Chairman of the Companys Board,
was Chairman of A. L. Industrier and together with certain
family-controlled private holding companies and certain of his
relatives owned approximately 54% of A.L. Industriers
outstanding ordinary shares entitled to vote. Accordingly, he
was deemed a controlling person of A.L. Industrier.
A. L. Industrier and Alpharma AS, one of the Companys
Norwegian subsidiaries, are parties to two leases pursuant to
which A. L. Industrier leases to Alpharma AS the land and
facility in Oslo, Norway where Alpharma AS principal
administrative offices and fermentation plant for one of its
bulk antibiotics are located, and adjoining land for a parking
facility for employees. Both leases have terms ending in 2014.
The terms are renewable, at the option of Alpharma AS, for up to
four additional consecutive five year terms. Basic rent during
the initial terms are $1.00 per year under the office and
plant lease and NOK 2,400,000 (approximately $372,000) per year
under the
57
parking facility lease and, during any renewal term thereafter,
basic rent under the office and plant least will be the then
prevailing fair rental value of the premises and basic rent for
the parking facility will remain at NOK 2,400,000. In addition
to basic rent, Alpharma AS pays documented expenses of ownership
and operation of such facilities, such as taxes and maintenance
expenses. Alpharma AS has the right to terminate the office and
plant lease at any time during its term upon
12 months written notice to A. L. Industrier and the
parking facility lease at any time during its term upon
24 months written notice to A. L. Industrier. These
leases were entered into on an arms length basis, and on
as favorable terms as could have been obtained from unrelated
third parties.
Prior to December 2006, substantially all transactions over
$50,000 with A. L. Industrier were subject to review by, and in
some circumstances prior approval of, the Companys Audit
Committee. (See Corporate Governance
Committees of the Board above.) On December 12, 2006,
the Audit Committee of the Board of Directors adopted the
Related Persons Transaction Policy, pursuant to which all
related person transactions (as defined therein) are subject to
the prior approval or ratification of the Audit Committee.
On December 28, 2006, the Company purchased 100% of the
Class B Stock held by A. L. Industrier through its
wholly-owned subsidiaries for $307.4 million, including
related fees. This transaction was approved by the
Companys Audit Committee. After such date A. L. Industrier
ceased being a controlling person of the Company. This
transaction received prior approval by the Board upon
recommendation by a special committee of the Board.
On December 28, 2006, the Company entered into an agreement
with Ms. Wiik pursuant to which Ms. Wiik consented to
the transfer of her aggregate pension liability to Vital
Forsikring ASA, a Norwegian insurance company. This transaction
received prior approval of the Audit Committee.
Certain
Other Relationships and Transactions
Mr. Sissener, who as of June 30, 1999, ceased acting
as President and CEO of the Company and as of March 31,
2006, ceased acting as Chairman of the Board, is party to an
agreement with the Company, effective July 1, 1999, as
amended, March 23, 2004, pursuant to which he received an
annual fee of $66,667 for serving as Chairman of the Board (and
director of certain of the Companys subsidiaries) during
2006. Mr. Sissener received fringe benefits similar to
those received by executive officers of the Company, in the form
of an automobile allowance, telephone and travel reimbursements,
and tax and financial planning and tax preparation
reimbursements. In addition, the Company provided
Mr. Sissener with a monthly allowance intended to cover the
cost of certain living expenses he incurred while working out of
the Companys Fort Lee, New Jersey offices.
Mr. Sissener had agreed to provide consulting services to
the Companys management for ten year term commencing
July 1, 1999 for an initial rate of $12,000 per month
(in addition to the payment of reasonable expenses incurred in
connection with the performance of such consulting services, as
described above). The consulting fee rate is adjusted annually
for inflation and is currently $14,207 per month. In
addition to the amounts described above, Mr. Sissener is
entitled to all benefits available under applicable plans and
policies in Norway arising from retirement from employment by
Alpharma AS and is entitled to receive from Alpharma AS an
amount which, when added to amounts he is entitled to receive
under Norwegian Social Security, Alpharma ASs pension plan
and his individual retirement benefits, equals NOK 718,688
(approximately $110,909). The current annual retirement benefit
that Mr. Sissener is receiving directly from the Company is
NOK 447,688 (approximately $69,088).
Mr. Hess professional corporation is a partner of
Kirkland & Ellis LLP, a law firm that, since 1978, has
performed and continues to perform significant legal services
for the Company.
58
STOCKHOLDERS
PROPOSALS FOR THE 2008 ANNUAL MEETING
In order to be considered for inclusion in the proxy statement
for the 2008 Annual Meeting of Stockholders, Stockholder
proposals must be submitted to the Company on or before
December 31, 2007. Such proposals will need to comply with
Securities and Exchange regulations regarding the inclusion of
Stockholder proposals in Company-sponsored proxy materials.
Similarly, in order for a Stockholder proposal to be raised from
the floor during next years annual meeting, written notice
must be received by the Company no later than December 31,
2007.
OTHER
BUSINESS
As of the date hereof, the foregoing is the only business which
management intends to present, or is aware that others will
present, at the Annual Meeting. If any other proper business
should be presented at the Annual Meeting, the proxies will be
voted in respect thereof in accordance with the discretion and
judgment of the person or persons voting the proxies.
Stockholders sharing a common address may receive only one set
of proxy materials to such address unless they have provided the
Company with contrary instructions. Any such stockholder who
wishes to receive a separate set of proxy materials now or in
the future may write or call the Company by contacting:
Secretary, Alpharma Inc., 440 Route 22, Bridgewater, New
Jersey 08807, or
(866) 322-2525.
Similarly, Stockholders sharing a common address who have
received multiple copies of the Companys proxy materials
may write or call the above address and phone number to request
delivery of a single copy of these materials in the future.
By order of the Board of Directors,
Robert F. Wrobel
Secretary
ALPHARMA INC.
YOUR VOTE IS IMPORTANT
PLEASE PROMPTLY COMPLETE AND SIGN THE ENCLOSED
FORM OF PROXY AND RETURN IT IN THE ENCLOSED ENVELOPE
59
Appendix A
ALPHARMA
INC.
Audit
Committee Charter
Organization
This charter governs the operations of the Audit Committee. The
committee shall be nominated by the Nominating and Corporate
Governance Committee and appointed by the Board of Directors
and, as required by the New York Stock Exchange, shall comprise
at least three directors, all of whom are independent directors
as that term is defined in the Alpharma Corporate Governance
Principles, provided that, to the extent the NYSE provides
relief from this requirement, the committee shall be comprised
of at least two members, all of whom are independent. All
committee members shall be financially literate, or shall become
financially literate within a reasonable period of time after
appointment to the committee, and at least one member shall have
accounting or related financial management expertise necessary
to be considered a financial expert under the rules
of the Securities and Exchange Commission.
Statement
of Policy
The committee shall provide assistance to the Board of Directors
in fulfilling the Boards oversight responsibility to the
stockholders, potential stockholders, the investment community,
and others relating to the integrity of the Companys
financial statements and the financial reporting process, the
Companys compliance with legal and regulatory
requirements, the independent auditors qualifications and
independence, the systems of internal accounting and financial
controls, the annual independent audit of the Companys
financial statements, the performance of the Companys
internal audit function and independent auditors. In so doing,
it is the responsibility of the committee to maintain free and
open communications between the committee, independent auditors,
and management of the Company.
In discharging its oversight role, the committee is empowered to
investigate any matter brought to its attention with full access
to all books, records, facilities, and personnel of the Company
and the power to retain outside counsel, or other experts for
this purpose. The Company shall provide funding necessary for
the committee to retain outside counsel and experts.
The committee should take the appropriate actions to set the
overall corporate tone for quality financial
reporting and sound business risk.
Responsibilities
and Processes
The following is a general expression of the responsibilities
and processes to be employed by the committee. However, the
committee believes its policies and procedures should remain
flexible in carrying out these responsibilities, in order to
react to changing conditions and circumstances.
It is the responsibility of the committee to oversee the
Companys financial reporting and risk management processes
on behalf of the Board and report the results of its activities
to the Board. Management is responsible for preparing the
Companys financial statements, and the independent
auditors are responsible for auditing those financial
statements. Management is also responsible for risk management
activities.
A-1
The following shall be the principal recurring processes of the
committee in carrying out its oversight responsibilities:
|
|
|
|
|
The committee shall have a clear understanding with management
and the independent auditors that the independent auditors are
directly accountable to the committee, as representatives of the
Companys stockholders. The committee shall be responsible
for the oversight of work of the independent auditors, including
the resolution of any disagreement between management and the
auditors and shall have the direct authority to appoint, approve
the compensation for and, where appropriate, replace the
independent auditors. The Company shall provide funding to the
committee for the purpose of engaging and compensating the
independent auditors. The committee shall discuss with the
auditors their qualifications and independence from management
and the Company and the matters included in the written
disclosures required by the Independence Standards Board.
|
|
|
|
The committee shall discuss with the independent auditors the
overall scope and plans for their respective audits, including
the level of fees paid. The committee shall direct the
activities of the internal audit function. Also, the committee
shall discuss with management and the independent auditors the
adequacy and effectiveness of the accounting and financial
controls. Further, the committee shall meet separately with the
Companys management, internal auditors and independent
auditors, with and without management present, to discuss the
results of their respective examinations. The committee shall
review with the independent auditor any audit problems or
difficulties and managements response.
|
|
|
|
The committee shall review the year-end financial statements and
Form 10-K
with management and the independent auditors and recommend the
signing of the
Form 10-K
by the entire Board of Directors. Also, the committee shall
discuss the results of the review and any other matters required
to be communicated to the committee by the independent auditors
under generally accepted auditing standards. The chair of the
committee shall prepare an Audit Committee Report for inclusion
in each Proxy Statement related to an Annual Meeting of
Stockholders.
|
|
|
|
The committee shall review the interim financial statements with
management and the independent auditors prior to the filing of
the Companys Quarterly Report on
Form 10-Q.
Also, the committee shall discuss the results of the quarterly
review and any other matters required to be communicated to the
committee by the independent auditors under generally accepted
auditing standards. The chair of the committee may represent the
entire committee for the purposes of this review.
|
|
|
|
The committee shall review and approve all financial press
releases, including earnings guidance prior to issuance by the
Company.
|
|
|
|
The committee shall adopt procedures by which it will
pre-approve all audit and non-audit services provided by the
independent auditors.
|
|
|
|
The committee shall adopt policies in connection with the
employment by the Company of present and former employees of the
independent auditors.
|
|
|
|
The committee shall discuss and take all oversight actions
required of, or deemed necessary by, the committee under the
Companys policies with respect to risk assessment and risk
management, including the risk of fraud. Annually, the committee
shall discuss the Companys major risk exposures and the
steps management has taken to monitor and control such exposures.
|
A-2
|
|
|
|
|
The committee shall take all actions required of, or deemed
necessary by, the committee under the Companys Related
Persons Transactions Policy.
|
|
|
|
To develop and institute a procedure for the general oversight
of the Companys Business Conduct Guidelines and the
receipt, retention and treatment of complaints received by the
Company concerning its Business Conduct Guidelines, accounting,
internal accounting controls or auditing matters, including a
procedure allowing employees to make such complaints on an
anonymous basis with assurance of no retaliation.
|
Committee
Operating Processes
Committee
Responsibilities
The committee shall have the following responsibilities and the
necessary power and authority to carry out such duties and
responsibilities:
|
|
|
|
|
Performs an annual performance evaluation of the committee.
|
|
|
|
At least annually, the committee shall obtain and review a
report by the independent registered public accountants
describing: (i) the firms internal quality control
procedures; (ii) any material issues raised by the most
recent internal quality control review, or peer review, of the
firm, or by any inquiry or investigation by governmental or
professional authorities, within the preceding five years,
respecting one or more independent audits carried out by the
firm, and any steps taken to deal with any such issues; and
(iii) all relationships between the independent auditor and
the Company.
|
Meetings
Meetings may be called by the Chairman of the Audit Committee by
oral or written notice, communicated to each member not less
than twenty-four hours before such meeting.
Action may be taken without a meeting if all members of the
committee consent to such action and confirm such unanimous
consent in writing either prior or subsequent to the taking of
such action.
Reports
The Audit Committee shall report to the Board at its next
regularly scheduled meeting on any material actions taken by the
committee. Minutes of all meetings of the committee shall be
kept in the ordinary course of business and shall be open for
inspection at all times upon the request of any member of the
Board of Directors.
Quorum
A majority of the committee shall constitute a quorum for the
transaction of business and an affirmative vote of the majority
of the members who attend the meeting shall be required for
approval of any action.
Use of
Third Party Providers
The committee shall have the authority to use third party
service providers in executing its duties. The committee shall
have the sole authority to approve retain, terminate and approve
the fees and other retention terms of any such third party
service providers.
END
A-3
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
000000000.000000 ext 000000000.000000 ext |
|
|
|
|
|
|
|
|
|
|
000000000.000000 ext 000000000.000000 ext |
|
|
|
|
|
|
|
000004 |
|
|
000000000.000000 ext 000000000.000000 ext
|
|
|
|
MR A SAMPLE
DESIGNATION (IF ANY)
ADD 1
ADD 2
ADD 3
ADD 4
ADD 5
ADD 6
|
|
|
Electronic
Voting Instructions
You can vote by Internet or telephone!
Available 24 hours a day, 7 days a week!
Instead of mailing your proxy, you may choose one of the two voting
methods outlined below to vote your proxy.
VALIDATION DETAILS ARE LOCATED BELOW IN THE TITLE BAR.
Proxies submitted by the Internet or telephone must be received by
1:00 a.m., Central Time, on June 5, 2007. |
|
|
|
|
|
|
|
|
|
|
|
|
Vote by Internet
Log on to the Internet and go to
www.investorvote.com
|
|
|
|
|
|
|
|
|
|
|
|
|
Follow the steps outlined on the secured
website. |
|
|
|
|
|
|
|
|
|
|
|
|
Vote by telephone
Call toll free 1-800-652-VOTE (8683) within the United
States, Canada & Puerto Rico any time on a touch tone
telephone. There is NO CHARGE to you for the call. |
|
|
|
|
|
|
|
|
|
|
|
|
Follow the instructions provided by the
recorded message. |
|
|
|
|
|
|
|
|
|
|
|
|
|
Using a black ink pen, mark your votes with an X as shown in
this example. Please do not write outside the designated areas. |
|
X |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Annual Meeting Proxy Card
|
|
|
|
C0123456789
|
|
|
12345 |
|
|
|
|
|
|
|
|
|
|
|
6
IF YOU HAVE NOT VOTED VIA THE INTERNET OR TELEPHONE,
FOLD ALONG THE PERFORATION, DETACH AND RETURN THE BOTTOM PORTION IN THE ENCLOSED ENVELOPE.
6
A
Proposals The Board of Directors recommends a vote
FOR
all the nominees listed and FOR Proposal 2.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1. Election of Class A Directors:
|
|
For
|
|
Withhold
|
|
|
|
|
|
For
|
|
Withhold
|
|
|
|
|
|
For
|
|
Withhold |
|
|
+ |
01
- Finn Berg Jacobsen
|
|
o
|
|
o
|
|
|
|
02 - Peter W. Ladell
|
|
o
|
|
o
|
|
|
|
03 - Dean J. Mitchell
|
|
o
|
|
o
|
|
|
|
|
04
- Ramon M. Perez
|
|
o
|
|
o
|
|
|
|
05 - David C. UPrichard
|
|
o
|
|
o
|
|
|
|
06 - Peter G. Tombros
|
|
o
|
|
o
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For |
|
Against |
|
Abstain |
|
|
2.
|
|
Ratification of the appointment of BDO Seidman, LLP as the
Companys independent registered public accounting firm for
the 2007 fiscal year.
|
|
o
|
|
o
|
|
o
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3. |
|
As such persons may, in their discretion, determine
upon such matters as may come before the meeting. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
B Non-Voting
Items Change of Address Please print new address below.
|
|
|
|
|
|
|
|
|
|
|
Meeting Attendance
Mark box to the right if you plan to attend the Annual Meeting.
|
o
|
|
|
|
|
|
|
|
|
|
|
C Authorized
Signatures This section must be completed for your vote to be
counted. Date and Sign Below |
|
|
|
|
|
|
NOTE: The signature should correspond exactly with the name of the stockholder as it appears hereon. Where stock is registered in Joint Tenancy, all tenants should sign. Persons signing as Executors, Administrators, Trustees, etc. should so indicate.
|
|
Date (mm/dd/yyyy) Please print date below. |
|
Signature 1 Please keep signature within the box. |
|
Signature 2 Please keep signature within the box. |
|
|
|
|
|
|
|
|
|
/ |
|
/ |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
n
|
|
|
|
C 1234567890
6 1 C V
|
|
J N T
0 1 3 5 5 6 1
|
|
MR A SAMPLE (THIS AREA IS SET UP TO
ACCOMMODATE
140 CHARACTERS) MR A
SAMPLE AND MR A SAMPLE AND MR A SAMPLE
AND MR A SAMPLE AND MR A SAMPLE AND
MR A SAMPLE
AND MR A SAMPLE AND MR A SAMPLE AND
|
+ |
April 27, 2007
Dear Stockholder:
You are cordially invited to attend the Annual Meeting of Stockholders to be held at 9:00 a.m. on
Tuesday, June 5, 2007 at the offices of the Company, 440 Route 22, Bridgewater, New Jersey. Detailed information is contained in the accompanying Notice of Annual Meeting and Proxy Statement.
Regardless of whether you plan to attend the meeting, it is important that your shares be
voted. Accordingly, we ask that you sign and return your proxy as soon as possible in the envelope provided. If you do plan to attend the meeting, please mark the appropriate box on the proxy.
Best Regards,
-s- Robert F. Wrobel
Robert F. Wrobel
Secretary
6
IF YOU HAVE NOT VOTED VIA THE INTERNET OR TELEPHONE, FOLD ALONG THE PERFORATION,
DETACH AND RETURN THE BOTTOM PORTION IN THE ENCLOSED ENVELOPE.6
Proxy ALPHARMA, INC.
440 Route 22, Bridgewater, New Jersey 08807
Proxy for Annual Meeting of Stockholders on June 5, 2007
Jeffrey S. Campbell, Executive Vice President and Chief Financial Officer, and Robert F. Wrobel, Executive Vice President, Chief Legal Officer and Secretary, or either one of them, with full
power of substitution, are hereby authorized to vote the shares of
Class A Common Stock of Alpharma Inc. (the Company), which the undersigned is entitled to vote at the 2007 Annual Meeting
of Stockholders to be held at the offices of the Company, 440 Route 22, Bridgewater, New Jersey on Tuesday, June 5, 2007 at 9:00 a.m., local time, and at all adjournments thereof, as follows on the reverse side.
The Board of Directors recommends that the Stockholders vote FOR the nominees set forth in item 1 and FOR Proposal
2. Shares represented by this proxy, when properly executed, will be voted in the manner directed by the undersigned stockholder
and in the discretion of the proxy holders as to any other matter that may properly come before the Annual Meeting of Stockholders or, if no
direction is indicated, will be voted FOR the nominees set forth in item 1 and FOR Proposal 2, and in the discretion of the proxy holders as to any other
matter that may properly come before the Annual Meeting of Stockholders.
Please mark, sign and mail this proxy promptly in the enclosed envelope, which requires no postage if mailed in the United States.
If you vote over the Internet or by telephone, please do not mail your card.
CONTINUED AND TO BE SIGNED ON REVERSE SIDE.